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Abstract 
Due to their underlying genetic complexity, chromosomal disorders such as 
Down syndrome (DS), which is caused by trisomy 21, have long been understudied and 
continue to lack effective treatments. With over 200 genes on the extra chromosome, 
even the specific cell pathologies and pathways impacted in DS are not known, and it 
has not been considered a viable target for the burgeoning field of gene therapy. 
Recently, our lab demonstrated that the natural mechanism of dosage compensation 
can be harnessed to silence the trisomic chromosome in pluripotent cells. Using an 
inducible XIST transgene allows us to study the effects of trisomy in a tightly controlled 
system by comparing the same cells with either two or three active copies of 
chromosome 21. In addition, it raises the prospect that insertion of a single gene into a 
trisomic chromosome could potentially be developed in the future for “chromosome 
therapy”.  
 This thesis aims to utilize this inducible system for dosage compensation to study 
the neurodevelopmental effects of trisomy 21 in vitro, and to answer basic epigenetic 
questions critical to the viability of chromosome silencing as a therapeutic approach. 
Foremost, for XIST to have any prospect as a therapeutic, and to strengthen its 
experimental utility, it must be able to initiate chromosome silencing beyond its natural 
context of pluripotency. Here I demonstrate that, contrary to the current literature, XIST 
is capable of initiating chromosome silencing in differentiated cells and producing fully 
dosage compensated DS neurons. Additionally, I show that silencing of the trisomic 
chromosome in neural stem cells enhances their terminal differentiation to neurons, and 
transcriptome analysis provides evidence of a specific pathway involved. Separate 
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experiments utilize novel three-dimensional organoid technology and transcriptome 
analysis to model DS neurodevelopment in relation to isogenic euploid cells. Overall, 
this work demonstrates that dosage compensation provides a powerful experimental 
tool to examine early DS neurodevelopment, and establishes that XIST function does 
not require pluripotency, thereby overcoming a perceived obstacle to the potential of 
XIST as a therapeutic strategy for trisomy. 
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CHAPTER I : Introduction 
Unlike many genetic conditions for which a causative mutation in one gene can 
be identified, Down syndrome (DS) is caused by the presence of an extra copy of an 
entire chromosome, chromosome 21 (chr21). This means that individuals with DS have 
an extra copy of ~250 protein-coding genes (including 16 transcription factors), at least 
5 functional microRNAs, and hundreds of potential non-coding RNAs. This presents a 
significant challenge to understanding the precise genetic causes underlying each of the 
myriad physiological abnormalities present in individuals with DS. An incomplete 
understanding of the causative genes in DS, as well as normal variation between 
individuals, has hindered progress in our understanding of the molecular and cellular 
basis for disease. Because of this, there are currently no effective treatments for the 
most prevalent finding in individuals with DS, cognitive disability. 
 Recently, our lab has introduced a novel approach to studying DS pathogenesis, 
which also has the potential to one day serve as the basis for a comprehensive therapy 
for DS. This “trisomy silencing” system utilizes a natural mechanism of chromosome 
silencing using the gene XIST, in this case inserted into one copy of chr21 in a DS 
patient-derived induced pluripotent stem cell (iPSC) line. In this thesis, I utilize this 
powerful system to study the effects that trisomy has on early neurodevelopment and to 
investigate whether XIST-mediated trisomy silencing can correct these deficits. I will 
investigate whether XIST is capable of functioning outside of its natural developmental 
context of pluripotency, contrary to the current literature. Additionally, I utilize newly-
developed three-dimensional cell culture techniques to further investigate the 
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neurodevelopmental effects of trisomy 21. This introduction will provide the necessary 
background on the subjects covered in this thesis, including dosage sensitivity, XIST 
biology, normal human neurodevelopment, DS neurobiology and its modelling in vitro, 
and the use of XIST to advance translational research in DS. 
The importance of dosage balance 
‘Sola dosis facit venenum’ 
(Latin: only the dose makes a thing not a poison) 
-Paracelsus (1493–1541) 
It has been appreciated for hundreds if not thousands of years that the toxicity of 
a substance depends entirely on its dosage. This idea also applies to gene dosage. In 
fact, it has been hypothesized that the major phenotypic differences between humans 
and our closest living relatives, chimpanzees, depends largely on regulatory differences 
that influence expression levels rather than differences in protein composition (King and 
Wilson, 1975). Thus, it could be the collective dosages of the building blocks of life, 
rather than the structure of the blocks themselves, that makes us human. 
Recent work has identified hominid-specific NOTCH2 paralogs as potentially 
dosage-sensitive regulators of the Notch pathway, which will be described in more detail 
in a later section, that may be partially responsible for the evolution of larger brains in 
humans (Fiddes et al., 2018). Strikingly, duplications of these paralogs have been linked 
to macrocephaly, and deletions have been associated with microcephaly. In the case of 
these paralogs, the building blocks are present only in hominids, yet they serve to tweak 
the degree of Notch pathway signaling, leading to our uniquely powerful cognitive 
capacities. 
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In addition to potentially shaping our species, gene dosage also plays an 
important role in health and disease, yet this is an area of genome biology that is not 
well understood. In fact, it is not well-known what fraction of genes in the genome are 
dosage sensitive. While many genetic disorders are caused by mutations in genes that 
render them nonfunctional or toxic, there are genes for which the presence of an extra 
non-mutant copy is known to be pathogenic. Perhaps the most well-known and striking 
example also happens to be located on chr21. As will be discussed in more detail in a 
later section, the amyloid precursor protein (APP) gene is the only gene on chr21 that 
has been strongly linked to a specific phenotype in DS: the near-universal development 
of Alzheimer’s disease (AD) (Olson and Shaw, 1969). The mapping of the APP gene to 
chromosome 21, in concert with the findings of prevalent AD in DS patients, led to the 
development of the amyloid hypothesis, the dominant theory in the pathogenesis of AD 
(Hardy and Selkoe, 2002). Further supporting that the dosage of this single gene can be 
sufficient for AD pathogenesis, euploid individuals with a duplication of the APP gene 
develop early-onset autosomal dominant AD (Rovelet-Lecrux et al., 2006). 
It is important to note that many, if not most, genes are not dosage sensitive, as 
evidenced by the prevalence of copy number variations (CNV) covering 12% of the 
human genome (Redon et al., 2006). Additionally, there are genes for which an 
increased copy number can be advantageous in certain scenarios, as exemplified by 
the gene encoding amylase, which is present in higher copy numbers in cultures that 
consume a high-starch diet (Perry et al., 2007), and presumably gives a competitive 
advantage to individuals who can more thoroughly digest starches.  
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While there are individual genes which are not dosage sensitive, the presence or 
absence of an entire autosomal chromosome is nearly always incompatible with life. 
Recent estimates suggest that up to 80% of spontaneous abortions are caused by 
chromosomal abnormalities (Hardy et al., 2016). A plurality of these cases is caused by 
trisomy, a trend that has been exacerbated recently by increasing average maternal 
age. The few trisomies that are compatible with life tend to be on the smaller 
chromosomes, which contain fewer genes, such as chromosome 21. Notable 
exceptions to these trends involve the large X chromosome; monosomy and trisomy X 
are both compatible with life and cause mild phenotypes compared to other 
chromosomal abnormalities. This is largely due to the unique process of dosage 
compensation. 
Concomitant with the evolution of heterogametic sex chromosomes came 
systems for dosage compensation, which ensure gene dosage balance between the 
sexes (Charlesworth, 1996). In drosophila, males (XY) upregulate expression from one 
X chromosome by the redundant action of two non-coding RNAs, roX1 and roX2, in 
order to equilibrate X chromosome expression between males and females (Franke and 
Baker, 1999). In contrast, female (XX) mammals downregulate expression from one X 
chromosome. This phenomenon is orchestrated by another non-coding RNA, the X-
inactive specific transcript (XIST). XIST RNA normally coats one X chromosome, 
eventually leading to its transcriptional silencing. In females with trisomy X, XIST is 
expressed from two copies of the X chromosome, ensuring the presence of just one 
transcriptionally active X chromosome and explaining viability of these trisomies. The 
mild phenotypes that are seen in trisomy X, and become more severe in the rare cases 
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of tetrasomy X, are thought to be caused by overexpression a subset of genes that 
escape silencing by XIST (Tartaglia et al., 2010). However, as will become evident 
throughout this thesis and is the case with most trisomies, the specific genes that lead 
to any potential phenotypes in cases of trisomy X have not been identified. One notable 
exception to this is the SHOX gene, which escapes X inactivation and has been linked 
to the short stature of women with Turner’s syndrome (XO) and the tall stature of both 
men and women with supernumerary copies of the X chromosome (Ottesen et al., 
2010). 
Case studies of specific dosage-sensitive genes, the high prevalence of 
chromosomal abnormalities in spontaneous abortions, and the potential role of gene 
expression changes in the evolution of our species make a clear case for the 
importance of gene dosage throughout biology. The natural phenomenon of X 
chromosome inactivation (XCI) provides an important window into understanding how 
perturbation of transcriptional gene dosage affects development, and the ability to 
harness this unique phenomenon to model and potentially treat disorders of dosage 
imbalance opens a new path for these previously untreatable diseases. 
XIST and X chromosome inactivation  
The discovery of X chromosome inactivation and XIST  
 Mary Lyon first put forward a comprehensive theory of X inactivation that has 
survived decades of scientific inquiry (Lyon, 1961). Her theory built on the then-recent 
discovery that the “sex chromatin” in female cells previously identified by Barr and 
Bertram (1949) was in fact one X chromosome (Ohno and Hauschka, 1960), and that 
monosomy X was compatible with a healthy and fertile female phenotype in mice 
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(Welshons and Russell, 1959). Additionally, work in mouse genetics had identified an 
interesting finding where heterozygous mutations in X-linked coat color genes led to the 
patchy appearance of female mice, suggestive of a mosaic phenotype (Fraser et al., 
1953). In this scenario, one X chromosome is randomly inactivated in the early female 
embryo. If the chromosome containing the nonmutant coat color allele is inactivated, 
then pigmented cells arising from this early progenitor will not produce pigment. On the 
other hand, cells derived from the progenitor that silences the other X chromosome will 
produce pigment, ultimately leading to the mottled phenotype seen in female animals of 
certain mouse mutants as well as in the common house cat. Putting these pieces 
together, Lyon’s hypothesis stated that the heteropyknotic (condensed) X chromosome 
can be either maternal or paternal in origin in different cells of the same animal, that this 
chromosome is genetically inactivated, and that this inactivation occurs early in 
development (Lyon, 1961).  
 Soon after proposing this theory, evidence from X;autosome translocations 
indicated that a certain portion of the X chromosome was required for chromosomal 
silencing to take place (Russell, 1963). This led to the idea that there exists a portion of 
the X chromosome called the X inactivation center (XIC) from which the inactivation of 
the X chromosome spreads (Cattanach, 1975). It was not until 30 years after Mary Lyon 
proposed the theory of X inactivation that the gene located in the XIC and associated 
with aberrant XCI was discovered (Brown et al., 1991a, 1991b). XIST was unique in that 
it was the only gene known to be expressed exclusively from the inactive X 
chromosome. Prior genes had been discovered that were expressed only from the 
active X (silenced genes) and genes expressed from both copies of X (genes that 
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escape silencing). Importantly, Brown et al. (1991a) also found that XIST expression 
increased with the number of inactive X chromosomes present, indicating that XIST is 
capable of effectively silencing multiple X chromosomes and rescuing these individuals 
from trisomy, as mentioned in the previous section, which is an important finding for any 
potential therapeutic applications of this unique gene. Soon after, once the entire 17kb 
sequence of XIST was determined (Brown et al., 1992), it became clear that this gene 
does not encode a protein, but instead is transcribed into a long RNA that is retained in 
the nucleus and spatially overlaps nearly perfectly with the inactive X chromosome 
territory, or Barr body (Clemson et al., 1996). In fact, XIST RNA established the 
precedent for a large non-coding RNA (lncRNA) which functions in chromatin. XIST was 
also determined to contain several well-conserved repeat elements known as repeats 
A-F (Brown et al., 1992). At about the same time, mouse mutant studies found that Xist 
was indeed required for X chromosome silencing. These studies showed that in mice 
with one mutant allele of Xist, the silenced chromosome in every cell was always the 
one containing the intact allele (Penny et al., 1996), indicating lethality of cells which 
attempted XCI using a non-functional mutant allele of Xist. 
Mechanisms of XIST-mediated chromosome silencing 
 In the nearly 30 years since the discovery of the XIST gene, numerous 
researchers have tried to understand how this RNA mediates transcriptional silencing of 
an entire chromosome. While there is much that remains unknown about this process, 
significant progress has been made in understanding the underlying mechanisms. It has 
long been understood that XIST recruits many factors in order to effectively and 
redundantly render the X chromosome transcriptionally silenced (Migeon, 1994), and 
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some of the mechanisms employed to this end, which have largely been discovered in 
the mouse, will be reviewed here and are summarized in Figure I-1. 
XIST RNA functions by triggering multiple repressive chromatin modifications 
that contribute to the silent state, such as polycomb protein repressive complexes PRC1 
and PRC2, which induce the canonical heterochromatin hallmarks: monoubiquitination 
of lysine 117 on histone 2A (H2AK119ub1) and trimethylation of lysine 27 on histone 3 
(H3K27me3), respectively (Cao et al., 2002; Fang et al., 2004; de Napoles et al., 2004; 
Plath et al., 2003). Initial experiments suggested that Xist RNA directly recruited PRC2 
to the X chromosome via the A-repeat segment of the RNA (Zhao et al., 2008). In this 
model, PCR2 would first lay down the H3K27me3 heterochromatin mark, which would 
then be bound by the CBX component of PCR1, allowing for H2AK119ub1 enrichment 
(Brockdorff, 2017). Subsequent studies, however, have come to the conclusion that it is 
in fact a non-canonical version of PRC1 that is first recruited to the X chromosome 
(Tavares et al., 2012), and that PRC2 recruitment depends on prior deposition of 
H2AK119ub1 (Almeida et al., 2017). 
The polycomb complexes and their respective histone modifications have long 
been associated with the inactive X chromosome, yet their role in transcriptional 
silencing of the chromosome has been debated. While there is evidence in the mouse 
of some extraembryonic cells requiring polycomb for maintenance of XCI (Wang et al., 
2001), one study found that these complexes did not seem to be required for initiation of  
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Figure I-1: Summary of XIST mechanisms for heterochromatin recruitment. 
XIST RNA (red lines and circles) has a complicated 3D structure including several 
hairpins. Genomic DNA (black lines) is wrapped in nucleosomes (blue circles) 
containing histones which can undergo modifications that make the DNA more or less 
accessible to transcriptional machinery. The A-repeat is known to directly interact with 
SPEN, which recruits HDAC3 through intermediate partners. The A-repeat may also act 
via other mechanisms to enact gene silencing. Other elements of XIST recruit PRC1, 
which lays down H2AK119ub1. This subsequently leads to the recruitment of PRC2, 
which lays down H3K27me3. HDAC3 may also affect PRC2 recruitment. Figure partially 
adapted from Brockdorff (2017). 
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XCI in the embryo itself (Kalantry and Magnuson, 2006). There is also early evidence 
for XIST mutants that do not recruit PRC1/2 to undergo effective silencing, although the  
extent of silencing or the requirement of these complexes for the maintenance of the 
silenced state could not be assessed (Bousard et al., 2018). However, other studies 
have shown that the embryonic lethality in PRC1 knockout mice may not be totally 
attributable to the failure of extraembryonic cells to complete XCI, and that PRC1 
mutant mouse embryonic stem cells (ESC) show impaired XCI (Almeida et al., 2017). 
Ultimately, further experiments, particularly in human cells, are required to determine to 
what extent the polycomb complexes are required for the initiation and maintenance of 
XCI. 
 The A-repeat sequence of XIST has been most tightly linked to the silencing 
function of this RNA. An Xist mutant in this portion of the gene leads to total abrogation 
of its silencing capability (Wutz et al., 2002), with no effect on the ability to recruit 
polycomb complexes and related heterochromatin modifications (Plath et al., 2003). The 
human A-repeat sequence alone was shown to be capable of silencing a reporter gene 
in the same transgenic construct (Minks et al., 2013), and may also be capable of 
silencing endogenous genes, potentially megabases away (Valledor et al., in 
preparation). Due to its importance in the role of silencing and its apparent uncoupling 
from the deposition of heterochromatin marks, there has been a concerted effort to 
determine how the A-repeat sequence induces transcriptional silencing. Through these 
efforts it was discovered that the RNA binding protein Spen was required for Xist-
mediated silencing (Moindrot et al., 2015; Monfort et al., 2015). Further, novel 
techniques for identifying RNA binding proteins, such as comprehensive identification of 
 11 
RNA binding proteins by mass spectrometry (ChIRP-MS), revealed that Spen interacts 
directly with the A-repeat of Xist RNA (Chu et al., 2015). Spen was also shown to 
activate histone deacetylase 3 (HDAC3) which is required for both exclusion of RNA 
polymerase II from the inactive X chromosome and recruitment of PRC2 (McHugh et al., 
2015; Żylicz et al., 2019). Interestingly, while the A-repeat mutant studies demonstrate 
decoupling of this sequence from PRC2 recruitment, it has been shown to be required 
for Spen binding, which in turn is necessary for recruitment of PRC2 to the X 
chromosome. This suggests a complex interaction between the XIST RNA, RNA 
binding proteins, and polycomb complexes that is still poorly understood. 
 In addition to polycomb-mediated heterochromatin marks and Spen-mediated 
histone deacetylation, a number of other chromatin modifications have been linked to 
XCI. For example, H3K9me was one of the earliest reported chromatin changes 
associated with XCI (Heard et al., 2001), and the histone variant macroH2A is highly 
enriched on the inactive X, but its functional significance for XCI is questionable 
(Pehrson et al., 2014). Recent work has identified adenosine methylation of XIST RNA 
as a requirement for transcriptional repression (Patil et al., 2016), yet the mechanism 
behind its action is not yet understood. DNA methylation is one of the final steps in the 
XCI process that is thought to be required for maintenance of the inactive state, for 
which XIST is dispensable (Brown and Willard, 1994). Another factor, SMCHD1, has 
been shown to be enriched on the XCI and to play a role in DNA hypermethylation on 
the inactive X chromosome (Blewitt et al., 2008). While the focus of most studies have 
been on histone modifications and DNA methylation, XIST RNA also interacts with 
architectural proteins, such as SAF-A, and may act directly at the level of chromatin 
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architecture (Creamer and Lawrence, 2017). Overall, the plethora of heterochromatin 
modifications and mechanisms involved in the induction and maintenance of the 
inactive X chromosome state highlight the complementary and redundant nature of XCI. 
Many of the factors involved have been shown to be insufficient for gene silencing on 
their own, but knockout of multiple factors can lead to erosion of the silenced state 
(Csankovszki et al., 2001). 
Once XCI has taken place, it is thought to be stable throughout the rest of 
development. Indeed, XIST RNA is largely dispensable for maintenance of XCI after it 
has been initiated (Brown and Willard, 1994). However, there is evidence that deletion 
of XIST in hematopoietic cells leads to inevitable hematological malignancy in mice 
(Yildirim et al., 2013), suggesting a possible role of XIST in fully maintaining long-term 
silencing. The importance of some factors for the induction of XCI, but not the long-term 
maintenance of silencing and vice-versa further complicates the identification of 
mechanisms involved, and it remains unclear what directly silences transcription as a 
result of XIST expression. Novel strategies to identify proteins that directly interact with 
XIST RNA have identified several pathways that may be crucial for gene silencing and 
bring us ever closer to a complete picture of the X inactivation process. 
Induction of chromosome silencing in development 
 Very soon after the discovery of the Barr body, the temporal dynamics of its 
formation in development began to be studied. It was quickly realized that this body was 
not present in human or macaque zygotes, but appeared several days later in both cells 
of the embryo and extraembryonic tissues (Park, 1957). Since these early studies, 
much progress has been made in understanding the onset of XCI in both mouse and 
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human development. Additionally, the ability of XIST to induce chromosome silencing 
outside its normal developmental window has been an important area of research and 
will be a major area of study in this thesis. 
 The differences in mouse and human XCI are most significant in the 
preimplantation embryo. Beginning in the four-cell embryo in mice, Xist expression is 
initiated from the paternally inherited X chromosome (Marahrens et al., 1997), a process 
known as imprinted XCI. In extraembryonic tissues this pattern of XCI continues 
throughout pregnancy, with exclusive silencing of the paternally-derived X chromosome 
being vital for extraembryonic tissue survival in female animals (Mugford et al., 2012). In 
contrast, the inner cell mass (from which the embryo is derived) reactivates the 
paternally derived X chromosome in late stage blastocysts before random XCI takes 
place (Mak et al., 2004). 
The XCI process in early human preimplantation embryos is just beginning to be 
explored, yet it is clear that imprinted XCI does not occur. Instead, beginning in the 
morula, XIST is expressed from both copies of the X chromosome (Okamoto et al., 
2011; Petropoulos et al., 2016a). Recent evidence indicates that at the same time, X 
chromosome gene expression is biallelically repressed in a process called X 
chromosome dampening (XCD) that has also been observed in naïve iPSCs (Sahakyan 
et al., 2017). The mechanism behind XIST-mediated XCD is not completely understood, 
but a recently discovered X-linked lncRNA called XACT (Vallot et al., 2013), which is 
also transcribed from both X chromosomes in the early human embryo (Vallot et al., 
2017), may play a role in attenuating the silencing action of XIST. 
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Post-implantation XCI in humans mimics that of embryonic mouse cells, where 
one X chromosome is randomly inactivated in each cell by XIST. The exact 
developmental timeline of the transition from XCD to random XCI in the human embryo 
is not well defined. This transition likely occurs in the blastocyst, where evidence of a 
single XIST paint and heterochromatin markers indicating XCI has been seen (van den 
Berg et al., 2009).  
Because XCI occurs very early in development, it is perhaps logical that this 
developmental context is ideal for the silencing initiation function of XIST. In fact, it was 
reported that inducing Xist expression in mouse ES cells that were differentiated for 48-
hours no longer leads to the induction of chromosome silencing (Wutz and Jaenisch, 
2000). Since then, it has largely been accepted that XIST is only capable of inducing 
silencing in the pluripotent state (or in the hours immediately following). This has led to 
research in search of factors present in the pluripotent state that allow for XIST-
mediated silencing. While one such factor, Satb1, was proposed as a “silencing factor” 
that allows for XCI outside of the normal developmental context (Agrelo et al., 2009), 
this finding has been challenged by a study that found Satb1 and Satb2 knockout 
animals to successfully undergo XCI (Nechanitzky et al., 2012). Other studies have 
demonstrated effective induction of XCI in neoplastic somatic cell lines (Chow et al., 
2007; Hall et al., 2002a), but the human fibrosarcoma cell lines used in these studies 
likely possess a particularly malleable epigenetic state that is common in cancers 
(Jones et al., 2016). Other work has shown that certain hematopoietic precursor cells 
are also capable of initiating XCI (Savarese et al., 2006), which the authors interpreted 
as a “transient re-establishment” of competence to initiate the XCI process. The authors 
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noted, however, that the ROSA26 locus, which contained the transactivator transgene 
required for Xist transgene expression, was known to be expressed in hematopoietic 
cells. Given that transgene silencing is a common occurrence, it is possible that other 
cell types did not express Xist in this transgenic system, and thus the potential of these 
cells to initiate chromosome silencing could not be fully assessed. 
There certainly could be factors that are present at high levels in pluripotent cells 
that allow for rapid and effective XCI. However, it is possible that these factors are also 
present at lower levels in differentiated cells which may support XCI, potentially at a 
slower rate. Certain cell types may lack key players, rendering them incapable of 
initiating XCI, but proper expression and localization of XIST must be assessed before 
such conclusions can be reached (Clemson et al., 1998). Currently, the ability of normal 
differentiated human cells to initiate XCI has not been evaluated. Work in this thesis will 
directly test this key question which has relevance for basic epigenetics and 
developmental biology but is also important for the potential therapeutic applications of 
XIST or derived sequences. 
Early human brain development and in vitro modeling  
 The human brain is the most complicated and least understood organ in the 
body. The transformation of a small group of embryonic stem cells to the cognitive 
powerhouse within our skulls is an immensely complex developmental process that is 
only beginning to be unraveled. Due to the potential breadth of this topic, I will limit 
discussions here to those areas most relevant to the goals and results of the present 
thesis work. This will include discussion of the early induction of neural lineage cells in 
the embryo and the onset of neurogenesis, major differences between human and 
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mouse brain development, selected signaling pathways involved in cell fate 
specification and differentiation, postnatal brain development, and attempts at in vitro 
modeling of neurodevelopment. 
Neural lineage commitment and neurogenesis 
 Cells committed to the neural lineage in human embryos arise following 
gastrulation, when the embryo transforms from a single-layer blastula to the gastrula 
containing three germ layers: ectoderm, mesoderm, and endoderm. Ectoderm gives rise 
to both the epidermal ectoderm (i.e. skin) and neuroectoderm which gives rise to 
neurons and macroglia (astrocytes and oligodendrocytes). Derivation of neuroectoderm 
(also known as neuroepithelium) is thought to be the “default” cell fate in the absence of 
other signals, such as bone morphogenetic proteins (BMP) (Khokha et al., 2005; Stern, 
2005; Zimmerman et al., 1996). Starting at about three weeks of human development, 
neuroepithelial cells at the neural plate begin folding to form the neural tube. The hollow 
cavity inside the tube will eventually become the ventricular system of the brain, and the 
progenitors surrounding this tube form a region known as the ventricular zone (VZ) and 
will give rise to the majority of cells in the brain. By embryonic day 28, there is clear 
separation of the neural tube into three primary vesicles: the prosencephalon, 
mesencephalon, and rhombencephalon, which will give rise to the forebrain, midbrain, 
and hindbrain, respectively. 
 The neuroepithelial cells of the neural tube form a single layer of pseudostratified 
epithelium and exhibit interkinetic nuclear migration, a process whereby the cell nuclei 
undergo mitosis at the apical surface of the VZ and then migrate basally during S phase 
(Huttner and Brand, 1997). Once the neural tube is closed, neuroepithelial cells switch 
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from symmetric proliferation, which expands the neuroepithelial cell pool, to asymmetric 
divisions, which mark the start of neurogenesis. At this point, the cell cycle of the 
neuroepithelial cells is lengthened, due to a four-fold lengthening of G1 phase 
(Takahashi et al., 1995), a change that is believed to be able to trigger neurogenesis in 
and of itself (Calegari and Huttner, 2003). These neurogenic asymmetric divisions form 
two classes of cells, epithelial and non-epithelial. The non-epithelial cells, which have 
lost their attachment to the apical surface of the ventricle, can be further divided into 
non-dividing cells (i.e. neurons and glia) and dividing cells (i.e. intermediate progenitors) 
which can divide symmetrically to produce two neurons (Englund et al., 2005; Huttner 
and Brand, 1997). The epithelial cells, which retain their apical attachment site, are 
known as a specialized type of neuroepithelial cell called radial glial cells (RGCs). 
Radial glia have long been known to serve a structural function in the developing brain, 
whereby their apical processes form a scaffold to guide newly born neurons to migrate 
apically to their final destination in the cortical plate (Rakic, 1971, 1972). Additionally, 
RGCs are now known to serve a vital function as neuronal progenitors through 
successive rounds of asymmetric divisions and as astrocyte progenitors after 
neurogenesis is complete (Malatesta et al., 2000; Noctor et al., 2001). In fact, direct or 
indirect progeny of RGCs make up the majority of neurons in the brain (Anthony et al., 
2004). A summary of early cortical neurogenesis is provided in Figure I-2. 
Human-specific neocortical development 
 A longstanding question in developmental neurobiology has been the cellular 
mechanism of the greatly expanded human neocortex. Mouse studies have shown that  
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most neurons are directly born through symmetric divisions of intermediate progenitors, 
which reside in a region just basal to the VZ known as the subventricular zone (SVZ)  
(Kowalczyk et al., 2009). The SVZ region is greatly expanded in the primate cortex 
(Lukaszewicz et al., 2005), which, unlike in the mouse, can be subdivided into an inner 
and outer SVZ and, in addition to containing non-epithelial intermediate progenitors like 
the mouse SVZ, also contains radially organized epithelial-like cells (Fish et al., 2008; 
Smart et al., 2002). These cells were recently shown to be another class of RGCs 
whose numbers are greatly increased in the outer SVZ, known as outer radial glia 
(oRG) (Hansen et al., 2010). These cells have the ability to divide asymmetrically into 
another oRG cell and an intermediate progenitor (IP), in contrast to mouse RGCs which 
generally only divide symmetrically to produce two neurons (Noctor et al., 2008). This 
ability to self-renew and enlarge the progenitor pool allows for a much larger number of 
progenitors that leads to the greatly increased neuron cell number in the primate brain. 
Additionally, many of these transit-amplifying cells retain pial contacts that allow for 
proper migration of the increased number of neurons. 
 The neurogenic events covered above are best described for the birth of 
excitatory neurons in the cortex. Inhibitory neurons in the mouse are known to originate 
from the ventral portion of the telencephalon (known as the ganglionic eminences) and 
migrate dorsally to integrate with excitatory neurons born from the VZ and SVZ of the 
dorsal telencephalon in order to form functional neuronal networks (Anderson et al., 
1997). The origin of human and primate cortical interneurons has been contentiously 
debated. Ever since it was suggested that a majority of human cortical interneurons 
originate in the dorsal telencephalon, based on classical markers of interneuron  
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Figure I-2: Summary of early cortical neurogenesis 
A) Schematic of a coronal section of one anterior telencephalic hemisphere during early 
human development. Ctx, cortex; LV, lateral ventricle; LGE, lateral ganglionic eminence; 
MGE, medial ganglionic eminence. B) Schematic of cellular composition of developing 
cortex, enhancement of dashed box from (A). Radial glia form apical-basal scaffold for 
radially migrating excitatory neurons. Interneurons from the ganglionic eminences enter 
the cortex tangentially and then switch to radial migration within the dorsal cortex. CP, 
cortical plate; oSVZ, outer subventricular zone; iSVZ, inner subventricular zone; VZ, 




progenitors like DLX1/2 and Mash1 (Letinic et al., 2002), numerous studies have 
supported these findings (Petanjek et al., 2009; Yu and Zecevic, 2011; Zecevic et al., 
2011). However, more recent studies using embryonic human tissues have found that 
the purported dorsal interneuron progenitors did not incorporate BrdU, suggesting that 
they are not proliferative (Hansen et al., 2013), and that interneuron-specific 
transcription factor expression patterns in the human telencephalon could be more 
similar to mice than previously appreciated (Ma et al., 2013). These studies did suggest 
that the SVZ of the ventral telencephalon, as well as the caudal ganglionic eminence in 
humans, is greatly expanded compared to mice. Together with another study which 
found that human interneuron neurogenesis takes place over a much longer period 
extending into the third trimester of gestation (Arshad et al., 2016) this provides a 
potential explanation for the greatly increased number and diversity of interneurons in 
the human brain. The growing evidence implicating interneuron function in a range of 
psychiatric and neurodevelopmental disorders due to their vital modulatory role in 
cortical neural networks (Chattopadhyaya and Cristo, 2012; Marín, 2012) necessitates 
further study into the developmental origins of interneurons in humans. 
Notch signaling in neurodevelopment 
 Notch is one of several signaling pathways that are necessary for proper brain 
development and plays a key role in several aspects of neurodevelopment. Here, I 
provide an overview of this pathway in particular detail due to our findings in chapter II 
that unexpectedly revealed a possible role for Notch in DS neurogenesis. 
Notch is vital for maintaining a proper balance between progenitors and 
differentiated neurons and also plays a role in a number of other key steps during 
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neurodevelopment. The canonical Notch signaling pathway is composed of single-pass 
heterodimeric notch receptors and single-pass ligands in neighboring cells that bind to 
the extracellular domain of these receptors. Each component of this pathway is subject 
to extensive post-translational modifications and proteolytic events (Kovall et al., 2017). 
Ligand-receptor binding leads to intracellular cleavage of the Notch receptor by the 
presenilin/γ-secretase complex (Selkoe and Kopan, 2003), releasing the Notch 
intracellular domain (NICD) which translocates to the nucleus and acts in a complex to 
drive target gene expression. 
 Notch plays a central role in the coordination of neurogenesis. Upon neuronal 
differentiation, neuronal genes induce expression of Notch ligands, which in turn 
activate Notch receptors on adjacent cells. Notch target genes, such as Hes1 and Hes5 
then repress proneuronal genes, which maintains these adjacent cells as neural 
progenitors (Gaiano and Fishell, 2002). This system of lateral inhibition prevents all cells 
from differentiating simultaneously into neurons and promotes cellular diversity in the 
developing brain. Experimental inactivation of Hes1 and Hes5 causes premature 
differentiation and depletion of late-born neuronal subtypes (Hatakeyama et al., 2004; 
Ishibashi et al., 1995), and Notch signaling has been shown to be absolutely required 
for the maintenance of neural stem cells in both embryonic and adult brains (Imayoshi 
et al., 2010). 
An interesting question arises when considering the role of Notch signaling in the 
asymmetric divisions of progenitors such as radial glial cells, which divide into another 
progenitor and a differentiated neuron. In asymmetric divisions, the cell divides during 
periods of high proneuronal gene levels, which are cyclically regulated (Hirata et al., 
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2002). One daughter cell then inherits the basal fiber of the radial glial cell that reaches 
into the SVZ, an area of high Notch ligand activity (Miyata et al., 2004). As a result, 
Notch receptors are activated in this daughter cell leading to downstream Notch 
signaling which maintains the progenitor state, while the cell without basal fiber is 
primed to differentiate into a neuron (Lui et al., 2011). 
In addition to its important role in regulated neurogenesis, Notch has also been 
shown to be important in astrogliogenesis. Neurons and astrocytes are sequentially 
derived from common progenitors, a process regulated by increased  gliogenic signals 
in the postnatal brain (Morrow et al., 2001). While an indirect role of Notch signaling in 
maintaining the progenitor pool and allowing for later astrogliogenesis to take place has 
long been inferred, a direct role of Notch in astroglial differentiation has also been 
identified. Notch ligand expression from neuronal precursors activates Notch signaling 
in nearby radial glial cells leading to demethylation of STAT3 binding sites on the glial 
fibrillary acidic protein (GFAP) gene, leading to astroglial differentiation (Namihira et al., 
2009; Takizawa et al., 2001). This finding potentially explains the sequential 
differentiation of neurons followed by astrocytes due to the important role that neuron-
to-progenitor signaling plays in this process. 
Beyond influencing neuron and astrocyte differentiation, Notch signaling also 
plays a vital role in the maturation, morphology, and function of neurons. The first hint 
that Notch may still play an important role in differentiated neurons came from the 
finding of robust nuclear Notch expression in postmitotic neurons (Ahmad et al., 1995). 
Indeed, Notch signaling has been shown to inhibit dendritic growth (Redmond et al., 
2000) and influence axon guidance (Song and Giniger, 2011). Additionally, mice with 
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reduced levels of Notch expression, which develop normally and have grossly normal 
brain morphology, demonstrate impaired hippocampal long term potentiation (LTP) and 
exhibit learning deficits (Costa et al., 2003; Wang et al., 2004). Together, these findings 
indicate that Notch plays an important role in both the development of the proper 
balance of cell types in the brain as well as the long-term maintenance of neuronal 
circuitry.  
Postnatal brain development 
Humans are born with nearly all the neurons they will ever have and, apart from 
some interneurons that continue migrating several months after birth (Paredes et al., 
2016), neuronal migration is also complete at birth (Sidman and Rakic, 1973). However, 
there may be ongoing neurogenesis in the external granule layer of the cerebellum for 
up to a year after birth (Walton, 2012). Additionally, although debated (Sorrells et al., 
2018), recent work suggests that there may be limited ongoing neurogenesis in the 
dentate gyrus of the hippocampus throughout human life (Boldrini et al., 2018), which 
could play an important role in memory formation and has been shown to be decreased 
in patients with AD (Moreno-Jiménez et al., 2019). Beyond neurogenesis, however, 
there is enormous ongoing change that occurs to the brain from infancy through 
childhood and adolescence that allows for its development to the adult form (Figure I-3). 
These postnatal changes would be most amenable to any potential therapeutic 
approaches, including traditional pharmaceuticals or XIST-mediated chromosome 
silencing. 
As alluded to above, gliogenesis follows neurogenesis and is incomplete at birth. 
Astrogliogenesis continues postnatally (Roessmann and Gambetti, 1986) and 
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astrocytes are known to maintain proliferative capacity throughout the lifespan, 
particularly in response to injury (Burda and Sofroniew, 2014). Another type of  
macroglial cell, oligodendrocytes, which play a central role in myelination of axons in the 
central nervous system, arise after astroglia and actively myelinate axons starting in the 
second half of pregnancy through early adolescence (Barnea-Goraly et al., 2005; 
Jakovcevski and Zecevic, 2005; Miller et al., 2012).  
Both astroglia and oligodendrocytes play a critical role in neuronal development 
(Zuchero and Barres, 2015), thus it is of no surprise that maturation of neurons also 
continues long after birth. Synaptogenesis, which is the process of forming functional 
connections between neurons, is rampant after birth. This leads to an overproduction of 
synapses that peaks at about two years of age. Synapses are subsequently pruned 
away over the next few decades until a stable adult level is reached (Huttenlocher, 
1979; Petanjek et al., 2011). Similarly, the dendritic fields of neurons in the prefrontal 
cortex have been shown to grow dramatically postnatally and stabilize at about one year 
of age (Koenderink et al., 1994). These cellular events all work in harmony to develop 
the neonatal brain through childhood and beyond, including maturation of motor, 
sensory, and cognitive circuits. While some measurable cellular properties may stabilize 
with adulthood, the adult neural circuitry remains plastic, allowing for both learning and 
forgetting throughout the lifespan. 
In vitro modeling of human neurodevelopment 
 The relative inaccessibility and scarcity of accessible human fetal brain tissue 
has hindered our understanding of human brain development, especially compared to 
animal models. Early work with embryonic stem cells (ESC) began to reveal the  
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Figure I-3: Timeline of major cellular processes during human neurodevelopment 
Summary of major cellular processes and events that occur in the developing brain and 
their estimated time course. The top panel describes the time course of human 
development in post-conception weeks (pcw) and post-natal years (y). Dashed lines 
indicate time of earliest currently available non-invasive prenatal testing (NIPT) for 
diagnosis of trisomies, as well as time of birth. The lower panel outlines estimated 
timing of cellular events in the developing brain. Rounded bars indicate peak 
developmental period and dashed lines indicate minor degree of feature development. 
Relevant references for each process are provided on the right: a) (Gould et al., 1990; 
Malik et al., 2013), b) (Bystron et al., 2006; Meyer, 2007; Workman et al., 2013), c) 
(Choi and Lapham, 1978; deAzevedo et al., 2003; Kang et al., 2011), d) (Kang et al., 
2011; Yeung et al., 2014), e) (Huttenlocher, 1979; Kwan et al., 2012; Molliver et al., 
1973; Petanjek et al., 2011), f) (Miller et al., 2012; Yakovlev, 1967), g) (Huttenlocher, 
1979; Petanjek et al., 2011). This figure has been adapted from Silbereis, et al. (2016). 
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potential therapeutic applications and developmental insights that pluripotent stem cells 
have to offer. The advent of iPSC technology (Takahashi and Yamanaka, 2006; 
Takahashi et al., 2007) allowed for an infinite supply of normal and patient-derived 
pluripotent stem cells, which has greatly accelerated research into early human 
neurodevelopment and its various pathologies. While iPSCs can theoretically be 
differentiated into any cell type in the body, the utility of iPSCs to model development 
relies on robust differentiation protocols to reproducibly generate the cell type(s) of 
interest.  
 As early evidence of the utility of PSCs to model early neurodevelopment, 
studies have found that differentiating ESCs follow developmental principles. For 
example, ESC and iPSC-derived neuroepithelia form neural-tube like structures that 
mimic early neurodevelopment (Shi et al., 2012a; Zhang et al., 2001). Additionally, in 
vitro differentiation follows a similar time course to in vivo neurodevelopment (Hu et al., 
2010; Tao and Zhang, 2016). These indications of the accurate modeling of in vivo 
development using in vitro methods has encouraged insights that can carry over from 
one to the other, and vice-versa. Knowledge of patterning in the early embryo has aided 
in the development of protocols to form a wide variety of region-specific neural cell 
types (Tao and Zhang, 2016). For example, by varying the concentration of sonic 
hedgehog (SHH) or SHH agonists, iPSCs can be induced to form more dorsal or ventral 
neural progenitors, which eventually differentiate to either more excitatory or more 
inhibitory neuron types, respectively (Li et al., 2009; Liu et al., 2013; Maroof et al., 
2013). Similarly, retinoic acid has been shown to direct progenitors towards a more 
caudal fate, which, in the presence of SHH, can lead to efficient production of motor 
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neurons (Li et al., 2005). The use of individual morphogens can lead to imprecise 
patterning that can have low yields of the specific cell types of interest. This efficiency 
can be improved with precise titration of opposing morphogens, for example 
coordinated SHH and Wnt signaling in addition to retinoic acid treatment allows for 
extremely pure generation of motor neurons (Du et al., 2015). Similar patterning 
techniques can also generate region-specific astrocytes (Krencik et al., 2011), allowing 
for differentiation of a variety of region-specific neural cell types. Generation of pure 
neural subtypes holds promise both for potential cell replacement therapeutic 
opportunities as well as for a more detailed molecular characterization of specific cell 
types.  
 Generally, in vitro differentiation protocols aim to form a pure population of a 
specific neural cell type of interest. However, in vivo neurodevelopment involves many 
interacting diverse cell types, which has led to the development of co-culture techniques 
that aim to mimic these complex interactions. Various techniques have been developed, 
including embedding neural stem cells in extracellular matrix to allow for extracellular 
plaque development in a model of AD (Choi et al., 2014), co-culture of astrocytes and 
neurons on a microfluidic platform (Majumdar et al., 2011), and a tri-culture system that 
can examine migration of microglia in the context of neuron/astrocyte co-culture (Park et 
al., 2018). 
In addition to these engineered systems, other methods have capitalized on the 
self-organizing capacity of cells in vitro to form complex three-dimensional structures 
known as organoids (Eiraku et al., 2008; Lancaster et al., 2013; Mariani et al., 2015; 
Paşca et al., 2015; Qian et al., 2018). These organoid techniques vary in their degree of 
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complexity and self-organization, but all include numerous cell types including neural 
progenitors, radial glia, early- and late-born neurons, and astrocytes. Additionally, these 
systems have been used to model numerous developmental disorders, such as 
microcephaly (Lancaster et al., 2013), Zika virus infection (Qian et al., 2016), autism 
(Mariani et al., 2015), and Timothy syndrome (Birey et al., 2017). Three dimensional 
culture provides a more natural developmental tissue context, but also allows for 
analysis of spatial events, such as the orientation of progenitor cell division relative to 
the ventricular plane, as was shown to be skewed towards perpendicular symmetric 
divisions in a model of microcephaly (Lancaster et al., 2013). While most protocols are 
currently limited to cells from the ectodermal lineage, from which the majority of the 
brain parenchyma is derived, others have also included mesodermal precursors 
(Quadrato et al., 2017), functional microglia (Ormel et al., 2018), and endothelial cells 
that form primitive vascular networks (Pham et al., 2018). These recent advances have 
allowed for visualization and dissection of embryonic human brain development in vitro 
in a complex three-dimensional environment that includes a variety of cell types 
involved in this intricate process. 
 Of course, even contemporary organoid protocols still fall far short of modeling 
the full complexity of human brain development. While organoids demonstrate a 
capacity for self-organization at the level of neural-tube like structures, they lack 
organization at a macroscopic level. Protocols have been developed to generate 
organoids that model differentiation of individual brain regions (Qian et al., 2016), and 
other labs have even gone as far as merging together dorsal and ventral patterned 
organoids in order to model interneuron migration (Bagley et al., 2017; Birey et al., 
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2017). Yet, there is still a long way to go towards modeling development of the human 
CNS. Currently, one must choose between directed protocols, which utilize high 
degrees of patterning, and less directed methods. Directed methods can accurately 
model a specific brain region but lack some of the cell diversity and tissue complexity of 
less directed methods which, on the other hand, tend to have a much higher degree of 
organoid-to-organoid variability (Kelava and Lancaster, 2016). Reproducibility is an 
important limitation of current neural differentiation protocols (Young-Pearse and 
Morrow, 2016), and while some groups claim to have consistent organoid differentiation 
protocols (Yoon et al., 2019), there is still considerable room for improvement. 
In addition to variability between differentiations, iPSC modeling in general is 
affected by genetic variability between individuals, variability between cell lines from the 
same individual, and variability of a cell clone over time (Koyanagi-Aoi et al., 2013; 
Liang and Zhang, 2013; Soldner and Jaenisch, 2012; Young-Pearse and Morrow, 
2016), although some of these limitations can be minimized by improved differentiation 
protocols, iPSC culturing techniques, and quality control measures. Additionally, recent 
advances in genome engineering have made production of isogenic control lines from 
mutant cells and insertion of specific mutations into control lines easier than ever. 
Finally, while current iPSC differentiation protocols closely mimic very early in vivo 
neurodevelopment, their ability to model neurodegenerative diseases is complicated by 
their fetal phenotype and transcriptomic profile (Abeliovich and Doege, 2009). Overall, 
human pluripotent stem cells, particularly iPSCs, have provided insight into a previously 
inaccessible tissue and, despite their limitations, have potential to drastically change our 
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approach towards studying neurodevelopment and treating neurodevelopmental 
diseases. 
The neurobiology of Down syndrome 
 Over 90 years after John Langdon Down described the features of the disorder 
that would come to bear his name (Down, 1867), Marthe Gauthier, Jérôme Lejeune, 
and Raymond Turpin (1959) discovered what is likely the first known cause of a genetic 
disorder: an extra copy of chromosome 21 in individuals with DS. In general, despite the 
hundreds of extra genes that these individuals have in three copies instead of the usual 
two, most lead happy and relatively healthy lives. Still, DS individuals suffer from a 
number of medical problems, and the specific genetic etiology of these various 
symptoms remains poorly understood. Apart from the APP gene which has been 
strongly linked to the development of Alzheimer’s disease in DS, no single genes have 
been linked to other DS phenotypes. In addition to single dosage-sensitive genes 
causing specific phenotypes, it is also possible that the presence of an entire extra 
chromosome, along with the associated transcriptional, translational, and proteomic 
burden, may be responsible for some DS phenotypes. In fact, studies in yeast and mice 
have shown that aneuploidy in general causes cellular stress, which may impact several 
cellular phenotypes such as metabolism and proliferation (Bonney et al., 2015; 
Oromendia et al., 2012; Williams et al., 2008). Importantly, the physical presence of an 
extra chromosome is known to not cause symptoms on its own, as demonstrated by 
trisomy X patients. 
Despite the unknown etiology of many DS symptoms, advances in prenatal 
testing now allow for the diagnosis of DS and other trisomies as early as 8 weeks of 
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gestation, meaning that newborns with DS are more likely to receive treatments for their 
specific needs, particularly for serious congenital heart defects that affect nearly half of 
DS individuals (Freeman et al., 1998). Children with DS are at an increased risk for 
several types of leukemia such as acute megakaryoblastic leukemia (AMKL), which is 
500 times more common in DS than in the general population (Zipursky et al., 1992). 
DS individuals are also prone to other endocrine, gastrointestinal, metabolic, and 
morphological abnormalities (Roizen and Patterson, 2003). Interestingly, DS individuals 
are less likely than the general population to develop solid tumors (Hasle et al., 2016; 
Satgé et al., 1998), a phenomenon which is not well understood but may relate to 
impaired angiogenesis (Baek et al., 2009). The most prevalent and perhaps least 
understood feature of DS, and one for which no effective treatments exist, is intellectual 
disability (ID). 
Intellectual disability in DS individuals and its neurological correlates 
 Individuals with DS exhibit a range of cognitive abilities, with IQs ranging from 30 
to 70 and averaging 50 (Chapman and Hesketh, 2000), which corresponds to mild or 
moderate ID. Learning delays are present from birth, and accelerate at ages 2-4. 
Communication skills are often particularly impaired from as early as two years of age 
(Dykens and Kasari, 1997) and include nonverbal communication (Mundy et al., 1995), 
suggesting that the language delay seen in older children with DS may not be limited to 
speech production difficulties. While there is no delay in the onset of babbling compared 
to typically developing children (Smith and Oller, 1981), DS children show a delay in first 
word acquisition and delayed use of multi-word phrases (Levy and Eilam, 2013). In 
contrast with language production, comprehension is relatively spared particularly with 
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regard to vocabulary (Rosin et al., 1988). Beyond communication, children with DS also 
have deficits in attention that persist in adulthood (Rowe et al., 2006), as well as deficits 
in working memory, again with particular impairment of verbal compared to visuospatial 
aspects of working memory (Jarrold and Baddeley, 1997; Yang et al., 2014). Explicit 
long-term memory is also severely impaired in DS individuals, even when compared 
with individuals with ID of another etiology, and this is thought to stem from deficits in 
both encoding and retrieval abilities (Carlesimo et al., 1997). Additionally, children with 
DS have a much higher incidence of comorbidities such as autism spectrum disorder 
(ASD) and attention-deficit-hyperactivity disorder (ADHD) compared to typically 
developing children (DiGuiseppi et al., 2010; Godfrey et al., 2019).  
 Given how common DS is, it is remarkable that precise neurobiological correlates 
of the cognitive deficits are so poorly understood and remain to be identified. However, 
there are several brain anomalies at both the macrostructural and cellular levels that 
have been reported. On average, individuals with DS have mild overall microcephaly, a 
difference which appears as early as mid-gestation and persists through adulthood, with 
disproportionately small frontal and temporal lobes (Guihard-Costa et al., 2006; 
Schmidt-Sidor et al., 1990). The hippocampus, which is vital for certain explicit memory 
tasks that are impaired in DS individuals, is smaller in the DS population and its size is 
negatively correlated with general intelligence and mastery of linguistic concepts (Raz et 
al., 1995). The cerebellum is also disproportionately small (Guihard-Costa et al., 2006), 
which could be associated with the hypotonia, motor dysfunction, and perceptual-motor 
coordination seen in DS individuals (Charlton et al., 2000; Savelsbergh et al., 2000), but 
may also impact a wide variety of cognitive abilities (Stoodley, 2016).  
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 At the cellular level, DS fetuses have been reported to have decreased neuron 
numbers in the hippocampus, neocortex, and cerebellum, with some studies finding 
differences as drastic as a 34% reduction in total cell number (Guidi et al., 2008, 2011; 
Larsen et al., 2008). Other studies have shown decreased cell proliferation in the 
hippocampus of mid-gestation DS fetuses (Contestabile et al., 2007), which may be 
responsible for the decreased neuron numbers. There have also been reports that 
decreased neuron numbers are specific to small, presumably inhibitory, granular 
neurons of the neocortex (Ross et al., 1984). In addition to decreased neuron numbers, 
the dendritic processes of DS neurons in the cortex and hippocampus have decreased 
branching and dendritic spine numbers (Becker et al., 1986; Ferrer and Gullotta, 1990; 
Suetsugu and Mehraein, 1980). Interestingly, unlike the decreased neuron numbers that 
were seen in fetal DS brains, dendritic morphology and spine numbers were considered 
normal at the fetal stage and only started showing pathological features in early 
childhood (Becker et al., 1986; Takashima et al., 1981; Vuksić et al., 2002). In addition 
to reduced dendritic spine numbers, the morphology of dendritic spines has also been 
reported to be altered in children with DS, showing both unusually long and unusually 
short spines (Marin-Padilla, 1976), which may reflect impaired spine maturation. A 
spine-related protein, drebrin, was reported to be consistently decreased in DS cortical 
tissue (Shim and Lubec, 2002). 
 Apart from neurons, DS brains may also show alterations in astrocyte and 
oligodendrocyte populations. While some studies have shown no change in absolute 
astrocyte number in DS brains in the context of decreased neuron numbers (and thus 
an increased percentage of astrocytes) (Guidi et al., 2008), others have reported 
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increased absolute non-reactive astrocyte number in DS fetal brains and increased 
reactive astrocytes in adult DS brains (Mito and Becker, 1993; Zdaniuk et al., 2011). 
However, increased astrogliosis in adult DS brains may also be related to the 
development of AD pathology (Griffin et al., 1989; Jørgensen et al., 1990), as will be 
discussed in a later section. Myelination by oligodendrocytes has also been reported to 
be impaired in DS brains, with both histological and transcriptional markers of delayed 
myelination in the frontal and temporal lobes as well as the hippocampus (Ábrahám et 
al., 2012; Olmos-Serrano et al., 2016; Wisniewski, 1990; Wisniewski and Schmidt-Sidor, 
1989). 
Overall, there have been numerous reported macro and microstructural 
alterations in the brains of individuals with DS involving many cell types and brain 
regions. However, analysis of human brains is limited by small sample sizes and 
differences in age, pathological status, and sample preparation. While some histological 
findings may correlate with clinical phenotypes, there are few direct links between 
precise morphological changes and behavioral or cognitive findings in individuals. 
Studies in DS mouse models have worked towards making such connections. 
Mouse models of DS neurobiology 
 Unlike the human genome, which is comprised of 23 pairs of chromosomes, the 
mouse genome contains only 20 pairs. This of course means that the syntenic regions 
of human chr21 are not all neatly arranged on one mouse chromosome. Instead, the 
syntenic genes are spread across three mouse chromosomes, with the majority residing 
on mouse chromosome 16 (Mmu16) and the rest on Mmu17 and Mmu10. Clearly, this 
complicates the creation of an accurate mouse model of DS. Despite these difficulties, 
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numerous mouse models have been generated. The best studied mouse model of DS 
contains a freely segregating marker chromosome that contains the centromere of 
Mmu17 and the distal segment of Mmu16 (Reeves et al., 1995). This model, named 
Ts65Dn, contains 125 genes syntenic to Hsa21, but also contains 35 protein-coding 
genes syntenic to Hsa6 (Gupta et al., 2016). Other models have improved on this by 
eliminating Mmu16 genes not syntenic to Hsa21 (Li et al., 2007) and including Hsa21 
syntenic genes from other mouse chromosomes (Yu et al., 2010). A different approach 
led to the creation of a mosaic mouse model in which some cells contain a single copy 
of human chromosome 21 (O’Doherty et al., 2005). While this model has substantial 
utility for studying the overexpression of human chr21 genes in the mouse, subsequent 
analysis has identified significant duplications and deletions within this chromosome, 
including for the important APP gene (Gribble et al., 2013). Many of these models 
present with wide-ranging phenotypes, some of which may correlate with defects seen 
in DS individuals, and others that may be model-specific. For example, a recent 
transcriptome study found little overlap in differentially expressed genes between three 
widely used mouse models of DS (Aziz et al., 2018).  
 In agreement with the previously described findings of decreased neuron number 
and cellular proliferation in DS brains, several mouse models show decreased numbers 
of radial glia in the cerebral cortex and hippocampus, including the dentate gyrus 
(Chakrabarti et al., 2007; Contestabile et al., 2007; Ishihara et al., 2010). These findings 
may be responsible for altered hippocampus-dependent learning and memory tasks 
(Belichenko et al., 2009, 2007; Reeves et al., 1995) and potentially broader cognitive 
impairment as well, such as in the novel object recognition task (Belichenko et al., 2009; 
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Fernandez et al., 2007). Also in line with findings in DS, several mouse models have 
significantly decreased cerebellar size and cell density, particularly in the granule cell 
layer (Baxter et al., 2000; Olson et al., 2004). Interestingly, evidence indicates that this 
is caused by a defective response to SHH signaling (Roper et al., 2006), and can be 
totally prevented in the Ts65Dn mouse by a single injection of SHH agonist at birth (Das 
et al., 2013). DS mouse models also exhibit altered dendritic spine morphology, 
potentially consistent with alterations seen in DS individuals. Specifically, projection 
neurons in Ts65Dn mice have reduced spine numbers and shorter dendrites (Dierssen 
et al., 2003). This is also true for pyramidal neurons in the hippocampus of several, but 
not all mouse models (Belichenko et al., 2009, 2004, 2007). 
 While several findings in mouse models are consistent with DS pathology, there 
are also findings in certain mouse models that conflict with the human condition and/or 
with other mouse models. For example, the Ts65Dn mouse has the well-described 
phenotype of increased GABAergic neuron number along with decreased excitatory 
neuron number leading to an over-inhibited state that impairs LTP in the hippocampus 
and can be ameliorated with GABA receptor antagonists (Belichenko et al., 2004; 
Fernandez et al., 2007; Kleschevnikov et al., 2004; Pérez-Cremades et al., 2010). The 
increase in GABAergic interneurons has been reported to be corrected by normalization 
of the gene dosage of Olig1 and Olig2 (Chakrabarti et al., 2010). However, a more 
genetically accurate mouse model of DS that does not include extra copies of non-chr21 
syntenic genes has the opposite finding, with a decrease in the number of interneurons 
(Goodliffe et al., 2016). This result is more in line with findings in human cells, as will be 
discussed in the next section. 
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Overall, mouse models of DS can provide a useful system for unveiling the 
effects of trisomy on early brain development, a process that is difficult to study in 
human samples. However, caution must be exercised in translating findings from 
imperfect mouse models to the human condition. The failure of a recent DS clinical trial 
of the GABAergic inverse agonist RG1662, despite promising pre-clinical results, has 
many potential explanations. However, a lack of shared genetic defect and physiology 
between mouse models and individuals must be taken into consideration as a possible 
cause. 
Human cellular models of DS neurobiology 
 Despite not having the in vivo relevance of mouse models, human cellular 
models of DS have the advantage of fully recapitulating the root cause of the syndrome, 
namely trisomy for chr21 in human cells. Neuro-cellular models come in two broad 
categories, ES or iPS-derived neural cells and primary fetal neural stem cells. Despite 
the difficulty in obtaining fetal brain tissue samples, several studies have examined the 
proliferative and differentiation capacity of primary neural progenitor cells from DS 
fetuses. Three such studies have found decreased neurogenesis in DS samples 
compared to controls (Bahn et al., 2002; Bhattacharyya et al., 2009; Esposito et al., 
2008). One of these studies described a critical window in neurogenesis whereby early 
passages of NSCs led to an equivalent degree of neurogenesis in DS and control 
samples, but later passages had decreased neurogenesis in the DS samples ,which 
was ascribed to a defect in interneuron formation (Bhattacharyya et al., 2009). In 
addition to a defect in neurogenesis, another study found upregulation of glial progenitor 
markers in DS samples (Esposito et al., 2008), while a third study found no such 
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differences in glial cell proportions (Bahn et al., 2002). These discrepancies could arise 
from differences in source tissue, gestational age, the anatomic location from which the 
cells were derived, and in vitro culturing conditions. 
 Circumventing these difficulties and allowing for an infinite number of cells 
available for experimental perturbation, advances in ES and iPS neuron differentiation 
protocols have led to many published reports investigating the effects of DS on specific 
neural subtypes. Several studies that have used “default pathway” neuron differentiation 
to generate mostly excitatory forebrain neurons have seen no difference in the 
propensity to form neurons when comparing DS to control cell lines (Gonzales et al., 
2018; Shi et al., 2012b; Weick et al., 2013), while one study did report decreased 
neurogenesis in DS cells (Lu et al., 2013). Additionally, while one report found no 
difference in either the number of synaptic punctae or the magnitude of synaptic 
currents (Shi et al., 2012b), another found both decreased synaptic punctae and 
decreased spontaneous postsynaptic currents (Weick et al., 2013), potentially due to 
the formation of more mature neural networks that also included GABAergic neurons. 
Differences in cell culture methodologies can also have significant impact on findings, 
as evidenced by the identification of shortened neurite length in DS cell lines grown for 
120 days (Ovchinnikov et al., 2018), but no such finding in the same cell lines grown for 
only 60 days (Briggs et al., 2013). Other studies have focused on specific neuron 
subtypes that are suspected of being pathological in DS. For example, one study found 
defective in vitro and in vivo migratory capacity of DS GABAergic interneurons as well 
as a change in the proportions of interneuron subtypes generated (Huo et al., 2018). 
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 In addition to potential deficits in stem cell derived neurons, in vitro studies have 
also investigated the astrogliogenic potential of DS cells. As described in a previous 
section, neural precursor cells undergo a gliogenic switch after most of neurogenesis is 
complete. Using primary neural stem cells from DS fetuses, it was reported that DS 
cells undergo a gliocentric shift that leads to increase glial cell production at the cost of 
neuronal production (Lu et al., 2011). Others have replicated this finding in iPSCs and 
have suggested that DS astroglia, potentially due to the extra copy of the chr21 gene, 
S100B, could negatively affect surrounding neurons through a secretory mechanism 
(Briggs et al., 2013; Chen et al., 2014). Other reports, in some cases using the same 
cell lines, have not seen a difference in astroglia production (Bahn et al., 2002; 
Ovchinnikov et al., 2018), suggesting that this finding may again be highly dependent on 
protocol specifics. The field of iPSC disease modeling has made significant progress 
over the course of its short existence. However, several technical and biological 
challenges, including difficult differentiation procedures and many poorly defined 
sources of variability, present significant obstacles towards accurate and reproducible 
disease modeling. 
Alzheimer’s disease in Down syndrome 
 The discussion above has focused on the neurodevelopmental aspects of DS, 
yet as mentioned in the first section of this introduction, AD pathology is a nearly-
universal finding in DS individuals. It is also perhaps the only DS neurological 
phenotype that has been unequivocally linked to a specific gene on chr21, APP. There 
are several interesting cases that solidify the role of APP in AD-DS, and which have led 
to the development of the amyloid hypothesis, a leading theory in non-DS AD. Notably, 
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several studies have identified multiple families with familial early-onset AD caused by 
duplications involving the APP gene (Cabrejo et al., 2006; Kasuga et al., 2009; Rovelet-
Lecrux et al., 2006, 2007; Sleegers et al., 2006), which, along with other lines of 
evidence, have solidified the role of APP in AD and, crucially, the importance of APP 
gene dosage in early-onset AD in DS. Additionally, two case studies of older DS 
individuals without any evidence of AD and only two copies of APP (due to partial 
trisomy for chromosome 21) further support the evidence that this single gene is 
sufficient for the AD phenotype in DS (Doran et al., 2017; Prasher et al., 1998). The 
evidence is clear that APP plays a central role in AD-DS pathogenesis, yet despite the 
near-universal prevalence of AD neuropathology in DS individuals above age 30, only 
~80% of these individuals develop dementia (Mann and Esiri, 1989; Wisniewski et al., 
1985a; Zigman et al., 1996). This raises the possibility that there may potentially be 
moderating factors on chr21 (Wiseman et al., 2015) in addition to well-known mitigators 
in the rest of the genome, like the APOE allele ɛ2 (Corder et al., 1994). 
 AD dementia in DS has both similarities and unique features when compared to 
the general AD population. Particular impairment of recent memory with sparing of 
distant memory and confusion are present in both populations, while impairments 
generally associated with frontal lobe degeneration, such as apathy, depression, and 
communication decline, are present at an earlier stage of disease in the DS population 
(Deb et al., 2007). There is evidence that this discrepancy may arise from pre-existing 
frontal cortex hypoplasia in DS individuals (Holland et al., 1998, 2000; Rowe et al., 
2006), which highlights the difficulty in assessing cognitive decline related to dementia 
in a population with pre-existing ID.  
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 Many of the pathological changes seen in AD-DS brains mimic those seen in AD, 
including the pathognomonic Aβ42-containing extracellular plaques and 
hyperphosphorylated tau intracellular tangles (Goedert et al., 1992; Wisniewski et al., 
1994). These lesions are present in many brain regions, and their number, particularly 
that of tau tangles, is correlated with the severity of dementia (Ropper and Williams, 
1980; Wisniewski et al., 1985b). Notably, there is a degeneration of basal forebrain 
cholinergic neurons (BFCNs) in both AD-DS and AD individuals which is not present at 
birth in DS (Godridge et al., 1987; Kish et al., 1989), emphasizing the distinction 
between developmental defects caused by DS and neurodegeneration related to AD.  
 While mouse models of DS do not exhibit the classical lesions of plaques or 
tangles (Reeves et al., 1995), there is marked degeneration of BFCNs beginning from 6 
months of age (Granholm et al., 2000; Holtzman et al., 1996), modeling the human 
syndrome. Human cellular models of AD-DS have also been developed, and have 
demonstrated both increased secretion of Aβ peptides in DS neural cultures as well as 
the reliance of this increase on trisomic APP gene dosage (Ovchinnikov et al., 2018; Shi 
et al., 2012b). Additionally, 3D human cellular models of AD have also managed to 
produce amyloid aggregates as well as tau inclusions, albeit in cells greatly 
overexpressing multiple mutant proteins (Choi et al., 2014; Raja et al., 2016). These 
systems provide useful models for drug testing in human neural cells and allow for 
modeling of early AD pathogenesis. 
 The pathology of AD in DS has been well described and its root cause in the 
APP gene is generally accepted. However, several recent clinical trials aimed at 
removing amyloid aggregation from AD patient brains have not succeeded in preventing 
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cognitive decline (Doody et al., 2014; Salloway et al., 2014). This suggests that either a 
new strategy must be undertaken and/or patients must be identified and started on 
treatment early in the disease course before symptoms arise (Mullard, 2016). To this 
end, DS individuals present a unique patient population at a high risk of developing AD 
that can be identified long before any symptom onset. Additionally, the AD aspect of DS 
is one that offers a much larger therapeutic window for intervention, particularly when 
compared to early neurodevelopmental defects, both for conventional therapeutics and 
potentially for gene/chromosomal therapy approaches. 
 Finally, it is interesting to note that the biological roles of APP are poorly 
understood, as much research has focused on its complex processing and role in AD. 
Since we and others find that APP is highly expressed in human iPSCs and throughout 
neurodevelopment, it is intriguing to consider that this dosage-sensitive gene could also 
play a role in neurodevelopment, and its potential impact in DS (van der Kant and 
Goldstein, 2015). While not detailed in this thesis, I have been involved in other ongoing 
work by others in the Lawrence lab examining the role of APP dosage in DS cells, 
including its impact on Ab pathology and initial studies on neurogenesis and organoid 
formation.  
Using dosage compensation to advance translational research in 
Down syndrome 
 Therapeutic approaches generally involve gaining a thorough understanding of 
disease mechanism through the use of cellular and/or animal models, followed by drug 
discovery aimed at modulating the disrupted pathways. This is a long and arduous 
process for even the simplest of genetic disorders, i.e. those known to be caused by 
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mutations in a single gene. While DS has the advantage of a well-established root 
cause, understanding the disease mechanism is complicated by the hundreds of 
potentially causative dosage sensitive genes on chr21. Thus, just like modern gene 
therapy aims to bypass the difficult task of gaining a complete understanding of disease 
pathogenesis by correcting the causative mutation, our lab has pioneered a strategy to 
harness the natural mechanism of dosage compensation to correct the root cause of DS 
in a cellular model. This provides an advantageous experimental approach to 
manipulate chr21 gene expression dosage in an otherwise identical population of cells. 
In addition, this innovative strategy may one day also provide the basis for a therapeutic 
approach to trisomy. 
 We demonstrated that targeted insertion of an XIST transgene into an intronic 
DYRK1A locus on one copy of chr21 is capable of robust chromosome-wide dosage 
correction of chr21 transcription in DS patient-derived iPSCs (Jiang et al., 2013). This 
provided strong evidence for robust chromosome-wide silencing of a human autosome 
by a targeted XIST transgene. In addition, this created a needed model to study the 
basic biology of human XIST. As an inducible non-lethal autosomal silencing system 
this can be utilized to study the timing and kinetics of the human chromosome silencing 
process. It can also be used to reveal any defects in the development of a wide variety 
of cell types derived from DS iPSCs by directly linking a given phenotype to the 
expression status of chr21. While this system has not yet been used for in-depth study 
of neurogenesis, our lab has provided initial evidence for an effect on the kinetics of 
neural rosette formation (Jiang et al., 2013). Additionally, we have demonstrated that 
transcriptional silencing of one chr21 beginning in iPSCs prevents development of the 
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hyperproliferative phenotype during hematopoietic differentiation in vitro (Chiang et al., 
2018). Despite this exciting progress, several questions in both the XIST and DS fields 
remain unanswered. 
 In order to have any potential as a therapeutic for any aspect of the syndrome, 
XIST must be able to initiate silencing in differentiated cells as DS can currently be 
diagnosed only as early as 8 gestational weeks (Bianchi et al., 2012). Early XIST 
literature suggests that the cell’s capacity to initiate silencing is no longer present 48 
hours after inducing ESC differentiation, which is many weeks before the diagnosis of 
DS is even known. Evidence from mouse and human carcinoma cell lines suggested 
that this initiation window might not be as narrow as previously described (Hall et al., 
2002a; Savarese et al., 2006), encouraging the studies in chapter II which examine the 
ability of normal differentiated human cells (iPSC-derived NSCs and neurons) to initiate 
chromosome silencing.  
 As described in the previous section, the cellular mechanisms behind ID in DS 
are still poorly understood, and many findings from in vitro models are contradictory. We 
believe that our isogenic and isoepigenetic cellular system, where the same cells in 
either the trisomic or disomic state can be studied in parallel, provides a uniquely 
powerful method for discerning the effects of trisomy on neurodevelopment. In the latter 
half of chapter II, I will utilize the chromosome silencing system to study the effects of 
trisomy on early neurogenesis. In chapter III, I will apply modern three-dimensional cell 
culture techniques to gain an understanding of the effects of trisomy 21 on early 
neurodevelopment. While we had initially hoped to combine organoid models with our 
dosage compensation system, difficulties with transgene expression, as discussed in 
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the appendix, led us to focus our exploration of organoid models to isogenic 
comparisons of trisomic and disomic lines, which is the current standard in the field. 
Ultimately, this thesis aims to provide insight into the biology of dosage compensation 
and early DS neurodevelopment in order to advance translational research for DS, 
including the prospect of chromosome therapy (further considered in chapter V) and to 
one day improve the lives of patients with chromosomal abnormalities. 
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CHAPTER II : Silencing trisomy 21 with XIST in neural stem 
cells promotes neuronal differentiation 
 
Preface 
 I performed all of the experiments described in this chapter, as well as all of the 
analysis, with helpful suggestions from Dr. Oliver King. This chapter was written by me 
and revised by me and Dr. Jeanne Lawrence. This work was submitted for publication 
and is currently in revision. 
 
Jan T. Czerminski and Jeanne B. Lawrence. Silencing Trisomy 21 with XIST in 
Neural Stem Cells Promotes Neuronal Differentiation. (2019) 
 
Introduction 
Chromosomal abnormalities are surprisingly common – detected in about 0.6% 
of newborns (Shaffer and Lupski, 2000) – yet because they involve a dosage imbalance 
for many genes, this major component of the human genetic disease burden has 
remained largely outside the hopeful advances in genetics research. Research into the 
most common chromosomal disorder, Down Syndrome (DS), has received more 
attention in recent years, with most studies attempting to identify chromosome 21 genes 
that cause specific phenotypic features which involve various physiological systems. It 
has been difficult to establish which cell-types and pathways are impacted in Down 
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syndrome, hence better experimental strategies to determine how trisomy 21 impacts 
cell function and development are needed. As with any developmental disorder, it is 
particularly challenging to determine when a deficit arises, and when in development it 
may remain correctible. Here, we further develop and apply an approach using 
epigenetics to advance translational research for chromosomal imbalances.  
Previously, our lab demonstrated that a natural epigenetic phenomenon could be 
harnessed to repress gene expression across one chromosome 21 in trisomic DS 
patient-derived iPS cells by targeted insertion of a single gene, XIST (Jiang et al., 
2013). XIST is a long non-coding RNA that functions in cis to silence one X 
chromosome in female cells and dosage compensate X-linked genes between female 
(XX) and male (XY) cells. The expression and accumulation of XIST transcripts across 
the nuclear chromosome territory is essential to initiate chromosome silencing (Brown et 
al., 1992; Clemson et al., 1996; Lee and Jaenisch, 1997; Penny et al., 1996). Although 
there are differences between mouse and human X-inactivation, in both organisms 
XIST RNA initiates random X-chromosome silencing in pluripotent cells of the inner cell 
mass (van den Berg et al., 2009; Payer and Lee, 2008; Petropoulos et al., 2016b; 
Sahakyan et al., 2018). Given that epigenetic changes are especially rapid and 
widespread as naïve cells begin to form facultative heterochromatin, it is logical that this 
developmental context is optimal for XIST function. The chromosome silencing process 
requires not only XIST RNA, but multiple responses of the cell to this RNA, hence it is of 
fundamental interest to understand whether the epigenetic plasticity of cells in this 
special developmental window is required for XIST RNA to enact chromatin 
modifications which stably repress chromosome-wide transcription.  
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Based on prior studies in mouse ESCs, the initiation of XIST-mediated 
chromosome silencing has long been thought to be stringently limited to within 48-hours 
of ESC differentiation (Wutz and Jaenisch, 2000). Cells of a fibrosarcoma tumor line 
showed partial chromosome silencing, although this potentially reflects a more 
malleable epigenetic state in cancer cells (Chow et al., 2007; Hall et al., 2002a). 
Savarese et al. (2006) studied Xist transgenic mice in which chromosome silencing 
would create cell lethality and concluded that some mouse hematopoietic cell types 
were unusual in that they “transiently reestablish permissiveness for X inactivation”. 
However, the authors mentioned that hematopoietic cells were known to avoid 
transgene silencing of the transactivator required for Xist expression in their doxycycline 
(dox) inducible system. Therefore, the silencing potential in other tissues in which Xist 
RNA might not have been expressed could not be assessed. Other studies suggest a 
role of SATB1 in the “pluripotency machinery” that supports chromosome silencing in 
mouse ES cells (Agrelo et al., 2009; Nechanitzky et al., 2012), but to our knowledge the 
capacity of normal human differentiated cells to respond to human XIST RNA has not 
been directly investigated.      
  The extent to which cells retain epigenetic plasticity beyond pluripotency is of 
fundamental interest for developmental biology, but whether or not XIST can induce 
chromosome silencing in later-stage somatic cells is also critical to the broader 
translational potential of this remarkable RNA. For this reason, the first priority of this 
study was to address this pivotal question, which we did using an inducible XIST 
transgene on one chromosome 21 in DS patient derived iPS cells, undergoing neural 
differentiation in vitro. Recently we demonstrated that XIST expression from one 
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chromosome 21, begun in pluripotent cells prior to differentiation, prevents development 
of well-known DS hematopoietic cell pathologies in vitro (Chiang et al., 2018). While this 
study did not attempt to induce post-differentiation chromosome silencing, the results 
support inducible chromosome silencing as a valid way to identify differences between 
trisomic and functionally euploid cells.  
Unlike the well-established effects of trisomy 21 on hematopoietic cells, specific 
cell pathologies that underlie other clinical phenotypes, including cognitive disabilities, 
remain unclear (Haydar and Reeves, 2012; Mégarbané et al., 2009; Roper and Reeves, 
2006). Some studies indicate trisomy 21 impacts post-natal neurodevelopment, such as 
myelination (Olmos-Serrano et al., 2016) or cerebellar growth (Das et al., 2013), and it 
is now recognized that there is often progressive cognitive decline in DS adults, as well 
as nearly-ubiquitous early-onset Alzheimer Disease. Importantly, variable results have 
been reported regarding the impact of trisomy 21 on early in vitro neural differentiation 
(Bhattacharyya et al., 2009; Briggs et al., 2013; Gonzales et al., 2018; Jiang et al., 
2013; Lu et al., 2013; Shi et al., 2012b; Weick et al., 2013), with most studies reporting 
no difference in the ability of DS stem cells to form neurons. However, studies have 
mostly compared the differentiation capacity of separate iPS lines, which may be limited 
by the fact that even iPSC lines from the same individual can demonstrate 
transcriptional heterogeneity (Liang and Zhang, 2013; Soldner and Jaenisch, 2012) and 
can show differences in their capacity for neural differentiation (Koyanagi-Aoi et al., 
2013).  
 Here, we first set out to test whether XIST can induce chromosomal silencing in 
differentiated neural cells, which led us to examine kinetic differences in the epigenetic 
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steps of chromosome silencing in differentiated cells. Our second major goal was to 
utilize this tightly controlled inducible chromosomal silencing system to compare the 
trisomic and disomic states without variability between cell lines or samples, to 
investigate the effects of trisomic chromosome 21 expression on in vitro DS 
neurodevelopment. 
Results 
The panel of isogenic DS iPSCs studied includes multiple transgenic clones 
carrying a dox-inducible XIST cDNA on one chromosome 21 (Figure II-1A), which were 
created and characterized as previously described (Jiang et al., 2013; and Methods). 
Since prior analysis of chromosome 21 transcriptional repression was only done in 
undifferentiated pluripotent cells (Jiang et al., 2013), we first determined the extent of 
gene silencing in cells induced to express XIST RNA beginning in pluripotency just prior 
to inducing neural differentiation, the natural developmental context for optimal XIST 
RNA function. If XIST can produce neural cells with robust dosage compensation for 
chromosome 21, this itself would be valuable to investigate potential effects of trisomy 
21 on neurogenesis. However, it would be even more advantageous if trisomy could be 
dosage corrected at later steps in cell development, which we tested by inducing XIST 
RNA later during in vitro neural differentiation.  
XIST RNA induces heterochromatin hallmarks in differentiated somatic cells  
To test whether XIST-mediated silencing is possible in differentiated cells, DS-
patient derived iPSCs were differentiated using established protocols which mirror  
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cortical neurogenesis (Cao et al., 2017; Chambers et al., 2009), with dox added to 
induce XIST RNA expression at different time points. These experiments used a 28-day 
neural differentiation time-course, with dox introduced at either day 0, 14, or 21 (Figure 
II-1B). By day 14 no OCT4+ cells are detected, while nearly all cells were SOX1+ and 
SOX2+, indicating efficient neural differentiation with no remaining pluripotent cells 
(Figure II-1C). By day 28 the cells are a mixture of SOX2+ neural stem cells (NSC) and 
TUBB3+ post-mitotic neurons (Figure II-1D). 
 XIST RNA functions by triggering multiple repressive chromatin modifications 
that contribute to the silent state, such as polycomb protein repressive complexes PRC1 
and PRC2, which induce canonical heterochromatin hallmarks H2AK119ub1 and 
H3K27me3, respectively (Cao et al., 2002; Fang et al., 2004; de Napoles et al., 2004; 
Plath et al., 2003). Cells with XIST induced from day 0 showed well-localized XIST RNA 
paints associated consistently with these two major repressive histone modifications 
(Figure II-2A, II-2B, and II-2D). This indicated that inducing XIST just before 
differentiation could produce differentiated DS neural cells with one chromosome 21 
silenced. In parallel samples we investigated whether XIST could trigger these 
heterochromatin hallmarks if induced at day 14 or 21 of differentiation, well outside the 
window of pluripotency. Most cells from each day of dox initiation accumulated 
characteristic XIST RNA paints, indicating proper localization to the nuclear 
chromosome territory. At later time points of differentiation there is some reduction in 
the proportion of cells in which dox can induce XIST transcription (Figure II-2C), likely 
reflecting transgene silencing, as commonly seen for the dox-inducible system during 
differentiation (Gödecke et al., 2017). Importantly, over 90% of XIST+ cells in samples  
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Figure II-1: Experimental design and neural differentiation of DS iPSCs 
 
A) Schematic of XIST-mediated chromosome 21 silencing system. B) Outline of neural 
differentiation protocol. Dox initiation days marked by red arrows. Analysis timepoints 
marked by blue arrows. C) IF at days 0 and 14 of differentiation for SOX2, OCT4, and 
SOX1. DAPI counterstain shown in blue. D) IF at day 28 of differentiation for SOX2 and 
TUBB3. Insets are single channel images. Scale bars are 50µm.  
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Figure II-1: Experimental design and neural differentiation of DS iPSCs  
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Figure II-2: Recruitment of heterochromatin hallmarks by XIST initiated in NSCs  
 
A-B) Combined RNA FISH for XIST RNA and IF staining for H2AK119ub1 (A) and 
H3K27me3 (B) in transgenic cells at day 28 of differentiation. Arrows indicate 
associated signals, and arrowheads indicate XIST paint without associated H3K27me3 
signal. Insets are magnified single channel images of outlined area. Schematics of 
experimental timelines illustrate dox addition (red) and analysis timepoints (blue). C) 
Quantification of XIST+ cells at day 28 of differentiation with different dox addition 
timepoints. D) Quantification of association of heterochromatin markers with XIST+ 
cells. Data are represented as mean ± SEM (n=3 differentiations). 309-926 cells were 
examined for each sample (median=556). *p = ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001; one-way 
ANOVA followed by Tukey’s multiple comparisons test. E) Combined RNA FISH for 
XIST with IF for H3K27me3 in day 21 sectioned neurospheres treated with dox 
beginning at day 0 or day 14. Micrographs are maximal intensity projections of 3D z-
stacks. Insets are magnified single channel images of outlined area. Arrows point to 
H3K27me3 enrichment associated with XIST paint. Arrowheads point to XIST paint 
without associated H3K27me3 enrichment. Scale bars are 5µm.  
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Figure II-2: Recruitment of heterochromatin hallmarks by XIST initiated in NSCs  
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treated with dox beginning at day 14 and day 21 clearly had H2AK119ub1 concentrated 
with the XIST signal (Figures II-2A and II-2D), indicating recruitment of this 
heterochromatin mark within 7 days. In cells induced at day 14, close to 90% of XIST+ 
cells had an associated H3K27me3 focus (Figures II-2B and II-2D), demonstrating that 
even in these differentiated cells XIST RNA can still recruit repressive modifications by 
two major polycomb complexes (PRC1 and PRC2). 
Interestingly, when XIST RNA was induced at day 21, H3K27me3 was enriched 
in just 34% of XIST+ cells by day 28 (Figures II-2B and II-2D). Since the entire 
chromosome silencing process takes just a few days in pluripotent human iPSCs (Jiang 
et al., 2013) and mouse ES cells (Chaumeil et al., 2006; Wutz and Jaenisch, 2000), this 
indicated that by 21 days of differentiation many cells had either lost competence to 
efficiently trigger the H3K27me3 modification, or, alternatively, that the process may 
occur over a substantially longer timeframe in differentiated cells. To determine if 
H3K27me3 enrichment may require more than 7 days of XIST expression, we analyzed 
sectioned neurospheres at day 21 which had been treated with dox starting on day 14. 
In neurospheres expressing XIST for just a week, few cells had H3K27me3 enriched at 
the XIST RNA locus (Figure II-2E) in contrast to the robust enrichment of this hallmark 
in the same condition analyzed after two weeks at day 28 (Figure II-2B and II-2D). This 
observation suggested that the multi-step process of heterochromatin formation is more 
prolonged in differentiated cells. Most importantly, these findings provide the first 
indication that XIST can function to induce at least some heterochromatin modifications 
in differentiated neural cells.  
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XIST induces chromosome 21 transcriptional silencing in neural cells 
Next, we used RNA sequencing (RNA-seq) to quantify the extent of silencing 
across chromosome 21 in neural cultures differentiated for 21 or 28 days, with XIST 
induced either at day 0 of differentiation or at later stages. As a benchmark for full 
chromosome 21 dosage compensation, we included comparison of a parental (trisomic) 
line to an isogenic disomic subclone. First, we examined the effectiveness of silencing 
for chromosome 21 genes in neural cells induced for XIST at day 0. We saw a 
significant decrease in the fraction of chromosome 21 reads in samples treated with dox 
(Figure II-3B). Dox treatment of the parental line, which does not contain the XIST 
transgene, did not cause a significant shift of chromosome 21 transcript levels, affirming 
that this effect is mediated by XIST RNA. Other chromosomes were not similarly 
affected by XIST (Figure II-3A). The effect seen on chromosome 21 gene expression is 
limited by the fraction of cells that express XIST (~60%, Figure 2.2C), which may 
account for a smaller decrease in chromosome 21 transcript levels in dox treated 
transgenic cells compared to isogenic disomic cells (Figure II-3B). 
Importantly, addition of dox at later stages of differentiation also leads to 
significant repression of transcripts from chromosome 21 genes (Figure II-3B). This 
effect is not driven by a few highly expressed genes. Instead, genes across the length 
of chromosome 21 are repressed (Figure II-3D). Although the repression seen is less 
than for cells expressing XIST from day 0, this provides direct evidence that XIST can 
initiate substantial transcriptional silencing in differentiated cells. Further examination of 
individual genes reveals various silencing patterns. For example, while USP25 and 
BACH1 demonstrate moderate to absent repression, respectively, with later dox  
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Figure II-3: Transcriptional chromosome 21 repression at all time points of XIST 
initiation  
 
A) Bar graph of bulk RNA-seq data of mean log2 fold change at day 28 of differentiation 
for all detected genes on each chromosome for each 3 vs. 3 comparison. Data are 
represented as mean ± SEM. Note: Y chromosome data represents only 9 detected 
genes. B) Day 21 and day 28 bulk RNA-seq data. Fraction of normalized chromosome 
21 reads over all reads for each sample. n=3 for each condition. Dashed line represents 
a 33% drop in chr21 transcription from mean parental level. Samples colored in blue are 
trisomic; samples colored in red are disomic or functionally disomic (XIST+). C) Violin 
plots of scRNA-seq data at day 28 of differentiation showing median (horizontal line), 
interquartile range (rectangular box), 95% confidence interval, and the kernel probability 
density at each value. For each cell, the fraction of UMIs from chromosome 21 is 
divided by total UMIs to determine expression from chromosome 21. Number of cells in 
each sample is provided. D) Bulk RNA-seq fold change between indicated comparisons 
for all chromosome 21 genes with FPKM>1 and normalized average read count >10 
plotted against ranked chromosomal position. Approximate chromosomal distance in 
megabases (Mb) relative to the XIST transgene locus is indicated on X-axis. Local 
average (LOESS) for each comparison is indicated by solid horizontal curves with 95% 
confidence intervals. Dotted horizontal line indicates 1.5-fold change. Significant 
differential expression (FDR<0.1) is indicated by larger dots. E) Dot plots of all samples 
for three selected chromosome 21 genes demonstrating various silencing kinetics. 
Dotted lines indicate each gene’s position in (D). **p = ≤ 0.01, ***p ≤ 0.001; one-way 
ANOVA followed by Tukey’s multiple comparisons test. Par, parental trisomic line; ParA, 
parental subclone A; Dis, disomic; C5A, Transgenic Clone 5a; nd, no dox; d0, day 0 dox 




Figure II-3: Transcriptional chromosome 21 repression at all time points of XIST 
initiation 
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addition, PSMG1 shows significant repression at all three dox addition timepoints 
(Figure II-3E). However, comparison of the degree of silencing is complicated by a 
lower fraction of cells expressing XIST at later dox addition timepoints (Figure II-2C), 
which will reduce overall silencing as measured by bulk RNA-seq. Therefore, to 
untangle the association between degree of silencing and proportion of cells expressing 
XIST, we performed single-cell RNA sequencing (scRNA-seq) on cells differentiated for 
28 days to identify a cell population confirmed to express XIST RNA. This approach 
may miss some XIST expressing cells due to the relatively low number of unique RNA 
molecules (nUMI) identified per cell (median = 9,677). Using this technique, we find that 
by day 28, XIST+ cells have decreased chromosome 21 expression by nearly one-third 
(31%) when XIST expression was initiated at the onset of differentiation, as compared 
to the same cells not treated with dox (Figure II-3C). This decrease in chromosome 21 
expression would be expected for complete silencing of one of three copies of 
chromosome 21 and is nearly equivalent to the 32% decrease seen when comparing 
the disomic cell line to the trisomic. In contrast, the pool of single cells in which XIST 
RNA was not detected (XIST-) showed a much smaller (7%) reduction in chromosome 
21 expression, reflecting a subset of false negative XIST expressing cells. As further 
illustrated below, using this approach to compare functionally trisomic to functionally 
disomic cells within the same population provides a powerful experimental approach to 
investigate how trisomy 21 impacts neural cells.  
Next, we used scRNA-seq to examine the extent of transcriptional silencing in 
the XIST+ population in cells with XIST induced at day 14, halfway into the 28-day 
differentiation time-course. In this case, XIST+ cells at day 28 clearly showed 
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substantial repression of chromosome 21 mRNA levels, although this was incomplete 
compared to full silencing (55% of the reduction seen when dox is initiated at day 0). 
The less complete silencing may reflect a reduced developmental competence to 
respond to XIST with differentiation, or the shorter time-period that XIST was expressed 
(4 weeks versus 2 weeks). Slightly more silencing at day 28 compared to day 21 in cells 
treated with dox at day 14 (Figure II-3B) suggested that increased duration of XIST 
expression may allow for more chromosomal silencing. Nonetheless, induction of XIST 
both in iPSCs and 14 or 21 days into neural differentiation leads to a neural cell 
population with extensive transcriptional repression of chromosome 21 genes, providing 
the first demonstration that normal differentiated cells have substantial competence to 
respond to XIST to repress transcription.  
XIST-mediated gene silencing in differentiated cells is a prolonged process           
 The reduced silencing seen at day 28 of differentiation in cells treated with dox 
starting on day 14 could reflect a chromosome-wide reduction in silencing or differences 
in the extent of silencing for individual genes. To investigate this, we compared the fold 
change of individual chromosome 21 genes (in XIST+ versus XIST- cells) for samples 
induced at day 0 and day 14. Many genes, such as CSTB, demonstrate an equivalent 
degree of silencing in both conditions (Figure II-4A-B), whereas several genes were 
substantially less repressed when XIST was induced later, including genes with high 
rates of detection/expression. This indicates there are late silencing genes, which we 
find are not correlated with gene distance from the XIST transgene locus (Figure II-4A). 
Interestingly, APP stands out as having a particularly large difference in degree 
of silencing between the two conditions (Figure II-4A-B). To test whether increased 
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silencing of APP would be seen if the time-frame of XIST expression was extended from 
two to three weeks, we used RNA FISH to examine APP gene silencing at 28 days and 
35 days of differentiation. As shown previously (Jiang et al., 2013; Xing et al., 1993), 
nuclear RNA FISH provides direct visualization of RNA transcription foci associated with 
each active APP allele, allowing for assessment of transcriptional silencing independent 
of any differences due to mRNA half-life. Silencing of APP transcription foci is 
essentially complete when XIST is initiated at the onset of differentiation and examined 
at either day 28 or day 35 of differentiation (Figure II-4C-D). In contrast, when XIST is 
initiated at day 14, the extent of APP silencing increases markedly at day 35 compared 
to day 28. Hence, when XIST expression is initiated later in differentiated neural cells 
the silencing process for some genes is still ongoing at day 28 and repression of this 
especially late-silencing gene is more complete 7 days later.  
The longer timeframe required for chromosome silencing in more differentiated 
cells would not be anticipated from the rapid 3-4 day process that occurs when XIST 
expression is initiated in pluripotent cells. This shorter timeframe is well established in 
mouse ES cells (Chaumeil et al., 2006; Wutz and Jaenisch, 2000) and was seen for 
chromosome 21 silencing in pluripotent cells, including for the APP gene (Jiang et al., 
2013; Valledor et al., in preparation). The prolonged kinetics of the process in 
differentiated cells could explain why gene silencing was not observed after XIST was 
expressed for a shorter period in differentiated mouse ES cells (Wutz and Jaenisch, 
2000). We have preliminary evidence of chromosome silencing in post-differentiation  
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Figure II-4: XIST-mediated transcriptional silencing and heterochromatin 
recruitment are prolonged processes in differentiated cells 
A) Difference in fold-change between d0 and d14 dox conditions plotted against 
chromosomal location relative to the XIST transgene locus. Each dot represents a gene; 
size of each dot is -log10(p-value). Color denotes the fraction of cells in which each 
gene is detected. Only genes demonstrating some degree of repression (>0.1 log10 FC) 
are plotted. B) Violin plots of expression level for CSTB and APP in each sample 
sequenced by sc-RNAseq. C) Representative images of RNA FISH for APP and XIST in 
cells differentiated for 28 and 35 days with dox initiated either at day 0 or day 14. 
Micrographs are maximal intensity projections of 3D z-stacks. Scale bars are 10µm. 
Insets are single channel images. D) Quantification of silencing of transcription foci in 
(C) for the APP gene as described in methods. Data are represented as mean ± SEM, 
n=2, with 293-473 cells scored per sample (median = 400) *p = ≤ 0.05; unpaired 
Student’s t-test. E) Schematic indicating temporal order of steps in chromosome 21 
silencing process as seen in differentiated cells.  
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cells using the same mouse transgenic cells induced to express XIST for 1-3 weeks, 
although analysis is complicated by monosomy-induced lethality (data not shown). 
In sum, these findings reveal that initiation of silencing by XIST is not limited to 
the early developmental context of pluripotent stem cells. Differentiated cells require 2-3 
weeks to complete various steps of this multifaceted process (Figure II-4E), but, most 
critically, chromosome-wide gene silencing still occurs when XIST is initiated in 
differentiated cells. 
XIST produces dosage corrected trisomic neurons 
The cell cultures analyzed above demonstrate that a mixed population of 
neurons and NSCs is capable of initiating XIST-mediated silencing at various stages of 
differentiation. Additionally, scRNA-seq analysis of chromosome 21 expression affirmed 
that this system can readily produce XIST+ neurons with one silenced chromosome 21. 
We next attempted to initiate XIST transcription in a pure post-mitotic neuronal 
population by synchronously inducing differentiation with compound E, a γ-secretase 
inhibitor which rapidly induces all NSCs to differentiate into neurons (Figure II-5A) 
(Ogura et al., 2013). As expected, post-mitotic neurons generated in this way from cells 
treated with dox prior to differentiation had robust XIST expression (Figure 2.5B) 
associated with heterochromatin marks (Figure II-5C). However, if dox was added after 
differentiation into neurons, cells did not even show any transcription focus for XIST 
RNA (Figure II-5B). These findings suggested that neurons can continually maintain 
XIST RNA expression when induced prior to their terminal differentiation, but transgene 
activation is prevented in post-mitotic neurons. 
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 To further investigate this phenomenon, we examined forebrain organoids grown 
for 50 days. These organoids contain clearly demarcated “ventricular-like” zones (VZ) 
containing NSCs which give rise to the surrounding differentiated neurons (Figure II-
5D), thus providing a clear delineation of NSCs and post-mitotic neuron-containing 
regions. We induced organoids with dox at day 48 for just two days prior to examination, 
which minimizes the number of NSCs that will have differentiated into neurons after 
XIST induction. In this case, nearly all XIST+ cells were in the VZs rather than the 
surrounding neurons (Figure II-5E). In contrast, in organoids treated with dox beginning 
at day 22 of differentiation, many XIST+ cells are evident in both the VZ and the 
surrounding neurons (Figure II-5E), demonstrating robust XIST expression in neurons 
and NSCs in trisomy 21 cerebral organoids. Together, results demonstrate that post-
mitotic neurons can continually express and localize XIST RNA and maintain 
comprehensive chromosome 21 silencing, even though the dox-inducible transgene 
needs to be activated prior to terminal differentiation, likely due to DNA methylation of 
the tetracycline response element with differentiation (Gödecke et al., 2017).  
 To our knowledge it has not been previously demonstrated whether XIST RNA 
requires S-phase to initiate recruitment of heterochromatin marks. To examine this, we 
induced XIST transcription concurrently with labelling of replicating DNA by BrdU 
incorporation, in both iPSCs and forebrain organoids. In both paradigms, there were 
cells that had not undergone DNA replication (BrdU-) but were XIST+, with a well-
localized XIST RNA paint associated with a clear recruitment of the heterochromatin 
hallmark H2AK119ub1 (Figure II-5F), seen as early as eight hours in forebrain organoid 
cells. Hence, XIST RNA does not strictly require S-phase to initiate the chromosome  
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Figure II-5: Neurons support continued XIST expression to maintain silent 
chromatin provided the transgene is activated in the NSC stage  
 
A) Representative IF images for SOX2 and TUBB3 of cells at day 28 of differentiation 
with and without compound E treatment at day 21 of differentiation. Scale bars are 
50µm. B) RNA FISH for XIST in day 35 differentiated cells treated with compound E at 
day 21 and induced with dox at day 0 or 28. DAPI counterstain in blue. Scale bars are 
5µm. C) Combined RNA FISH for XIST and IF for H3K27me3 and TUBB3 in day 35 
differentiated cells treated with compound E at day 21. Insets are magnified single 
channel images of outlined area. Scale bars are 10µm. Arrows point to XIST RNA 
paints. D) IF of day 50 sectioned forebrain organoid for NeuN and SOX2. Dashed white 
line delineates NSC-containing SOX2+ VZ-like area and neuron containing NeuN+ 
area. Scale bars are 50µm. E) Combined RNA FISH for XIST and IF for NeuN in 
transgenic forebrain organoids. Micrographs are maximal intensity projections of 3D z-
stacks. Scale bars are 50µm. F) Combined RNA FISH for XIST and IF for H2AK119ub1 
and BrdU with concurrent addition of dox and BrdU in both iPSCs and day 50 
organoids. Insets for the iPSCs are single channel images; insets for organoid are 
magnified single channel images of the outlined area. Arrows point to XIST RNA paints. 




Figure II-5: Neurons support continued XIST expression to maintain silent 
chromatin provided the transgene is activated in the NSC stage 
  
 68 
remodeling process, suggesting that the lack of cell-cycling in post-mitotic neurons does 
not preclude XIST RNA expression or function. 
 Together, these results demonstrate that this system can produce XIST-
expressing dosage compensated neurons, despite the inability to initiate XIST 
expression with dox in neurons. Additionally, the S-phase of the cell cycle is not 
required for XIST expression and early recruitment of heterochromatin hallmarks. 
XIST RNA enhances neuron formation indicating correction of a 
neurodevelopmental deficit  
scRNA-seq was instrumental to quantify chromosome 21 gene silencing in 
differentiated neurons and NSCs, however this approach may also be advantageous to 
determine if trisomy 21 expression impacts neural differentiation, because it compares 
cells within the same sample sorted for XIST expression. This strategy minimizes 
sources of variability unrelated to trisomy and intrinsic to most other studies using 
patient-derived iPSCs (Liang and Zhang, 2013; Soldner and Jaenisch, 2012). 
Therefore, we examined the single-cell data to address whether XIST+ cells were 
distinct from XIST- cells beyond the difference in chromosome 21 expression.  
As described above, after 28 days of differentiation cultures were histologically 
determined to be a mixture of NSCs and neurons. The scRNA-seq data confirmed the 
presence of two major cell-type clusters that we classified as NSC and neuron based on 
cell-specific markers such as SRY-box 2 (SOX2), Vimentin (VIM), Doublecortin (DCX), 
and Tau (MAPT) (Figure II-6A-B). Further affirming this classification, the NSC cluster 
contained about 40% of cells in G2/M and S-phase (based on cell-cycle specific gene 
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expression), whereas the neuron cluster contained only a small fraction (2%) of cells 
predicted to be cycling (Figure II-6C), as expected for post-mitotic neurons. 
Next, we analyzed the proportion of XIST+ cells that were in the neuron cluster 
compared to XIST- cells in the same sample. Surprisingly, this revealed that XIST+ cells 
with dox initiated at day 0 were significantly more likely to be neurons compared to 
XIST- cells (Figure II-6D). This is despite the findings described above that neurons do 
not initiate XIST expression in this dox-inducible system, and evidence that the 
tetracycline transactivator (TET3G; required for XIST expression) transgene is more 
highly expressed in the NSC cluster, as shown by a dox-treated trisomic control line that 
contains just the TET3G transgene (data not shown). These results show that DS cells 
in which one chromosome 21 was silenced by XIST expression produced a higher 
proportion of neurons relative to NSCs. Given the potential importance for 
understanding DS neuropathology, this observation merited further investigation. 
A difference in the rate with which trisomic NSCs transition to neurons could 
have its root at any point during the 28-day differentiation time course. The inducible 
XIST system makes it possible to investigate the onset of this defect by examining cells 
induced for XIST later during in vitro differentiation. We examined whether this 
phenotype could be reproduced by initiating XIST expression 14 days into 
differentiation. Remarkably, as shown in Figure II-6D, even when XIST expression was 
not initiated until midway through the time-course, XIST+ cells were still significantly 
more likely to form neurons, and to the same degree as cells induced for XIST at day 0. 
This indicates the developmental step which underlies reduced neuron formation occurs 
after 14 days of differentiation. 
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These results strongly suggest that trisomy 21 in DS is associated with some 
dysregulation in neurogenesis that delays and/or reduces neuron formation. In this 
study, we included one trisomic and one disomic cell line primarily as a benchmark for 
full chromosome 21 gene silencing, however we noted that no difference was seen in 
the proportion of neurons produced between these two isogenic lines. To rule out any 
possibility of this finding resulting from technical limitations of scRNA-seq or in analysis 
of one transgenic line, we tested the production of neurons in cultures of multiple 
transgenic lines using a different single-cell approach which combines RNA FISH for 
XIST RNA with immunofluorescence (IF) for SOX2 and TUBB3 (Figure II-6E). This was 
done in three independent transgenic clones each differentiated independently 1-2 
times, with dox added at both day 0 and day 14. In accordance with sequencing results, 
XIST+ cells were again more likely to become neurons compared to XIST- cells (Figure 
II-6F). This was consistent for all three lines and, importantly, occurred to similar 
degrees at both dox addition timepoints. 
Using this tightly controlled inducible system in multiple transgenic lines analyzed 
by two different approaches, we find strong evidence that trisomy 21 expression 
significantly impedes terminal differentiation of NSCs to neurons. This occurs after early 
formation of NSCs but prior to terminal differentiation of neurons. Together, the facts 
that we are comparing functionally disomic and trisomic cells within the same sample, 
that we are analyzing a difference in the proportion of neurons to NSCs rather than total 
neuron number, and that this proportion is altered even when XIST is initiated half-way 
into the differentiation protocol, all suggest that neuron formation is enhanced in XIST+ 
cells independent of an effect on cell density or proliferation. Implicit in this analysis is  
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Figure II-6: XIST expressing cells are more likely to be neurons than cells that do 
not express XIST 
A) t-distributed stochastic neighbor embedding (t-SNE) plot of day 28 scRNA-seq data 
for neuron- (MAPT and DCX) and NSC- (SOX2 and VIM) specific genes. Gray dots 
represent low and purple represent high expression levels. Each dot represents a single 
cell. B) t-SNE plot colored for cell type classification. C) t-SNE plot colored for predicted 
phase of cell cycle. D) Fraction of cells in Clone5a d0 and d14 dox scRNA-seq samples 
identified as neurons separated based on XIST expression. Error bars are SE. E) 
Combined RNA FISH for XIST with IF for SOX2 and TUBB3 in day 28 cells. Example 
XIST+/-;NSC/Neuron cells are labeled. Micrograph is a maximal intensity projection of a 
3D z-stack. Scale bars are 10µm. F) Quantification of (E) for 1-2 differentiations of three 
transgenic clones. Lines connect data points derived from the same sample. Between 
419-1311 cells were analyzed for each sample (median = 868). **p = ≤ 0.01, ***p ≤ 
0.001; Student’s paired T-test. 
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that this specific neural phenotype can be rescued by expression of XIST RNA from one 
copy of chromosome 21. 
Non-chromosome 21 differential expression identifies altered Notch pathway 
genes 
Several studies have examined the transcriptomes of trisomic versus euploid 
(disomic) individuals in fetal or adult human brain samples (Lockstone et al., 2007a; 
Olmos-Serrano et al., 2016), yet transcriptome differences will be confounded by 
differences in cell-type representation, as well as due to variation between non-isogenic 
samples or sample processing. While not our primary goal, our scRNA-seq analysis 
could reveal in a specific cell population (neuron or NSCs) whether non-chromosome 21 
genes are impacted, directly or indirectly, by chromosome 21 dosage. Due to limitations 
in sensitivity, the scRNA-seq data would not necessarily identify changes in weakly or 
variably expressed genes. Nonetheless, changes genuinely due to chromosome 21 
dosage could be revealed with higher-confidence, because this approach compares 
XIST+ and XIST- cells within the same sample, with each cell serving as a biological 
replicate of the disomic and trisomic state. 
Indeed, this analysis identifies a small number of genes which change 
expression in NSCs and/or neurons as a function of chromosome 21 silencing (Figure 
II-7A). Notably, when PANTHER Pathway analysis (Mi and Thomas, 2009; Mi et al., 
2017) is conducted on the total of 9 unique non-chr21 genes that differentially 
expressed, “Notch signaling pathway” (accession: P00045) is the only significantly 
dysregulated pathway (FDR=0.0274). Additionally, the gene Tweety Family Member 1 
(TTYH1), recently implicated in Notch signaling (Kim et al., 2018) but not included in the  
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Figure II-7: Non-chromosome 21 differential expression identifies altered Notch 
pathway genes 
A) Volcano plot of results from Wilcoxon rank-sum test between XIST+ and XIST- cells 
in NSC and neuron clusters for d0 and d14 dox samples examined at day 28 in scRNA-
seq dataset. Chromosome 21 genes are in red, and all other genes are in blue. Circled 
genes are significantly differentially expressed (p-adj<0.05). Non-chr21 DE genes are 
labeled. “Dox effect” genes found to be DE between ParA nd and parA d0 dox samples 
and transgenes were removed from the plots. B) Expression levels of TTYH1 in NSCs 
of all samples sequenced. ParA, parental subclone A; Dis, disomic; C5A, Transgenic 
Clone 5a; nd, no dox; d0, day 0 dox initiation; d14, day 14 dox initiation. C) Schematic 
of experimental design and major results. Chromosome silencing is prolonged in 
differentiated cells and has variable kinetics between genes. XIST+ cells in both d0 and 
d14 dox conditions have increased neuron proportions, decreased TTYH1 expression in 
NSCs, and increased Notch pathway gene expression compared to XIST- cells. 
  
 74 
Notch pathway annotation, is also differentially expressed in NSCs expressing XIST. A 
similar more modest difference is seen between the trisomic and disomic cell lines 
(Figure II-7B), and no difference is seen between TET+ and TET- NSCs in the trisomic 
parental subclone treated with dox (data not shown). As summarized in Figure II-7C, the 
effects on neuron formation and non-chromosome 21 gene expression occur similarly 
whether one chromosome 21 is silenced from the beginning or far into the differentiation 
process, providing insight into the developmental timing of these effects. To our 
knowledge, this is the first data able to identify genes that likely reflect ongoing 
functional effects of trisomy 21 on expression of non-chromosome 21 genes in a given 
neural cell type. 
Discussion 
The results presented here have broad implications for basic developmental 
biology, DS neurobiology, and for potential translational applications of a unique non-
coding RNA, XIST. Results with scRNA-seq further demonstrate the singular capacity of 
XIST to dosage compensate duplicated autosomal chromatin, allowing production of 
trisomy 21 neurons with a euploid transcriptomic profile. While this alone is valuable, 
this study addresses a critical question regarding the epigenetic plasticity of cells to 
respond to XIST, with encouraging results which heighten the experimental power and 
therapeutic prospects of XIST. These findings demonstrate for the first time in normal 
human cells that XIST can initiate chromosome silencing well beyond the “critical 
window” of pluripotency. Our findings demonstrate that the chromosome silencing 
process still occurs in differentiated cells, but is more prolonged, which could explain 
earlier findings suggesting a strict developmental window for initiation of chromosome  
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silencing. Additionally, single cell analyses of otherwise identical cells, with and without 
XIST-mediated dosage compensation, provide strong evidence that over-expression of 
chromosome 21 genes confers a developmental delay in the transition of NSC to 
neurons. Importantly, this change in the neuron versus NSC balance was consistently 
and equivalently corrected whether XIST expression was initiated at the onset or 
midway through the differentiation time-course. These findings demonstrate the value of 
this approach to investigate the developmental biology of DS. Moreover, these results 
overcome a perceived barrier to developing XIST as a potential therapeutic for DS and 
other trisomies, and further support the effectiveness of chromosome silencing to 
mitigate cell phenotypic effects of trisomy. 
Our results provide new insights into basic developmental biology by revealing 
the unanticipated epigenetic plasticity of more differentiated cells to enact a multi-
layered chromosome remodeling process that normally occurs within the inner cell 
mass. Previously it was thought that the limited reports of XIST-induced 
heterochromatin in somatic cells reflected a peculiarity of some cancer cells or an 
unusual regaining of competence specific to a subset of mouse hematopoietic cells. By 
thoroughly re-visiting this key point in normal human neural cells, our results bode well 
for the potential of XIST function in other cell-types. Using our 28-day time course to 
produce post-mitotic neurons, XIST expression begun at day 14 or 21 initiates 
chromosome-wide repression evident within just 1-2 weeks. Interestingly, some genes 
silence more slowly – and thus complete silencing requires over 3 weeks of XIST 
expression – as shown for the important APP gene, critical to the development of early-
onset Alzheimer’s disease in DS. Even when XIST expression was induced in cells of a 
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48-day old organoid, early heterochromatin hallmarks became apparent on the 
chromosome. Given that XIST triggers multi-layered repressive chromatin modifications, 
the highly-redundant process may still provide transcriptional repression even if certain 
chromatin modifying enzymes are absent or expressed at low levels in differentiated 
cells.  
A complication we encountered using ectopic promoters to drive XIST expression 
is the common phenomenon of transgene silencing with differentiation (Gödecke et al., 
2017; Huebsch et al., 2016; Laker et al., 1998; Oyer et al., 2009; Xia et al., 2007). In our 
system this could be occurring at the tetracycline transactivator locus on chr19 and/or 
the tetracycline response element/XIST locus on chr21, as discussed in detail in the 
appendix. This issue could have also influenced results of a previous study in which 
mice were fed dox to induce an XIST transgene on a disomic autosome, with cell/tissue 
lethality serving as the read-out for XIST function (Savarese et al., 2006). Our results 
clearly show that neurons maintain XIST expression and remarkably complete 
chromosome 21 silencing, yet the dox-inducible system was blocked in neurons unless 
it was already activated in NSCs prior to terminal differentiation. Additionally, there is 
precedent in the literature that dramatic epigenetic changes occur in post-mitotic 
neurons, such as activity-mediated neuronal plasticity achieved by epigenetic 
mechanisms (Ma et al., 2009), or the conversion of post-mitotic neurons from one 
distinct subtype to another by exogenous factors (Rouaux and Arlotta, 2013; Ye et al., 
2015). 
scRNA-seq not only affirmed chromosome 21 silencing in XIST-expressing 
neurons, but unexpectedly revealed that cells expressing XIST were more likely to 
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become neurons. The increased proportion of cells that transitioned from NSC to 
neurons was corroborated by a second approach and consistently seen for three XIST 
transgenic clones. We believe the ability to demonstrate a modest but reproducible 
developmental delay in neurogenesis in vitro rests on the inducible experimental 
approach that examines essentially identical cells in the same culture of the same 
subclone, with and without one chromosome 21 silenced, thereby circumventing other 
sources of variation even between isogenic iPSC clones (Koyanagi-Aoi et al., 2013; 
Liang and Zhang, 2013; Soldner and Jaenisch, 2012). For example, we can conclude 
that the increased rate of neuron formation in dosage-compensated cells is not due to 
culture density, which is difficult to control (Jiang et al., 2013). Importantly, the ability to 
induce dosage correction at later stages also makes it possible to examine the timing 
and reversibility of a developmental defect. Enhanced neuron differentiation occurred 
equivalently whether XIST-mediated silencing was initiated at day 0 or 14 days into 
neural differentiation, indicating a defect that is correctible at either time point. 
Additionally, given that complete transcriptional silencing takes over two weeks after 
XIST is induced, this suggests that either especially early-silenced chr21 gene(s) are 
responsible for this phenotype, or the defect arises after day 21 and potentially close to 
the final division of NSC to form post-mitotic neuron. 
While studies using DS iPS cells have described variable results with neural 
differentiation (see introduction), some studies have reported hypocellularity in small 
samples of DS fetal cortex (Guidi et al., 2008; Larsen et al., 2008; Ross et al., 1984), 
which has been attributed to decreased neuron number. Using a very different approach 
involving experimental manipulation of chromosome 21 expression, results here provide 
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direct evidence that trisomy 21 over-expression causes a neurodevelopmental delay in 
the transition of NSCs to neurons. Recently, we showed that trisomy 21 silencing 
(beginning in pluripotency) prevents development of hematopoietic defects of DS, 
reducing and normalizing the well-known over-production of megakaryocytes and 
erythrocytes (Chiang et al., 2018). The contrasting effects seen where XIST enhances 
neuron production are consistent with the different clinical impact of trisomy 21 on the 
hematopoietic and neural systems.  
 Results further indicate that this experimental strategy can provide insights into 
target pathways dysregulated by trisomy 21, which might identify targets amenable to 
conventional drug therapies. Of particular interest are the significant number of Notch 
pathway related genes that stand out as impacted when comparing trisomic and 
functionally disomic cells. The role of Notch signaling in neural differentiation is well 
described, and its inhibition using γ-secretase inhibitors induces rapid differentiation of 
NSCs to neurons, as illustrated in this study and others (Kawaguchi et al., 2008; Ogura 
et al., 2013). However, the role of Notch in DS neurodevelopment is less clearly 
understood. Some transcriptome studies of DS adult brain samples have reported 
upregulation of Notch signaling genes, and the potential role of specific chromosome 21 
genes in Notch signaling has been of interest (Fernandez-Martinez et al., 2009; Fischer 
et al., 2005; Lockstone et al., 2007a). TTYH1 and related pathway genes, HEY1 and 
RBPJ, are increased in the trisomic state and strongly downregulated after chromosome 
21 silencing. Of particular interest was a recent report showing that TTYH1 impacts the 
Notch pathway to promote maintenance of the NSC state (Kim et al., 2018), which could 
explain our finding of a higher fraction of NSCs in uncorrected trisomic cells. 
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Additionally, the role of Notch signaling in astrogliogenesis is well described (Louvi and 
Artavanis-Tsakonas, 2006), and aberrations in astrocyte number have been reported in 
DS brains and in vitro models (Chen et al., 2014; Colombo et al., 2005; Mito and 
Becker, 1993).  
 Finally, the fundamental finding here that differentiated cells retain substantial 
epigenetic plasticity is encouraging for the forward-looking prospect that XIST or derived 
sequences could be developed as a therapeutic strategy for aspects of DS and 
potentially a diversity of smaller duplication disorders only now being described 
(Theisen and Shaffer, 2010). Although our results implicate a specific cell transition 
during neural development, potentially due to mis-regulation of the Notch pathway, with 
over 200 genes on chromosome 21 it is likely that other steps in earlier neuroepithelial 
differentiation (Jiang et al., 2013) or later neuron function could also be impacted by a 
myriad of mechanisms. In addition, recent studies indicate that aneuploidy in general 
may cause proteomic cell stress due to low-level over-expression of many genes 
(Bonney et al., 2015; Sheltzer et al., 2012). Therefore, with enormous advances in 
genome editing and delivery technologies, we continue to advance the prospect that a 
single-gene could target the root cause for a complex chromosomal disorder to 
potentially mitigate effects of trisomy 21 in several physiologic systems. We have 
demonstrated that XIST-mediated silencing can correct known DS cell pathologies in 
vitro (Chiang et al., 2018), and now show that epigenetic correction may be possible 
long into development for the neural cell lineage and potentially other cell systems. 
Clearly, many challenges remain, including the need for a smaller XIST transgene 
amenable to current delivery methods and the fact that neurogenesis is largely 
 80 
complete prenatally. However, several major aspects of neural development, such as 
myelination and synaptic pruning, continue long after birth (Silbereis et al., 2016), as 
does the development Alzheimer dementia in most DS individuals (Wiseman et al., 
2015). 
Great efforts from many investigators have led to breakthroughs in understanding 
dosage compensation of the X-chromosome, yet the translational relevance to common 
chromosomal dosage disorders of this basic epigenetic mechanism is only beginning to 
be explored.  
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Materials and Methods 
iPS cell culture and neural differentiation 
The isogenic XIST-transgenic and disomic subclones were derived and 
characterized as described in Jiang et al. (2013). The initial DS iPSC parental line (DS1-
iPS4) was provided by G.Q. Daley (Park et al., 2008). Clone5a is a subclone of the 
previously characterized clone5 (Jiang et al., 2013) which was altered for this study to 
include a second copy of the tetracycline transactivator driven by the CAG promoter in 
the AAVS1 locus (Addgene plasmid #60431) in an attempt to minimize transgene 
silencing with differentiation. All clones except the original parental line contain the 
TET3G transgene in the AAVS1 locus. iPSCs were maintained on vitronectin-coated 
plates with Essential 8 medium (ThermoFisher) and tested periodically for mycoplasma. 
Cells were passaged every 3-4 days with 0.5mM EDTA.  
Neural differentiations were performed as previously described (Cao et al., 2017; 
Chambers et al., 2009) with some modifications. Briefly, iPSCs were dissociated into 
single cells and plated at a density of 50,000 cells/well in a vitronectin-coated 24-well 
plate with 10µM of the ROCK inhibitor Y-27632 (Tocris Bioscience). The next day, 
media was changed to Neural differentiation media (NDM) consisting of 50% 
DMEM/F12, 50% Neurobasal, 0.5X Glutamax, 1X N-2 supplement, 1X 
penicillin/streptomycin (all from ThermoFisher), and supplemented with 2uM DMH1 and 
SB431542 (both from Tocris Bioscience). After 14 days, cells were broken into clumps 
after EDTA treatment and cultured in suspension for 7 days in NDM. On day 21 or 28 of 
differentiation, neurospheres were dissociated into single cells with StemPro Accutase 
(ThermoFisher) and plated onto coverslips (Electron Microscopy Sciences) coated with 
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Matrigel (Corning) at a density of 25,000-50,000 cells/coverslip and fed every 2-3 days 
with Neuron media consisting of Neurobasal, 1X N-2, 0.5X B-27 without vitamin A, 1X 
penicillin/streptomycin, 1X Glutamax (ThermoFisher), 0.3% Glucose, 10ng/ml GDNF 
(Peprotech), 10ng/ml BDNF (Peprotech), 10ng/ml ascorbic acid (Sigma-Aldrich), and 
1µM cyclic AMP (Sigma-Aldrich). Doxycycline diluted in distilled water was added to the 
culture media starting at various time points at a concentration of 500ng/ml. In cultures 
where NSCs were synchronously differentiated to neurons, compound E (EMD 
Millipore) was added for 3 days at day 21 of differentiation at a concentration of 200nM.  
Forebrain organoids were generated as previously described (Qian et al., 2016, 
2018) with the following modifications: embryoid bodies were formed by dissociated of 
iPSCs into single cells and re-aggregating in U-bottom 96-well plates (Lancaster and 
Knoblich, 2014). On day 7, aggregates were transferred to ultra-low attachment 6-well 
plates (Corning) for Matrigel embedding, and on day 14 the plates were moved to an 
orbital shaker set at ~100rpm.  
Cell fixation, RNA FISH, and immunofluorescence 
For iPSC and monolayer neural culture, cell fixation with 4% paraformaldehyde 
(PFA) was performed as previously described (Byron et al., 2013). Forebrain organoids 
were fixed for 30min in PFA at room temperature, washed three times with PBS, and 
cryopreserved in 30% sucrose/PBS at 4°C overnight. Fixed organoids were embedded 
in O.C.T. compound (Sakura Finetek), frozen in an ispropanol/dry ice slurry, and 
sectioned at 14µm on a cryotome. Sections were attached to Superfrost Plus slides 
(Electron Microscopy Sciences) and stored at -20°C until staining. Prior to staining, 
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sections were rehydrated in PBS for 5min, and detergent extracted in 0.5% Triton X-100 
(Roche) for 3min. 
RNA FISH and IF were performed as previously described (Byron et al., 2013; 
Clemson et al., 1996). For RNA FISH and combined RNA FISH/IF in iPSCs and 
monolayer neural culture, detergent extraction was performed prior to fixation. For IF 
alone, fixation was performed prior to detergent extraction. The XIST probes used were 
G1A (Addgene plasmid #24690; Clemson et al., 1996) and a Stellaris FISH probe 
(Biosearch Technologies, SMF-2038-1), which was used according to the 
manufacturer’s instructions. The APP probe is a BAC from BACPAC resources (RP11-
910G8). DNA probes were labelled by nick translation with either biotin-16-dUTP or 
digoxigenin-11-dUTP (Roche). For simultaneous IF and RNA FISH, cells were 
immunostained normally with the addition of RNasin Plus (Promega) to the incubation 
buffer and fixed in 4% PFA prior to RNA FISH. The primary antibodies used in this study 
are provided in Table II-1. The conjugated secondary antibodies used in this study were 
Alexa Fluor 488, 594, and 647. BrdU staining was performed after RNA FISH and 
subsequent fixation by incubating coverslips or slides at 80°C in 70% formamide in 2X 
SSC for 5min (coverslips) or 30min (cryosections on slides) followed by dehydration in 
70% and 100% cold ethanol for 5min each and standard IF.  
RNA isolation, cDNA library preparation, and high-throughput sequencing             
RNA was extracted using TRIzol reagent (ThermoFisher) according to 
manufacturer’s instructions. RNA samples were cleared of contaminating genomic DNA 
by DNAse I (Roche) treatment for 1hr at 37°C. RNA cleanup and DNAse I removal was 
performed using RNeasy MinElute columns (Qiagen) according to manufacturer’s 
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instructions. Clean RNA was assessed for quality on an Advanced Analytical Fragment 
Analyzer, and all samples had an RQN > 7.5. 100ng of RNA per sample was used to 
prepare mRNA strand-specific sequencing libraries using the NEBNext® Ultra™ II 
Directional RNA Library Prep Kit for Illumina® in conjunction with the NEBNext® Poly(A) 
mRNA Magnetic Isolation Module and NEBNext® Multiplex Oligos for Illumina® (New 
England Biolabs). Sequencing was performed by the UMass Medical School Deep 
Sequencing Core Facility on the Illumina HiSeq4000 platform to a depth of ~8 million 
reads/sample. 
Reads were aligned to the hg19 human genome build (GRCh37) using hisat2 
(v2.0.5). Reads were counted to genes using the featureCounts function of the subread 
package (v1.6.2). Within R, the DEseq2 package was used to normalize reads between 
samples and determine significantly differentially expressed genes. Significance in 
Figure 3D was determined by performing multiple comparison correction on all 
expressed chr21 genes (n=125) and setting an FDR of <0.1. The ggplot2 package was 
used to generate most graphs. 
Single-cell RNA sequencing 
 On day 28 of differentiation, neurospheres were dissociated with StemPro 
Accutase (ThermoFisher) and passed through a 40μm strainer to remove remaining 
clumps. Cells were washed twice in PBS + 0.4% BSA, counted and assessed for 
viability (>80%). Cells were then processed using the 10x Genomics Chromium™ 
Single Cell 3’ Library and Gel Bead Kit v2 per manufacturer’s instructions. Sequencing 
was performed by the UMass Medical School Deep Sequencing Core Facility on the 
Illumina HiSeq4000 platform. Alignment, filtering, barcode counting, and UMI counting 
 85 
was performed using the Cell Ranger pipeline (10x Genomics - v2.1.1) using the hg19 
reference genome which was altered to include the TET3G transgene sequence. 
Further normalization, filtering, and analysis was performed using the Seurat R package 
(v2.3.4). Cell cycle scoring was performed as previously described (Tirosh et al., 2016). 
Microscopy and cell scoring 
 Cells were visualized using a Zeiss AxioObserver 7, equipped with Chroma multi-
bandpass dichroic and emission filter sets (Brattleboro, VT), with a Flash 4.0 LT CMOS 
camera (Hamamatsu). Images were minimally corrected for brightness and contrast to 
best represent signals observed by eye using ZEN software (v2.3 Blue, Zeiss). Where 
indicated, 3D z-stacks of several focal planes were computationally deconvolved and a 
maximal image projection was created using ZEN software in order to visualize all 
signals in one image. For scoring of heterochromatin marker association with XIST 
signal, we examined at least 8 random fields in three independent differentiations per 
sample. For APP gene silencing, we examined at least 6 random fields in two 
independent differentiations per sample, and silencing was assessed using the following 
formula, which corrects for variable hybridization efficiency between samples: Degree of 
silencing = 100 * (1 - (fraction of XIST+ cells with 3 APP foci / fraction of XIST- cells with 
3 APP foci)). For scoring of neuron/NSC cell type, TUBB3+ cells were counted as 
neurons, SOX2+/TUBB3- cells were counted as NSC, and SOX2-/TUBB3- cells were 
not counted. After a cell was determined to be a neuron or NSC, its XIST status was 




Table II-1: Primary antibodies used in chapter II 
Antibody Host Source Identifier 
NeuN  mouse monoclonal Millipore MAB377 
Trimethyl-Histone H3 
Lys27 (H3K27me3)  
rabbit polyclonal Millipore 07-449 
Oct3/4 goat polyclonal Santa Cruz 
Biotechnology 
sc-8629 
Sox2  rabbit polyclonal Millipore AB5603 
Tubulin β 3 (TUBB3)  mouse monoclonal Biolegend Tuj1 (MMS-435P) 
BrdU mouse monoclonal Sigma-Aldrich BU-33 (B8434) 
Ubiquitl-Histone H2A 
Lys119 (H2AK119ub)  
rabbit monoclonal Cell Signaling 
Technology 
D27C4 (#8240) 








 I performed all of the experiments described in this chapter, with help from Meg 
Byron in the culturing and processing of over 1,000 organoids for the largest 
experiment. I performed the analysis of results from the early experiments myself, 
whereas most of the computational analysis on the largest experiment was performed 
by Dr. Oliver King, with input from me and Jeanne Lawrence. 
 
Introduction 
Cognitive disability is a universal feature of DS, and while the genetic basis of DS 
is clear, the direct molecular and cellular causes for this phenotype are not well defined. 
Studies in mouse models of DS have identified several brain pathologies and 
corresponding behavioral or cognitive phenotypes, although various studies of different 
or even the same mouse models do not always agree (Belichenko et al., 2009, 2007; 
Haydar and Reeves, 2012; Reeves et al., 1995). Additionally, discerning which models 
more faithfully reflect the various aspects of neurodevelopment and cognitive features of 
human DS is challenging. Several studies report evidence of genetic or pharmaceutical 
correction of specific phenotypes in specific mouse models of DS, such as for increased 
interneuron number and decreased cerebellar size (Chakrabarti et al., 2010; Das et al., 
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2013). However, some of these findings do not correlate well with the human syndrome. 
For example, several studies have suggested that interneuron number may be 
decreased in DS patients and human cell models (Bhattacharyya et al., 2009; Huo et 
al., 2018; Ross et al., 1984; Wisniewski, 1986), in contrast to reports in trisomic mice 
that interneuron numbers are increased. Further complicating the current state of 
knowledge in this area, at the recent meeting of the Trisomy 21 Research Society, a 
panel discussion highlighted the important issue that neural phenotypes have not been 
consistent for the same DS mouse model bred and studied at different times or places.  
In recent years, with the advent of whole genome sequencing approaches, 
studies have begun to examine differences in the transcriptomes of DS versus euploid 
samples. However, among several published studies there have been few consistent 
conclusions. While studies invariably find chr21 genes to be disproportionately 
upregulated in DS tissues and cells, the number and identity of these genes is 
inconsistent. A meta-analysis of 45 transcriptome studies found only 77 chr21 genes to 
be consistently upregulated in DS samples (Vilardell et al., 2011). If there is no 
feedback regulation of a specific gene, then trisomy for that gene would be expected to 
result in a relatively modest 1.5-fold increase in mRNA level, which could be further 
confounded by differences in cell types or pathological states. Most recently, several 
studies have claimed that trisomy 21 causes broad transcriptome-wide changes, with 
some studies reporting global upregulation of non-chr21 genes (Mowery et al., 2018) or 
the presence of domains of up- and down-regulation across the genome (Letourneau et 
al., 2014). However, the latter phenomenon has recently been called into question (Do 
et al., 2015), and very recently has been shown to be unrelated to trisomy and 
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detectable in both normal and trisomic samples (Ahlfors et al., 2019). Studies in adult 
DS brain tissue have found hundreds of differentially expressed genes even using 
extremely stringent statistical cutoffs (Lockstone et al., 2007b), which may reflect 
differences in cell type representation and/or cellular states. For example, some 
evidence from post-mortem DS brain samples as well as human cellular DS models 
have demonstrated increased astroglial numbers (Briggs et al., 2013; Chen et al., 2014; 
Lu et al., 2011; Mito and Becker, 1993; Zdaniuk et al., 2011). If true, this difference in 
cell-type representation alone could cause broad changes in the overall transcriptome 
of brain tissue, complicating identification of specific pathways directly perturbed by 
trisomy 21.  
Hence, it remains a challenge to understand the neurodevelopmental basis for 
cognitive deficits in DS children and adults, deficits that can vary between patients in 
severity and are now generally accepted to progress throughout adulthood. It is now 
understood that triplication of the chr21 APP gene plays a critical role in the almost 
inevitable early-onset of AD in DS, but the neurodevelopmental changes are far less 
understood than the later-stage neurodegeneration. In summary, numerous molecular 
pathways have been touted as central to DS pathogenesis, however, little consensus 
has been reached as to the transcriptional changes and pathways impacted nor on the 
specific cellular pathologies that characterize differences in the DS human brain. Thus, 
new methods are needed to investigate and better characterize the cellular changes of 
DS neurodevelopment and allow identification of the molecular pathways involved, 
information essential for the development of effective therapeutic targets and strategies 
of any kind.  
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In the prior chapter, I used primarily monolayer neural differentiation to examine 
the functionality and effects of XIST-mediated chromosome silencing in a defined 
pathway of neurogenesis. This proved a valuable approach to examine a precise 
developmental window of neurogenesis. However, studies in this chapter pursued a 
complementary approach, using cerebral organoids, a new technology that I introduced 
into the Lawrence laboratory. 
Recently, cerebral organoids have emerged as a new model system for studying 
early human neurodevelopment in a more developmentally appropriate three-
dimensional environment (Di Lullo and Kriegstein, 2017). In addition to providing the 
potential to examine spatial relationships between developing neural cells and tissue 
layers, organoid systems also allow for the generation of a variety of cell types and to 
examine them over longer time frames without the need for passaging or other 
manipulation during differentiation. Not long after an early paper on human cerebral-
organoid technology was published (Lancaster et al., 2013), I became intrigued by the 
opportunity to examine development of more complex neural tissues and over a longer 
time-frame. Given that this was a new and more complex approach to studying human 
neurodevelopment, the first major goal of the studies of this chapter was to establish 
this technology in the Lawrence lab. This ultimately involved reproducing and evaluating 
three different organoid protocols to assess their suitability for our experimental goals, 
to determine if the presence of trisomy 21 causes discernible neurodevelopmental 
differences of human organoids compared to those derived from isogenic euploid 
iPSCs. I quickly learned that the greater complexity provided by these structures 
presents substantial advantages as well as significant challenges requiring more 
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quantitative analysis techniques. Therefore, a theme that shaped the goals and 
experiments throughout this chapter was to develop experimental design strategies that 
avoid or minimize sources of variation between isogenic samples other than those due 
to presence of an extra chromosome 21. Some of the methodological points 
demonstrated by this work have value for the field of disease modeling with human 
iPSCs more generally, whereas other specific results have significant implications for 
the fundamental biology of trisomy 21. 
Here, we test three organoid generation protocols out of a larger compendium of 
recently-developed organoid protocols as representing the range of undirected to 
directed organoid approaches. We use DS patient-derived iPSCs and utilize a directed 
forebrain spheroid method to perform in-depth transcriptional investigation of trisomic 
and disomic conditions. We examine both potential cell type representation differences 
as well as non-chr21 expression changes in three trisomic and three isogenic disomic 
cell lines. 
Results 
The results below detail the progression of experimental design improvements 
based on results of earlier observations. The last and largest experiment was 
formulated based on lessons learned from our initial cerebral organoid studies, which 
highlighted the need to address several sources of variation between samples that are 
often present but not due to trisomy 21. A summary of potential sources of confounding 
variation that are often present (but not due to trisomy 21) are listed in Table III-1, most 
of which are also relevant to human disease modeling with iPSCs generally. DS studies 
have reported numerous phenotypic and transcriptional differences attributed to trisomy  
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Table III-1: Potential sources of variability in iPSC disease modeling 
Sources of variability Strategies used in this study to 
lessen variability 
Genetic differences between individuals Isogenic cell lines 
Between isogenic clones Subclones from same reprogramming 
event 
Within a clone 
- Genetic drift 
- Epigenetic drift 
- Freeze/thaw bottleneck 
No freeze/thaw between differentiations 
in same experiment 
Difference between individual organoids Pooling large numbers of organoids 




in human or mouse neural tissues and cells, however it is often difficult to know whether 
other potential differences between samples has been ruled out. In order to examine 
whether trisomy 21 per se impacts the development of cerebral organoids in any given 
assay, part of our goal here became to understand the extent to which differences may 
arise from other factors: e.g. variation between organoids, cell lines, experiments, cell 
representation, etc. This led us to focus on quantitative transcriptome analyses using an 
expanded experimental design of isogenic organoids, providing what we believe is the 
most comprehensive comparison of differences in trisomic versus disomic organoids 
available to date. 
Evaluating three approaches for generating cerebral organoids with DS iPSCs 
Several 3D cell culture models of cerebral development have recently been 
developed, each with its own set of advantages and drawbacks. Most significantly, 
protocols differ in the usage of exogenous patterning molecules. Lancaster et al. (2013; 
2014) utilize a protocol with minimal patterning and make use of the “default fate” of 
differentiating pluripotent cells to become rostral neuroectoderm. This results in the 
generation of several cerebral cell types, including meninges, choroid plexus, and 
cortical zones including self-organizing neural stem cell niches and surrounding 
neurons. The potential advantages of minimal patterning in generating a model of 
neurodevelopmental disorders include diminishing the potentially overriding effects of 
non-physiologic levels of patterning and mitotic factors on a subtle defect in 
differentiation and/or proliferation. Additionally, modeling a wide range of cell types that 
could be involved in disease pathogenesis in a dense 3D environment could reveal 
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phenotypes absent in monoculture. On the other hand, the broader range of cell types 
produced may include those that are likely of peripheral relevance to cognitive disability. 
Because of this, protocols based on advances in developmental neurobiology 
and 2D culture techniques have utilized patterning molecules to establish region-
specific 3D models of human neurodevelopment. In particular, Paşca et al. (2015) utilize 
dual-SMAD inhibition, high concentrations of the mitogens FGF2 and EGF, as well as 
the neurotrophins BDNF and NT3 to generate spheroids that include only cortical-like 
cells, including both neurons and astroglia. A third protocol utilizes SMAD inhibitors as 
well as mild WNT signaling activation, which ameliorated apoptotic cell death and 
potentially further dorsalized the organoids (Qian et al., 2016, 2018).  
Protocols also differ in their attempts to minimize necrosis in the center of 
organoids that is largely inevitable due to the lack of vascularization and poor oxygen 
penetration. While some have cultured organoids in very high (40%) oxygen 
environments (Kadoshima et al., 2013), most protocols involve aeration of the media 
with bioreactors and orbital shakers (Lancaster et al., 2013) or miniaturized bioreactors 
(Qian et al., 2016). In addition to aiding with necrosis and increasing overall organoid 
size, spinning in a bioreactor has also been shown to improve formation of large 
ventricular-like zones compared to stationary culture conditions (Lancaster et al., 2013). 
Interestingly, one protocol reports static culture of spheroids that grow up to 4mm in 
size, but does not attempt to reduce necrosis through aeration or increased oxygen 
concentration (Paşca et al., 2015). 
Finally, some protocols rely on a provided extracellular matrix in the form of a 
mouse tumor-derived gelatinous protein mixture (Matrigel) to enhance production of 
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cortical ventricular-like zones (Lancaster et al., 2013; Qian et al., 2016). This comes at 
the cost of increased variability due to inconsistent embedding and lot-to-lot variability of 
growth factors present in this biologically derived material, as well as increased labor 
costs and decreased throughput associated with this added step. Protocols that omit 
Matrigel embedding still generate ventricular-like zones, though smaller and less 
complex (Mariani et al., 2012; Paşca et al., 2015).  
 In order to develop a model of DS neurodevelopment in the lab, I tested these 
protocols using isogenic iPSCs with trisomy 21 and their disomic controls. First, I 
generated cerebral organoids, as previously described (Lancaster and Knoblich, 2014; 
Lancaster et al., 2013). This protocol generated large ventricular-like zones with tightly 
packed neural stem cells surrounded by outwardly migrating postmitotic neurons 
(Figure III-1A). However, these structures constituted a minority of cells in each 
organoid, which were largely composed of self-organizing cells in a non-ventricular 
pattern, reminiscent of choroid plexus-like tissue as well as other cells lacking clear 
organization (Figure III-1A’). Because we aim to examine the effects of trisomy on 
cortical neurogenesis, we decided that this protocol was not sufficiently reproducible to 
achieve this goal. 
 Next, we created forebrain organoids with minor modifications (see methods) 
(Qian et al., 2018). After ~50 days, these organoids formed a large number of large, 
well-organized ventricular-like zones (Figure III-1B). The organoids were largely 
comprised of VZs with very few regions that showed organization of a different cerebral 
cell type. These organoids demonstrated a particularly striking contrast between NSC-
containing VZs and surrounding neuron-containing regions. This characteristic was  
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Figure III-1: Evaluating three approaches for generating cerebral organoids with 
DS iPSCs 
 
A-C) Immunofluorescence photomicrographs of representative cortical regions in three 
selected organoid generation protocols. A’) Non-cortical region in organoid generated 
with Lancaster protocol, which resembles choroid plexus in organization. B’) Cortical 
region of organoid generated with Qian protocol but lacking the distinct radial 
organization seen in (B). D) Visual summary of protocol generation protocols. All 
protocols utilize the same first step of single-cell dissociation and re-aggregation in 96-
well plates. E) Example of 90-day organoids generated with Paşca protocol and 
demonstrating robust GFAP expression, suggestion formation of astrocytes. Wide 
variability between individual organoids can be seen, which makes quantification of cell 




Figure III-1: Evaluating three approaches for generating cerebral organoids with 
DS iPSCs 
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taken advantage of in the previous chapter to validate the monolayer findings of 
impaired initiation of XIST transcription in postmitotic neurons, and this protocol could 
be used for other studies going forward, particularly for examination of early VZ 
formation and the cell dynamics within VZs. While some batches generated robust VZ-
containing organoids, others did not produce the characteristic morphology, potentially 
due to inconsistencies in Matrigel embedding and subsequent disembedding (Figure III-
1B’). This, along with the increased labor required to generate these organoids with 
Matrigel embedding, motivated us to find another protocol that could generate 
organoids with higher throughput.  
 To this end, we generated cortical spheroids, this time with some significant 
modifications in order to consistently generate organoids in our hands (Paşca et al., 
2015). Most significantly, the exposure to SMAD inhibitors was increased from one to 
two weeks, and the subsequent mitogen and neurotrophin treatments were thus 
delayed by one week. Nevertheless, this protocol produced large spheroids containing 
smaller VZ-like zones along with some unorganized progenitor containing areas (Figure 
III-1C). A visual summary of the organoid differentiation protocols tested in this chapter 
is provided in Figure 3.1D. Additionally, prolonged culture generated significant 
numbers of GFAP-expressing astrocytes (Figure III-1E), production of which is limited in 
other protocols due to the lack of a progenitor expansion step. Together, these 
favorable characteristics encouraged us to utilize this organoid generation protocol 
going forward to examine the effects of trisomy on neurodevelopment in aged 
organoids. 
 99 
After early attempts to analyze potential differences in cell type representation 
using histological methods, we quickly came to the conclusion that the still-large degree 
of variability from organoid to organoid makes accurate quantification a particularly 
difficult task (Figure III-1E). For this reason, we turned to bulk RNA sequencing to 
determine cell type representations of trisomic and disomic organoids. 
Initial studies identify differences in organoid cell type representation  
Our first pilot RNA sequencing experiment in organoids used bulk RNAseq of 10 
organoids aged for 160 days, five from an isogenic trisomic (parental) line and five from 
the euploid control line. Use of isogenic lines avoids differences in genetic background, 
and the comparison of subclones of the same iPS line avoids differences in the iPS 
reprogramming process or the somatic cell of origin. The overall strategy was to 
generate bulk sequence data and use published gene sets for different cell-types to 
deconvolve the cell-type representation of the bulk sequencing. To evaluate the 
variation between individual organoids in this first experiment, we sequenced the 10 
organoids individually. 
We generated RNAseq data for the 10 organoids, each sequenced to a depth of 
~30 million reads with 100bp paired-end reads, which provided strong quantification of 
mRNA levels for each gene, as evidenced by the reproducible difference in chr21 
expression between trisomic and disomic organoids (Figure III-2A). Further analysis of 
the transcriptome differences between disomic and trisomic organoids indicated that, in 
addition to changes in upregulation of many chromosome 21 genes (red), there were 
widespread changes in expression levels of non-chromosome 21 genes between these 
samples (Figure III-2B). As described in the introduction, widespread differences in non- 
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Figure III-2: Initial studies identify differences in interneuron or glia cell 
representation between small pools of disomic and trisomic organoids  
 
A) Fraction of chromosome 21 reads in each individual organoid sequenced. Trisomic 
organoids have close to the expected 1.5-fold increase in chromosome 21 expression 
compared to disomic organoids. B) Volcano plot comparing 5 trisomic vs. 5 disomic 
organoids. Chr21 genes are circled in red and expression level is signified by colors 
ranging from blue (low expression) to green (high expression). DLX family genes and 
GFAP are labelled. C) Estimated composition of each organoid into cell types using 
defined gene sets (further described in methods section). D-E) Pooled qPCR 
quantification of DLX1 (D) and GFAP (E) expression, normalized to GAPDH. Each dot 





Figure III-2: Initial studies identify differences in interneuron or glia cell 
representation between small pools of disomic and trisomic organoids 
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chromosome 21 gene expression is currently a common finding in published studies of 
trisomy. 
Most notably, analysis of differentially expressed non-chr21 genes between the 
two conditions showed many DLX family genes, each identified as downregulated on 
average in the trisomic organoids (Figure III-2B). These genes are well-known for their 
involvement in the specification and migration of ventral forebrain-derived interneurons 
(Anderson et al., 1997; Cobos et al., 2007; Paina et al., 2011; Stühmer et al., 2002), and 
there have been mixed reports in human samples and cell models of whether 
interneuron generation is decreased or increased due to trisomy (Bhattacharyya et al., 
2009; Huo et al., 2018; Ross et al., 1984; Wisniewski, 1986; Xu et al., 2019). 
To further investigate whether other interneuron-related genes followed the same 
pattern, and to determine whether other cell types also had altered representations in 
trisomic organoids, we utilized marker gene lists recently generated by single-cell RNA 
sequencing of human cerebral organoids (Quadrato et al., 2017). There could be a 
statistically significant difference on average between these two samples of five versus 
five organoids, but that does not itself address whether this reflects a consistent 
difference in neurodevelopment between these trisomic versus control cells. 
Deconvolution of cell type representations for each individual organoid demonstrated 
overrepresentation of forebrain-derived cells in the disomic condition, largely driven by 
an increase in interneuron generation (Figure III-3C). Importantly, this effect was driven 
by three disomic organoids which had large numbers of this cell type, whereas two 
disomic organoids had similar interneuron composition to the trisomic organoids. A 
second difference in cell-type representation was observed for radial glia cells, which 
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were overrepresented in trisomic organoids, with a corresponding increase in GFAP 
expression, a gene also expressed in astrocytes, in these samples (Figure III-2B). Thus, 
despite using a directed organoid generation protocol, significant variability between 
individual organoids in interneuron formation weakens any conclusions that can be 
drawn on this point.  
 In an attempt to minimize differences between individual organoids, and to 
investigate whether similar findings could be identified in younger organoids, we 
generated several batches of organoids grown for 90 days and examined them in pools 
of ~8 organoids by RT-qPCR for a prominent marker of interneurons, DLX1, as well as 
for GFAP. We found that DLX1 expression remained highly variable between 
experiments and inconsistently showed an increase in disomic organoids over trisomic, 
although we note that higher expression in organoids from the parental (trisomic) line 
was not seen in these experiments (Figure III-2D). On the other hand, GFAP expression 
was consistently upregulated in the trisomic organoids, by about 3-fold (Figure III-2E). 
This indicates that either the trisomic cells generate more radial glia and/or astrocytes, 
or that these cell types produce higher levels of GFAP mRNA in the trisomic condition.  
Expanded experimental design to discriminate differences due to trisomy 21 
The above findings provide some evidence of differences in organoid 
development that correlates with the trisomic condition, but questions remain as to 
whether these differences could reflect other sources of variability. Therefore, we 
greatly expanded the experimental design in order to increase the power to discriminate  
differences due to trisomy from differences due to variability between individual 
organoids, different experiments, or even between isogenic cell lines. In this experiment  
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Figure III-3: Expanded experimental design to discriminate differences due to 
trisomy 21 
 
A) Micrographs of nearly all organoids generated in this experiment. Independent 
differentiations are signified by “org”, isogenic trisomic lines by “par”, and isogenic 
disomic lines by “dis”. B) Schematic of samples generated. Each of the 48 dots 
represents 12 organoids and one sample for sequencing, while the 3D cylinders signify 
in silico collapsing for statistical comparison. C) Fraction of chromosome 21 reads for 
each pooled sample sequenced. D) Estimated composition of each sample into cell 
types using defined gene sets. E) Estimated cell-type composition of collapsed samples 




Figure III-3: Expanded experimental design to discriminate differences due to 
trisomy 21 
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we generated a total of over 1,000 organoids from three trisomic and three disomic 
isogenic iPSC lines (Figure III-3A), which were derived from the same iPS cell 
reprogramming event. To minimize effects of individual organoid differences, we 
examined pools of 12 organoids, generating four pools per cell line, and this scheme 
was repeated in four independent batches of organoids. Roughly half of these 
organoids were used for bulk RNA sequencing, with 2 pooled samples per cell line per 
batch, for a total of 48 samples (Figure III-3B). The remaining organoids were frozen for 
histology and media preserved for potential future analyses on parallel samples. 
Initial sequencing analysis confirmed expected differences in chromosome 21 
expression, with all trisomic lines having ~1.5-fold higher levels of chromosome 21 
transcripts compared to disomic lines (Figure III-3C). We next set out to use this 
transcriptome data to determine the cell type composition of each sample using the 
same list of gene markers described above, based on published single-cell seq studies 
defining specific gene sets. We found that nearly every sample was mostly composed of 
forebrain-type cells, with significant contributions from astroglia, dopaminergic neurons, 
neuroepithelial cells. Surprisingly, this analysis revealed that some organoid samples 
contained a subset of mesodermally-derived cells (Figure III-3D), suggesting some 
degree of off-target differentiation.  
Notably, there was no consistent or statistically significant difference in the 
proportions of the categorized cell-types between the disomic and trisomic states 
(Figure III-3E). Differences in cell-type representations between cell lines of the same  
state (disomic or trisomic) were detected, but these were not consistent between the 
disomic versus trisomic lines. Comparison of results for a given line between 
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independent differentiations suggested that some variation appears sporadic but may 
also reflect inherent epigenetic differences between even isogenic cell lines which may 
evolve in culture (Table III-1). We cannot rule out that the variability detected between 
cell lines may mask the presence of more subtle differences in the propensity of disomic 
and trisomic organoids to form different neural cell types.  
 A theme of recent transcriptome studies in DS cells and tissues is the finding of 
extensive transcriptome-wide differences between trisomic and euploid samples. This is 
also suggested in our initial experiment comparing individual organoids from trisomic 
and disomic iPSCs. To determine whether this expanded organoid experiment would 
affirm a similar finding, we examined differentially expressed genes (DEGs) between 
disomic and trisomic organoids. An important aspect of this statistical analysis was to 
avoid amplification of clone-specific differences by treating repeated measurements 
from different experiments on the same cell sample as four independent measurements, 
a form of pseudoreplication which results in inappropriately inflated p-values. Thus, our 
analysis collapsed replicate samples and samples from different differentiations of the 
same cell line and compared organoids generated from the 3 trisomic lines to 3 isogenic 
disomic lines (Figure III-3B).  
This analysis detected strong upregulation of genes across chromosome 21, with 
159 of 250 expressed chr21 genes meeting statistical criteria for differential expression, 
generally at or near the 1.5-fold level expected in trisomic cells (Figure III-4A). 
Interestingly, a notable exception was the RWDD2B gene, which was over 13-fold 
upregulated in trisomic samples. The most striking finding, however, was that despite 
the robust detection of differentially expressed chromosome 21 genes, no non-chr21  
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Figure III-4: Genome-wide transcriptome analysis of expanded organoid 
experiment 
 
A) Volcano plot of collapsed 3 vs. 3 comparison of trisomic and disomic conditions. 
Chr21 genes are circled in red. No statistically significant (FDR<0.1) genes are 
detected. B) Volcano plot of the same comparison as in (A) but including the degree of 
forebrain representation as a covariate for each sample. The 3 non-chr21 genes that 
are identified as statistically significant (FDR<0.1) are labelled. C) Individual gene plots 
for two astrocyte marker genes, GFAP and AQP4 which do not meet statistical 
difference thresholds but trend towards higher levels in trisomic samples. D) Expression 
level in each sample of two of the non-chr21 genes identified in (B) as statistically 









transcriptome changes were detected (FDR<0.1) in this greatly expanded experiment. 
This suggests that the genome-wide differences found in the smaller-scale experiment 
above (Fig III-2B) may reflect biological differences between the cell lines compared, 
rather than due to trisomy. However, two astrocyte marker genes, GFAP and AQP4, 
both showed a trend towards upregulation in trisomic samples, although these did not 
meet this significance threshold, likely due to variable expression between samples 
(Figure III-4C).  
 The paucity of non-chr21 DEGs detected in this expanded study fits with the lack 
of consistent differences in cell type representation between the two groups shown 
above, since consistent differences in cell-type representation would likely result in 
many cell-type specific genes being differentially expressed between the two groups. 
On the other hand, inconsistent variation in the cell type representations between all the 
cell samples (not correlated with trisomy/disomy) might increase gene expression 
variability that potentially could obscure any subtle changes in gene expression 
between the two groups. In an attempt to correct for this possible effect, we normalized 
the data in each sample for the dominant cell type, the proportion of forebrain cells. 
Importantly, this correction increased the number of significantly DE chr21 genes to 175 
(Figure III-4B), indicating an increase in power due to decreased variance by correcting 
for differences in cell type representations between cell lines. Off of chr21, three hits 
emerged, SOX4, APOE, and a lowly expressed pseudogene RP11-848P1.9. As 
expected for the emergence of significant genes when correcting for cell type  
representation, SOX4 and APOE are correlated, positively and negatively, respectively, 
with the estimated proportion of forebrain cells (Figure III-4D). Of these, SOX4 
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expression was downregulated in trisomic samples, whereas APOE and RP11-848.9 
were more highly expressed. The implications of these findings are considered in the 
discussion. 
Discussion 
 The overall goal of this study was to use recently developed cerebral organoid 
technology to shed light on the molecular and cellular pathways altered in early DS 
neurodevelopment. Understanding how and when brain development and/or function is 
impacted in DS is critical to assess therapeutic prospects to mitigate cognitive or 
neurological deficits due to trisomy 21. Numerous studies report a variety of differences 
thought to be due to trisomy in mouse models or human DS tissues and cells. However, 
results are often inconsistent or even contradictory between studies. Experiments here 
focused on disease modeling with human iPSC and organoid technology and the overall 
findings have significant implications for understanding the extent to which trisomy 21 
impacts early fetal neurodevelopment.  
 As this study progressed from smaller scale experiments to the much larger final 
experiment, we worked to minimize or account for potential sources of variation in 
human cell modeling of DS on several levels. From the start we used a totally isogenic 
system, generated organoids with a semi-directed (less variable) forebrain protocol, and 
used multiple large pools of organoids per sample in order to control for individual 
organoid variability. The larger numbers of pooled organoids were generated from each 
of six isogenic lines (three trisomic and three disomic) that are subclones representing 
the same iPSC reprogramming event, which may be important, as some have reported 
a differential capacity for neurogenesis of different iPSC lines derived from single 
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somatic cells (Koyanagi-Aoi et al., 2013). Finally, the entire large organoid production 
scheme was repeated four times, allowing us to assess and account for variability 
between experiments.  
Due to these efforts we were able to improve detection of what is a relatively 
subtle 1.5-fold expected increase in expression for individual chromosome 21 genes, 
with over 70% of expressed chr21 genes meeting statistical criteria for differential 
expression due to trisomy. This is substantially more chr21 DEGs than detected in our 
smaller experiment or in most studies of DS tissues or cells, which, paradoxically, report 
many more off-chr21 DEGs than found here (Letourneau et al., 2014; Mowery et al., 
2018; Olmos-Serrano et al., 2016; Vilardell et al., 2011; Weick et al., 2013). Despite 
especially robust detection of chr21 DEGs, our largest experiment did not find 
significant evidence for genome-wide transcriptional deregulation of non-chr21 genes. 
In our smaller experiment (comparing five organoids each from a trisomic and a disomic 
line), more genome-wide expression differences were detected between these samples, 
but, importantly, the larger analysis leads us to reinterpret these results as likely 
reflecting other sources of biological variability that we cannot conclude is 
“dysregulation” due to trisomy 21.  
Consistent with a lack of abundant non-chr21 DEGs, the more powerful 
experimental design did not detect statistically significant differences in cell-type 
representations between trisomic and disomic organoids. Instead, despite pooling large 
numbers of organoids to eliminate individual organoid variability, we saw considerable 
variability between cell lines of the same chr21 state. Additionally, while some lines, 
such as DisB, consistently generated similar proportion of cell types from differentiation 
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to differentiation, others, like ParA, had considerable variability from one differentiation 
to another. These differences between cell lines of the same condition could obscure 
subtle changes in cell type representation caused by trisomy 21. 
 Organoid technology affords the opportunity to examine development of a 
greater complexity of cell-types, however that complexity also can introduce analytical 
challenges. Our analysis showing overall variation in cell-type proportions persists 
between samples, even in a more highly powered experiment than generally used, and 
this variation can weaken the power to identify differences genuinely due to trisomy 21. 
In an effort to minimize this noise, we normalized results for the proportion of forebrain 
cells in each sample. Following this correction, three statistically significant non-chr21 
genes were found, two of which link to important cellular processes which could be 
aberrant in a range of DS neural cell types. Notably, SOX4 has been shown to affect 
oligodendrocyte development by induction of a Notch target gene (Braccioli et al., 2018) 
and missense mutations in SOX4 have recently been identified in patients with 
intellectual disability and facial dysmorphism (Zawerton et al., 2019). The role that 
SOX4 plays in DS neurodevelopment has not been examined but results here suggest 
a new hypothesis and opportunity to explore both the upstream cause (stemming from 
trisomy 21) of SOX4 dysregulation and its downstream consequences. Similarly, it 
seems striking that results also indicated dysregulation of the APOE gene which, 
through its isoforms, has been strongly linked to the risk of developing AD (Poirier et al., 
1993). Interestingly, it has been suggested that the expression level of APOE, which we 
found to be elevated in trisomic samples, may play also play a role in AD pathogenesis 
(Riddell et al., 2008). 
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Previous studies in iPS-derived DS cells have described a range of findings with 
many reporting no difference in the neuronal differentiation capacity of DS cells (Briggs 
et al., 2013; Gonzales et al., 2018; Lu et al., 2013; Shi et al., 2012b; Weick et al., 2013). 
Other studies using unrelated disomic and trisomic iPSCs in a monolayer culture 
system have demonstrated an increase in the proportion of astroglia formed by trisomic 
cells (Chen et al., 2014). Another very recent study generated patterned ventral 
forebrain organoids using DS cells and found an increase in the propensity of trisomic 
cells to form interneurons, which was correctible by knockdown of a chr21 gene, OLIG2 
(Xu et al., 2019). This finding is surprising given previous studies in iPSCs and primary 
human cells that describe the opposite finding (Bhattacharyya et al., 2009; Huo et al., 
2018; Ross et al., 1984; Wisniewski, 1986). While our findings are not directly 
comparable to this study due to significant differences in the organoid generation 
protocol, one clear advantage of utilizing organoids patterned towards a specific 
forebrain subregion as in Xu et al. (2019), is a decrease in the variability between 
organoids and the number of different cell types formed, which may allow for enhanced 
detection of disease-specific differences.  
Overall, these results raise caution about false-positive results, but also potential 
false negative results, arising due to variability from organoid to organoid, batch to 
batch, and cell line to cell line. Neurodevelopmental phenotypes may be quite subtle 
and difficult to model with iPSCs, as discussed elsewhere (Soldner and Jaenisch, 
2012). In the current study we believe we have sufficiently minimized the variability 
between organoids by studying over 500 trisomic and 500 disomic organoids. However, 
our analysis reveals that in the end, when other sources of variability are addressed, 
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these organoids are derived from three trisomic and three trisomic isogenic cell lines, 
and differences between those cell lines exist and can over-shadow milder phenotypes. 
In fact, epigenetic drift in pluripotent cells was earlier demonstrated in our lab and others 
by demonstrating variability in X-chromatin modifications and XIST RNA status in 
female ES cell lines (Hall et al., 2008; Silva et al., 2008), which we showed evolve even 
between colonies within the same culture dish (Hall et al., 2008). Thus, even isogenic 
subclones can develop epigenetic differences over time that complicate disease 
modeling. 
Ultimately, recently-developed cerebral organoid techniques offer the possibility 
to more accurately model the early stages of human neurodevelopment with the added 
potential to apply modern cellular biology techniques and manipulations to study 
previously inaccessible developmental programs in unprecedented detail. However, 
precise differentiation protocols must be tailored to the specific experimental question at 
hand and currently may result in highly variable differentiation conditions which 
necessitate examination of a large number of independent samples to identify 
interesting differences that emerge from the noise of variability. 
Materials and Methods 
iPSC culture 
 iPSCs were cultured and maintained as described in the previous chapter. Cell 
lines were verified for appropriate number of copies of chromosome 21 by FISH for a 
chr21 gene, APP, before each series of differentiations. RNA sequencing confirmed 
appropriate chr21 copy number. 
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Cerebral organoid differentiation 
 Lancaster protocol: organoids were generated as previously described 
(Lancaster and Knoblich, 2014; Lancaster et al., 2013). Briefly, iPSCs were dissociated 
into single cells and plated at a density of ~9,000 cells/well in 96-well round-bottom 
ultra-low attachment plates (Corning) in iPSC media containing 4ng/ml thermostable 
FGF-2 (Millipore) and 50µM Y-27632 (Tocris Bioscience). After 6 days, organoids were 
transferred to ultra-low-attachment 24-well plates in N2 and heparin-containing neural 
induction media. Organoids were embedded in Matrigel droplets on day 11 of 
differentiation and grown for 4 days before transferring to an orbital shaker set at ~100 
RPM.  
 Paşca protocol: spheroids were generated as previously described (Paşca et al., 
2015) with significant alterations. The first steps of the protocol were performed as 
above, using a re-aggregation strategy. Cells were re-aggregated in 96-well plates in 
iPSC media containing 20ng/ml thermostable FGF-2 and 50µM Y-27632. The next day, 
half the media was exchanged with neural differentiation media (NDM) containing 2uM 
DMH1 (Tocris Bioscience) and SB431542 (Tocris Bioscience) as described in the 
previous chapter. Organoids were fed with this media every day for 14 days. After 14 
days, media was changed to neural media containing 20ng/ml FGF-2 and EGF 
(Peprotech) as described (Paşca et al., 2015) and moved to ultra-low attachment 24-
well plates. From this point forward, organoids were grown on an orbital shaker set at 
~100 RPM to improve aeration. At day 32, FGF-2 and EGF were replaced with 20ng/ml 
of BDNF (Peprotech) and NT-3 (Peprotech) for 18 days. At day 50, organoids were fed 
every other day with neural media without any supplements. 
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 Qian protocol: forebrain organoids were generated as described in the previous 
chapter. 
Cell fixation, RNA FISH, and immunofluorescence 
 These steps were performed as described in the previous chapter for organoid 
samples. Primary antibodies used in these experiments are listed in Table III-3. 
RNA isolation, cDNA library preparation, and high-throughput sequencing 
 These steps were performed as described in the previous chapter with the 
following modifications. Whole organoids were washed once with 1X PBS and placed 
into 2ml microcentrifuge tubes containing one 5mm steel bead (Qiagen) and 1ml of 
Trizol reagent (ThermoFisher). These samples were homogenized using the 
TissueLyserII instrument (Qiagen) on the P1 setting. Beads were then removed using a 
magnet and samples were either stored at -80C or RNA extraction, DNAse treatment, 
and RNA cleanup was performed immediately as described in the previous chapter. All 
samples had an RQN > 7.5 and strand-specific sequencing libraries were prepared 
using the NEBNext® Ultra™ II Directional RNA Library Prep Kit for Illumina® in 
conjunction with the NEBNext® Poly(A) mRNA Magnetic Isolation Module and 
NEBNext® Multiplex Oligos for Illumina® (New England Biolabs). 
Sequencing was performed by the UMass Medical School Deep Sequencing 
Core Facility on the Illumina HiSeq4000 platform to a depth of ~8 million reads/sample 
in the case of the large organoid experiment or on the NextSeq instrument to a depth of 
~30 million reads/sample in the case of the pilot experiment. 
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RNA sequencing analysis 
Read alignment and counting was performed as described in the previous 
chapter.  
Cell type representation deconvolution was performed using the BSeq-SC 
algorithm (Baron et al., 2016). Pre-averaged pseudobulk estimates of single cell 
sequencing data from Quadrato et al. (2017) were used as the basis vectors for 
deconvolution. The top 20 marker genes ranked by p-value for each cell cluster were 
used to determine cell type representation estimates. 
The quasi-likelihood test in the edgeR package for R was used to determine 
differential gene expression. Replicate samples and repeated differentiations of the 
same cell line were summed together to form a 3 vs. 3 comparison. Multiple comparison 
correction was performed separately for chr21 and non-chr21 genes to determine 
significant differential expression. For cell type representation correction, the estimated 
proportion of forebrain cells was included as a covariate in the statistical model. 
Reverse transcription and qPCR 
 RNA was extracted and processed as described above and in chapter II. 
Reverse transcription was performed using SuperScript III reverse transcriptase 
(ThermoFisher) per manufacturer’s instructions and using random hexamers for first 
strand synthesis. cDNA was then diluted, and qPCR reaction was set up using iTaq 
Universal SYBR Green Supermix (BioRad) per manufacturer’s instructions with the 
primers listed in Table III-2. The qPCR reaction was performed on the BioRad C1000 
Touch thermal cycler. GAPDH was used for normalization and quantification was 





Table III-2: qPCR primers used in chapter III 
Gene Primer Sequence 
GFAP F 5’-AAG-CTG-CTA-GAG-GGC-GAG-GAG-AAC-3’ 
R 5’-TGA-CAC-AGA-CTT-GGT-GTC-CAG-GCT-3’ 
DLX1 F 5’-GGC-TGT-TTG-CCA-ATT-CAG-GGT-TCT-3’ 
R 5’-TTC-GGC-TCC-AAA-CTC-TCC-ATA-CCA-3’ 
GAPDH F 5’-TGC-ACC-ACC-AAC-TGC-TTA-GC-3’ 
R 5’-GGC-ATG-GAC-TGT-GGT-CAT-GAG-3’ 
F = forward; R = reverse 
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Table III-3: Primary antibodies used in chapter III 
Antibody Host Source Identifier 
NeuN  mouse monoclonal Millipore MAB377 
Sox2  rabbit polyclonal Millipore AB5603 
TUBB3 (Tuj1)  mouse monoclonal Biolegend MMS-435P 
Sox1   goat polyclonal R&D Systems AF3369 
GFAP rabbit polyclonal Chemicon AB5804 




CHAPTER IV : Discussion and conclusions 
 The work presented in this thesis aims to demonstrate the utility of dosage 
compensation and cerebral organoids as experimental model systems to study DS 
neurodevelopment and to advance the possibility of chromosome therapy as a 
therapeutic strategy. A discussion of the results using these experimental model 
systems will be presented here, and a forward-looking evaluation of the potential of 
XIST as a therapeutic will be considered in chapter V. 
Dosage compensation to model disease 
 Work in our lab has translated the natural mechanism of dosage compensation 
orchestrated by the XIST gene to Down syndrome. We have demonstrated that an XIST 
transgene is capable of silencing an entire autosome in an inducible manner in DS 
iPSCs (Jiang et al., 2013), and that silencing of the extra chromosome can prevent 
known in vitro pathologies, such as in the hematopoietic system (Chiang et al., 2018). 
This system provides a novel way to study DS pathology by allowing for comparison of 
otherwise identical cells, with either two or three active copies of chromosome 21. This 
bypasses some of the limitations of in vitro modeling that relies on comparison of 
different cell lines, which, particularly in the case of iPSCs, can diverge over time in 
culture in ways that are unrelated to the pathology in question (Soldner and Jaenisch, 
2012; Young-Pearse and Morrow, 2016). The work presented in this thesis further 
advances the utility of this model on several fronts. 
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Dosage compensation in differentiated cells 
 In chapter II I demonstrated that contrary to the current literature, XIST is capable 
of inducing chromosome silencing in differentiated cells. This was demonstrated for 
NSCs at several timepoints in differentiation. In addition to the therapeutic possibilities 
of XIST being able to silence in differentiated cells, this also has important implications 
for both basic epigenetics and disease modeling.  
 The initial finding that XIST was incapable of initiating silencing just 48 hours 
after differentiation in mouse ESCs (Wutz and Jaenisch, 2000) generally fits with the 
idea that pluripotent cells, unlike differentiated cells, exist in a malleable epigenetic state 
that is amenable to drastic chromosomal restructuring processes like X chromosome 
inactivation. Indeed, studies have confirmed that pluripotent cells, when compared to 
their lineage-committed daughters, have unusually high levels of open chromatin marks 
(Azuara et al., 2006; Mikkelsen et al., 2007). Regions of open chromatin in pluripotent 
cells are balanced by marks of heterochromatin at the same loci (Azuara et al., 2006), 
preventing precocious expression of lineage-specific genes. It is easy to imagine how 
this “razor’s edge” of pluripotency is naturally permissible to chromosome-wide 
silencing, and how this ability may be lost in differentiated cells with narrowed 
developmental competence where large swaths of the genome have already been 
packed away in heterochromatic compartments. 
 Of course, this supposed unmalleable differentiated state has been shown to be 
malleable experimentally by the relatively recent finding that somatic cells can revert to 
the pluripotent state by the addition of a few key transcription factors (Takahashi and 
Yamanaka, 2006). Indeed, the chromatin state of iPSCs has been shown to be largely 
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identical to ESCs (Guenther et al., 2010), demonstrating a complete restructuring of 
nuclear architecture by the relatively minor perturbation of exogenous transcription 
factor expression. These findings force the reimagination of what a “stable” epigenetic 
state truly entails. 
Our results demonstrating the natural ability of differentiated cells to enact a 
chromosome-wide silencing process provide further evidence that the differentiated 
state is more malleable than previously believed. While differentiated cells are capable 
of initiating the silencing process, the prolonged silencing process that we describe may 
reflect their altered epigenetic status compared to pluripotent cells. While others have 
demonstrated the ability of mouse hematopoietic progenitors to undergo chromosome 
silencing (Savarese et al., 2006), it is unknown whether all differentiated cell types are 
capable of undergoing this process. The current study focused on neurodevelopment 
and demonstrated the silencing capacity of neural stem cells. An important area of 
future work will involve empirical testing in other cell types to determine their silencing 
capacity. An intriguing possible outcome is that differentiated cells generally show 
significant capacity to initiate silencing, but potentially with varying competency or 
kinetics, which could enable high-resolution examination of the order of XIST-mediated 
chromosome silencing events. For example, the extended silencing timeline of NSCs in 
this study allowed us to easily discern the temporal order of polycomb-mediated 
heterochromatin modifications, which further supported recent findings suggesting that 
H2AK119ub1 is laid down prior to H3K27me3 (Almeida et al., 2017; Tavares et al., 
2012). Further analysis of different cell types could help elucidate key factors required 
for the silencing process, and those involved in its modulation. 
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In addition to providing important insights into basic epigenetics, the ability of 
differentiated cells to initiate silencing also provides the unique ability to study the 
development of pathology in trisomy. Most genetic disease modeling studies use iPSCs 
or mouse models to compare control cells or animals to mutant cells harboring a genetic 
insult, but it is a challenge to determine when defects arise over the course of 
development. The studies presented here demonstrate the ability of our inducible 
system to harness a natural epigenetic mechanism to functionally correct the gene 
dosage imbalance of DS at different stages of differentiation. This powerful strategy will 
allow for a suite of studies in different cell types that may elucidate the specific cell-
types and developmental origins of pathology in DS. Moreover, this approach can 
address at what points these pathologies are reversible. 
For example, in this thesis we demonstrated the enhanced neurogenic capacity 
of neural stem cells in which XIST expression was not initiated until halfway through the 
differentiation process, implying a correctible defect in NSCs. This would provide a 
particularly powerful technique to study postmitotic neurons, whose possible ongoing 
dysfunction (Caviedes et al., 1990; Weick et al., 2013) could account for at least part of 
the cognitive disability in DS individuals. While we have shown that neurons are capable 
of maintaining XIST expression and chromosome silencing, if DS neurons were also 
shown to support the initiation of silencing, then this would afford a unique perspective 
into how trisomy 21 affects the ongoing function of a neuron. Comparison of trisomic 
and euploid cells with an identical differentiation history could eliminate several 
confounding variables unrelated to trisomic transcription and could more definitely 
address these key questions.  
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The ability to initiate chromosome-wide silencing in differentiated cells has wide-
ranging implications beyond the dosage compensation field. It clearly illustrates the 
natural epigenetic plasticity of differentiated cells that has been increasingly appreciated 
in recent years and offers a previously unachievable opportunity to study the effects of 
transcriptional correction of trisomic cells at different stages of development. 
Identification of affected pathways in DS neurodevelopment using dosage 
compensation 
 In addition to demonstrating the ability for differentiated cells to initiate dosage 
compensation, we also discovered a specific effect that reducing trisomic cells to 
functional disomy had on their neurogenic potential. We saw that cells with a silenced 
third copy of chromosome 21, either from the onset of differentiation or halfway through, 
formed a higher proportion of neurons than trisomic cells. This was initially revealed by 
single-cell RNA sequencing analysis and confirmed cytologically in multiple transgenic 
iPSC clones. Transcriptional analysis further identified a significant difference in Notch 
pathway genes between trisomic and disomic cell states. The well-known involvement 
of the Notch pathway in controlling the transition of NSCs to neurons suggests that the 
downregulation of this pathway in silenced cells may be responsible for their enhanced 
neurogenic potential or kinetics. Additionally, the finding that one of our most significant 
hits, TTYH1, has been reported to function upstream of Notch signaling (Kim et al., 
2018), suggests a new potential area of investigation to look for regulators of TTYH1 or 
its upstream mechanisms encoded on chr21.  
The association of chr21 genes to specific cellular phenotypes has been a major 
challenge in the field, and future studies could utilize classical biological perturbation 
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tools for interrogating the involvement of single chr21 genes in generating this 
phenotype. One association that has been proposed, the dependence of an over-
production of interneurons in a mouse model on the Olig1/2 genes (Chakrabarti et al., 
2010), has recently been suggested to play a similar role in a human in vitro cell model 
(Xu et al., 2019). However, substantial evidence from other mouse models and human 
studies suggest this association may not be a consistent effect across model systems 
(Bhattacharyya et al., 2009; Huo et al., 2018; Ross et al., 1984; Wisniewski, 1986). 
Perhaps one of the few reproducible associations with strong evidence in patients is the 
role of APP in AD pathology. Thus, novel strategies to elucidate genotype-phenotype 
associations are needed, and XIST-based tools being developed in our lab to inducibly 
silence small portions of chromosome 21, including the important DYRK1A locus, could 
play a role in narrowing key chr21 loci in DS pathology.  
We believe our phenotypic findings in chapter II reflect the ability of inducible 
dosage compensation to identify chr21-dependent cellular effects because of the 
uniquely well-controlled nature of this system. As discussed in that chapter, we did not 
identify a difference in the neurogenic capacity between the trisomic and disomic cell 
lines examined. As detailed in chapter III, a wide assortment of variables affects iPSC 
disease modeling in general (Table III-1), most of which are mitigated or eliminated by 
comparison of trisomic cells to dosage corrected cells in the same culture. 
For example, we found that the dosage corrected cells preferentially 
differentiated over trisomic cells while in the same exact environment with identical 
Notch ligand expression. The initial preferential differentiation of dosage compensated 
cells could be due to a cell autonomous effect of reduced intrinsic Notch signaling. 
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However, the Notch pathway acts through well-known mechanisms of lateral inhibition 
(Gaiano and Fishell, 2002) whereby a newly differentiated neuron expresses Notch 
ligands that enhance Notch signaling in adjacent cells, reducing their propensity to 
differentiate. Thus, newly-differentiated dosage compensated cells would upregulate 
Notch ligand expression, preventing differentiation of adjacent cells and potentially 
amplifying the difference seen between disomic and trisomic cells. This possibility has 
implications beyond DS for studying many developmental diseases. Examining disease 
and non-disease cells grown together has the potential to identify differences that could 
otherwise be masked by a variety of non-disease related factors. 
Of course, the use of XIST-mediated chromosome silencing is not without its own 
set of limitations. As shown in chapter II, corrected XIST+ cells are more likely than 
XIST- cells to also express the tetracycline transactivator that is required for XIST 
expression in this system. While we did not see a difference in Notch gene expression 
between TET+ and TET- cells in a non-XIST transgenic line also treated with dox, other 
findings from our lab have shown that many genes are differentially expressed when 
such transactivator-containing cells (without an inducible XIST transgene) are treated 
with dox (data not shown). Thus, inclusion of such a line is important in any studies 
using an inducible system. Additionally, it is possible that XIST expression itself, 
independent of its chr21 silencing function, could somehow affect the neural 
differentiation potential of NSCs. We consider this to be a remote possibility based on 
the biology of XIST and its ubiquitous expression in female cells, but future studies 
could also include plasmid-based XIST expression as a control for this unlikely 
possibility.  
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Ultimately, we have demonstrated the ability of the recently-developed system of 
dosage compensation to correct neurodevelopmental defects in trisomy 21, potentially 
through its action on specific signaling pathways. Additionally, the demonstrated ability 
of this system to dissect precise developmental windows of opportunity has enormous 
potential to advance our understanding of DS pathogenies, which could ultimately lead 
to the development of conventional therapeutics targeting specific affected pathways. 
However, there has been suggestion in the literature that many aneuploid phenotypes 
could be caused by overall cellular stress caused by trisomic transcription and/or 
translation (Bonney et al., 2015; Oromendia et al., 2012; Sheltzer et al., 2012), which 
would imply that there may not be simple gene-phenotype associations for at least 
some aspects of DS. Addressing these phenotypes would thus necessitate a 
chromosome silencing approach, as discussed further in chapter V. 
 Cerebral organoids to study DS neurodevelopment 
Challenges to organoid modeling of subtle neurodevelopmental phenotypes 
In chapter III, we evaluated several novel organoid protocols with the goal of 
modeling trisomy 21 neurodevelopment in a more biologically relevant three-
dimensional environment. Our smaller early experiments identified promising alterations 
in cell type representation between trisomic and disomic organoids. However, due to 
high organoid-to-organoid variability we questioned if these differences were genuinely 
due to trisomy, and thus pursued expanded studies utilizing large numbers of organoids 
and three isogenic lines per condition, which could not confirm these conclusions. Thus, 
we did not identify consistent cell type representation differences due to trisomy in this 
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system. This raises the question as to whether any strong cellular phenotypes should 
be expected at this stage of DS neurodevelopment. 
As discussed in detail in chapter III, there are a number of sources of variation 
that we worked to control for in this study (Table III-1). While we believe this is a 
stronger study than most, variability between samples could still have influenced our 
results. While the experimental design has likely minimized false positive findings, the 
significant degree of variability in cell type representation between subclones of the 
same condition could mask any subtle differences in cell type representation that are 
due to trisomy. Additionally, while some lines had consistent cell type composition from 
differentiation to differentiation, others had a drastically different cell make-up from one 
experiment to the next. This could imply either epigenetic or environmental factors that 
significantly affect the differentiation of organoids and could make elucidation of cell 
type differences due to trisomy quite difficult. As in any in vitro cell culture modeling, it is 
also possible that the experimental conditions and exogenous factors present in the 
media, like mitogens and neurotrophins, could override real biological differences 
between chr21 states and lead to roughly similar cellular composition. Finally, it is 
possible that at the modeled stage of neurodevelopment, there is negligible or no effect 
of trisomy 21 on cerebral organoid development. The same factors described above 
could also explain the associated finding of very few non-chr21 gene transcription 
changes detected in the cerebral organoids. 
Future studies utilizing isogenic iPSC clones and cerebral organoids to model DS 
neurodevelopment should take into account these numerous possible sources of 
variability. Additionally, future studies could further improve upon this initial investigation 
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by increasing the number of isogenic clones used, which could increase the power to 
detect true differences related to chr21 state. Minimizing passage number from the 
initial derivation of isogenic lines could also decrease the chance for lines to undergo 
significant epigenetic drift over time in culture. Finally, utilizing an even more directed 
organoid generation protocol could decrease the number of different cell types formed 
and thus further minimize organoid to organoid and batch to batch variability. Several 
such brain-region-specific protocols have been described in the literature (Bagley et al., 
2017; Birey et al., 2017; Monzel et al., 2017; Qian et al., 2016; Xu et al., 2019), and very 
recent advances in organoid generation protocols (Velasco et al., 2019) promise to 
further improve the reproducibility of results between organoids, batches, and lines. 
Prospects and hurdles towards combining dosage compensation and cerebral 
organoids  
 Of course, many of the sources of variability described above could be 
completely eliminated by comparing cells within the same organoid, those with three 
transcriptionally active copies of chr21 and those that, due to XIST, have two. In chapter 
II, we demonstrated that this approach could be used in a monolayer culture system to 
reveal both a difference in the propensity for dosage corrected cells to terminally 
differentiate, and a potential mechanism for this finding. In principle, a similar approach 
could be used to study functionally disomic and trisomic cells in long-term organoid 
cultures. This would have the advantage over short-term monolayer cultures of being 
able to study a wider range of cell types, such as later-born astrocytes, inhibitory 
neurons, and upper-layer projection neurons. Additionally, studying more mature 
neurons has the potential to address if there are ongoing functional deficits in 
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synaptically active neurons, which could provide a more therapeutically accessible 
target for pharmaceutical intervention. 
 While this was our initial goal and represents an exciting area of potential future 
studies, we struggled to maintain long-term XIST transgene expression in aged 
organoids, as described in further detail in the appendix. However, some of the insights 
that we’ve come to as we attempted to mitigate this common problem in transgene 
studies could be applied to generate a system capable of long-term XIST expression. 
Since natural or endogenous promoters may be less likely to be silenced, this could 
include using brain-specific promoters to drive either transactivator or XIST expression, 
especially if temporal inducibility is not a requirement for the particular experimental 
question. Additionally, in an inducible system, constitutive expression of a 
transactivator-demethylase construct may potentially prevent methylation of the 
tetracycline response element in fully differentiated neurons (as further discussed in the 
appendix).  
 Still, several potential caveats of this approach must be taken into consideration. 
One difficulty is that even if a considerable number of cells remain XIST+ in aged 
organoids, it would be important to compare this number to the starting proportion of 
XIST-expressing cells. If there is significant discrepancy in these proportions, then there 
is likely a large population of cells that expressed XIST at one point in the past or are 
derived from XIST-expressing cells. This could complicate interpretation of any 
differences found between these populations, because it is possible that seemingly 
XIST- cells still retain some transcriptional silencing due to past XIST expression, or that 
their developmental trajectory was altered by their dosage compensated progenitors. 
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 Ultimately, if a robust XIST expression system could be put in place with minimal 
change in the proportion of XIST expressing cells over time in culture, this could prove 
to be a powerful resource for revealing the true effects of trisomy 21 on DS 
neurodevelopment.  
Concluding remarks 
 Together, the results presented in this thesis demonstrate the utility of a powerful 
new approach to studying DS neurodevelopment. I have demonstrated the ability of 
XIST to initiate chromosome-wide transcriptional silencing in differentiated cells, which 
opens the door to a wide variety of studies examining the dynamics of XIST-mediated 
transcriptional silencing in many cells types, allows for precise determination of critical 
developmental steps in DS pathogenesis, and overcomes a perceived obstacle towards 
the application of XIST transgenes as a therapy for DS. I identify a specific alteration in 
neurogenesis that is potentially driven by alterations in a defined pathway, Notch, that 
may be responsible for key aspects of altered DS neurodevelopment. Finally, I explored 
the ability of cerebral organoids to model DS neurodevelopment in a natural three-
dimensional environment which could allow for studying more mature in vitro cell types 
that are altered in DS. Overall, I hope these studies provide some insight into the 
cellular events that lead to cognitive disability in DS, and that these insights may 




CHAPTER V : XIST: from natural trisomy rescue to potential 
therapy  
 
The mechanisms of female X-inactivation for dosage compensation have been 
studied for decades, and yet the therapeutic possibilities of this unique biological 
phenomenon have hardly been considered. Chromosomal disorders, which are 
detected in nearly 0.6% of newborns (Shaffer and Lupski, 2000), have largely been 
regarded as beyond the reach of modern advances in gene therapy due to their 
complex underlying genetic basis. Largely unappreciated case studies in patients with 
unbalanced X;autosome (X;A) translocations have demonstrated the remarkable ability 
of XIST to rescue otherwise lethal trisomies. Additionally, recent breakthroughs have 
confirmed the ability of XIST transgenes to dosage correct chromosome 21 transcription 
in Down syndrome (DS) iPSCs. Of course, many challenges remain regarding 
translating this natural mechanism of dosage compensation to disorders of gene 
dosage imbalance. Here, I review the case study literature on trisomy rescue via X;A 
translocation, discuss the state of the art and limitations of current gene therapy 
technologies, and evaluate the biological questions that still need addressing to bring 
this transformative strategy for chromosomal disorders closer to reality. 
XIST rescues lethal trisomies in patients 
Due to the increased dosage of hundreds to thousands of genes, trisomies are 
nearly always incompatible with life. The few exceptions include small chromosomes 
with relatively fewer genes, such as chr21, trisomy for which causes DS, and the X 
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chromosome, which possesses the unique ability to undergo dosage compensation via 
the gene XIST. In fact, many women with trisomy X, who have two silenced X 
chromosomes instead of the usual one, lead perfectly normal lives and show no signs of 
harboring an extra chromosome in each of their cells (Tartaglia et al., 2010). These 
individuals demonstrate two findings critical for the translational potential of XIST: the 
complete compatibility of two XIST-expressing chromosomes with normal health, and, 
as evidenced by all XX women, that it is not the physical presence of millions of 
basepairs of extra DNA that is pathogenic in trisomy, as has been proposed by others 
(Plona et al., 2016), but rather their transcriptional output. Trisomy X patients 
demonstrate the ability of XIST to silence multiple chromosomes and render trisomy for 
a chromosome containing thousands of genes non-pathogenic. Additionally, these 
patients demonstrate that the presence of multiple XIST RNA coated Barr bodies in 
every nucleus of a person is non-toxic, and indeed necessary to rescue an otherwise 
lethal chromosomal abnormality. However, it is rare patients with X;A translocations that 
establish the power of this remarkable RNA to function beyond the X chromosome. 
One such case involves a boy with Klinefelter syndrome and a few mild 
malformations despite the presence of nearly an entire extra copy of chromosome 14, 
which contains nearly 2,000 genes (Allderdice et al., 1978). This condition, generally 
incompatible with life, was possible due to an X;14 translocation containing XIST. 
Further analysis demonstrated that the translocated chromosome late replicating, 
indicating it was transcriptionally silenced (Allderdice et al., 1978), leading to effectively 
disomic chromosome 14 dosage. Another case involved a woman with two normal 
copies of chromosome 9 in addition to a derivative chromosome containing the long 
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XIST-containing arm of the X chromosome translocated to the long arm of a third copy 
of chromosome 9 (Leisti et al., 1975). This patient did exhibit morphological 
abnormalities and learning disabilities, but considering her karyotype, the effects were 
remarkably mild due to the silencing of the trisomic genetic material. Examination of 
cultured cells from these patients demonstrated that XIST RNA from the translocated 
chromosome spread across the autosomal chromatin, albeit incompletely, along with 
hallmarks of inactivation (Hall et al., 2002b). Finally, a third case of a girl with mild 
developmental delay and dysmorphic features was shown to be caused by trisomy 15 
with an X;15 translocation (Stankiewicz et al., 2006). Even partial trisomy for 15q has 
been associated with severe cognitive disability and dysmorphic features (Kristoffersson 
and Bergwall, 1984; Pedersen, 1976), further implying that at least a large portion of 
15q is silenced in this patient leading to her mild phenotype. Together, these cases 
demonstrate that XIST is capable of effective autosomal silencing that can rescue 
otherwise lethal trisomies and lead to relatively mild phenotypes in patients.  
Recent work in our lab has further applied these natural phenomena to the most 
common autosomal trisomy, DS (Jiang et al., 2013). We inserted an inducible transgene 
for XIST into one copy of chromosome 21 in DS iPSCs as a proof of concept that these 
natural phenomena could be reproduced in the lab using modern stem cell and gene 
editing technologies. Importantly, this work demonstrated that an XIST transgene 
inserted into an autosome leads to robust transcriptional silencing chromosome-wide, in 
addition to deposition of several heterochromatin marks associated with X-inactivation 
as well as DNA methylation. While this work opened the door to the possibility of a 
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“chromosome therapy” for DS and other trisomies, several biological questions and 
technological barriers still need to be addressed. 
Biological considerations for chromosome therapy 
 The general concept of chromosome therapy has been demonstrated in living 
patients with trisomies that would be otherwise lethal were it not for the transcriptional 
silencing action of XIST. Additionally, our lab has provided a proof-of-concept that this 
powerful technique can be harnessed in vitro to target a trisomic chromosome and lead 
to its transcriptional inhibition. However, patients with a rescued trisomy have been 
dosage compensated by XIST since conception, and thus there are several outstanding 
questions relating to the function of XIST in differentiated cells and the reversibility of 
cellular phenotypes later in development that must be addressed in order to evaluate 
the viability of chromosome therapy. 
Somatic cell silencing 
 In order for chromosome therapy to be feasible in utero or postnatally, XIST must 
be able to initiate silencing in differentiated cells. As discussed in detail in the 
introduction and in chapter I, inducing XIST-mediated silencing in differentiated cells, 
potentially with the exception of hematopoietic cells (Savarese et al., 2006), has long 
been considered unfeasible because these cells are thought to lack the epigenetic 
plasticity to respond to XIST. I have shown in iPSC-derived neural stem cells that 
inducing silencing in differentiated cells is no longer a strict barrier and is not a unique 
property of hematopoietic progenitors. I have shown that silencing indeed takes place in 
differentiated neural stem cells, albeit requiring a longer timeframe than in pluripotent 
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cells. It remains possible that certain cell types will be found to be incapable of initiating 
silencing via XIST. This requires empirical testing in a variety of cell types that are 
particularly affected in trisomy. I have shown evidence that S-phase is not required for 
XIST expression, localization, and recruitment of early marks of heterochromatin, 
however the ability of postmitotic cells to initiate silencing should be tested in such cells 
capable of initiating XIST transcription. The confirmed competence of differentiated cells 
to enact the chromosome silencing process is a vital step forwards towards bringing 
chromosome therapy closer to reality. 
Correction of cellular function 
 Perhaps the biggest unknown in chromosome therapy is whether transcriptional 
silencing of the trisomic chromosome in a cell will lead to improvement in cellular 
function, and ultimately improved health and well-being of patients. This thesis 
demonstrates that early neurodevelopmental defects, such as impaired neurogenesis, 
can be corrected with chromosome silencing. Additionally, we have shown that known 
hematopoietic defects can be prevented when silencing is initiated in iPSCs (Chiang et 
al., 2018). Importantly, in this thesis we have shown that initiation of silencing in 
differentiated cells can also improve neurogenesis, suggesting that initiating silencing in 
pluripotent cells is not a requirement for phenotypic benefits. 
Currently, diagnosis of DS and other trisomies is only possible at around 8 weeks 
of gestation. At this point, neurogenesis has already begun and will continue until the 
third trimester (Bystron et al., 2006; Malik et al., 2013). This provides a potential window 
of opportunity for correcting some of the earliest defects in neurogenesis via in utero 
delivery. Clearly, animal models of trisomy silencing are required to gain an 
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understanding into whether correction at different developmental stages could mitigate 
trisomic phenotypes, such as delayed neurogenesis. Even if the earliest effects of 
trisomy are already in place at the time of intervention, later cellular events that have 
been found to be dysregulated in DS brains, such as defective myelination (Olmos-
Serrano et al., 2016), could still be mitigated since the myelination process continues 
well past adolescence. 
Additionally, trisomy 21 may not just impact cell differentiation and development, 
but also cellular function. Chromosome 21 encodes a number of ion channels that are 
expressed in the brain (Cramer et al., 2010; Lipsky and Goldman, 2003), and may affect 
ongoing function of trisomic neurons, which evidence indicates is altered in vitro 
(Caviedes et al., 1990; Weick et al., 2013). If XIST expression and chromosome 
silencing can be initiated in postmitotic neurons, it is possible that reversal of these 
ongoing defects could improve neuronal function and potentially cognition. 
Perhaps most significantly, the overproduction of amyloid precursor protein 
(APP) is thought to be the driving factor in the extremely high prevalence of early-onset 
AD in DS patients (Zigman et al., 1996). Reducing the transcription of this gene to 
functionally disomic levels in young DS patients prior to detectable AD pathology (Mann 
and Esiri, 1989) could prevent the development of this devastating neurodegenerative 
process. While many individuals with DS and their families have adjusted to the 
challenges of living with DS, there is considerable concern about the looming prospect 
of cognitive decline and prolonged course of AD-related dementia in relatively young 
individuals. 
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While the focus of this thesis has been on the cognitive deficits in DS, 
chromosome silencing, like all gene therapies, is of course potentially applicable to any 
tissue and cell type. Other cell systems, such as the hematopoetic system, could also 
be amenable to ex vivo therapies, which have a much longer history of success in 
clinical trials and offer potentially higher efficiencies (Grossman et al., 1994; Hacein-
Bey-Abina et al., 2002; Naldini, 2011). Additionally, while XIST-mediated chromosome 
therapy may be the only prospect for reducing cells to functional euploidy in vivo, ex 
vivo approaches could also involve other strategies for chromosomal correction, such 
as ring chromosome induction (Bershteyn et al., 2014) or selectable chromosome 
knock-out (Li et al., 2012). 
There is considerable pre-clinical testing that needs to be undertaken in order for 
the prospect of chromosome therapy to gain further momentum. We have demonstrated 
that there is no longer evidence for the previously perceived hard barrier preventing 
differentiated cells from initiating chromosome silencing. Additionally, we have shown 
that chromosome silencing is capable of correcting some in vitro phenotypes, even 
when induced in differentiated cells. Further work in mouse models of trisomy and 
advanced human cellular models, such as cerebral organoids, is necessary to 
determine what the developmental limits are for dosage compensation to correct 
trisomic transcription and cellular phenotypes.  
Technological hurdles towards chromosome therapy 
The concept for chromosome therapy reduces the problem of hundreds of 
trisomic genes down to the challenge of insertion of one gene. In this respect, 
revolutionary progress in gene therapy for less genetically complex single gene 
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disorders becomes relevant to DS and other trisomies. However, chromosome therapy 
with XIST would require other technical hurdles to be overcome. In its current form, 
chromosome therapy would require efficient delivery of a large XIST DNA transgene to 
a high proportion of cells followed by allele-specific insertion into one trisomic 
chromosome and subsequent expression of the transgene leading to transcriptional 
silencing of the chromosome. 
Efficient transgene delivery in vivo 
The necessary number of cells required for phenotypic benefit varies from 
disease to disease and from tissue to tissue. While it is hard to predict the precise 
number of corrected cells needed to improve DS phenotypes, it is safe to assume that 
delivery will need to be much more efficient than for disorders of secreted enzyme 
deficiency like b-thalassemia (Ricciardi et al., 2018), for example. Additionally, unlike for 
loss of function disorders for which plasmid-based expression or random genomic 
integration is suitable, the targeted insertion of an XIST transgene requires efficient 
delivery in the same cells of both gene editing factors and the transgene itself. 
Luckily, great strides in gene delivery techniques have been made in recent 
years, largely focused on viral vectors. While randomly integrating vectors, such as 
lentiviruses, would not be amenable to chromosome therapy requiring targeted 
insertion, others, such as adeno-associated viruses (AAV) do not readily integrate and 
instead form stable episomes carrying transgenes capable of targeted insertion (Hirsch 
et al., 2010). Several serotypes of AAV have been shown to effectively cross the blood 
brain barrier (BBB) leading to robust long-term expression in neurons and astrocytes 
(Gray et al., 2010; Miyake et al., 2011) and novel capsid selection methods have led to 
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the creation of an increasing number of neurotrophic AAV variants (Deverman et al., 
2016). Most significantly, the promising results of clinical trials (Lowes et al., 2019) and 
recent FDA approval of intravenously delivered AAV-based therapy for spinal muscular 
atrophy reinforces the incredible progress that has been made in developing viral 
vectors with efficient delivery to cells even across the BBB. One important limitation of 
many viral vectors, and AAV in particular, is their limited cargo capacity of ~5kb. This 
poses a particular problem for XIST, which has a cDNA of ~17kb, as will be discussed 
in the next section. Recombinant viruses with larger cargo capacity have been identified 
and used in preclinical trials, but their safety profiles are not as well described 
(Lachmann, 2004; Sweeney et al., 2017). 
In addition to viral delivery systems, non-viral approaches have also seen 
enormous progress in recent years. While non-viral systems lack the natural tropism of 
viral vectors and therefore generally have lower delivery efficiency, their main 
advantage is lower toxicity and immunogenicity. Lipid nanoparticles (LNPs) are currently 
the leading non-viral delivery method, with clinical trials currently underway for small 
RNA-containing LNPs, and progress is being made towards encapsulating and 
delivering mRNAs and DNA (Cullis and Hope, 2017). Additionally, viral-like particles 
containing gene editing tools and repair templates have also been developed (Mangeot 
et al., 2019), along with hybrid models utilizing LNP-delivered gene editing tools and 
virally-delivered repair templates (Yin et al., 2016). Taken together, as this fast-moving 
field progresses with ever-more efficient technologies, chromosome therapy will be able 
to take advantage of delivery tools with broad applicability to any gene therapy requiring 
highly efficient delivery. 
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Smaller functional XIST transgenes 
 As alluded to above, the XIST gene poses a particularly difficult problem for 
delivery technologies due to its large size. Additionally, because it does not encode a 
protein, elucidation of the function of each of its domains is particularly difficult. Despite 
this, progress has been made toward identifying regions of the XIST genes necessary 
for certain attributes of this lncRNA, such as recruitment of heterochromatin modifiers 
and gene silencing. Most significantly, the A-repeat region of XIST has long been known 
to be necessary for its silencing function (Wutz et al., 2002) and has also been shown to 
be sufficient for silencing of adjacent reporter genes (Minks et al., 2013). Recent work 
suggests that the A-repeat alone is also capable of silencing endogenous genes several 
Mb away from its site of insertion (Valledor et al., in preparation). Intriguingly, the A-
repeat has been shown to modestly repress gene expression when recruited to a 
genomic location via catalytically inactive dCas9 enzymes (Shechner et al., 2015), 
suggesting that integration into the chromosome may not be required for its silencing 
function. Together, there is considerable evidence to suggest that insertion of a full-
length XIST transgene may not be necessary to lead to a relevant degree of 
transcriptional repression, which could considerably lower the barriers to chromosome 
therapy.  
Directed allele-specific transgene insertion 
 Once the transgene can be delivered to a large proportion of cells it must then be 
inserted into one copy of the trisomic chromosome in order to initiate transcriptional 
silencing. The first step in this process is accurate generation of double strand breaks 
(DSB) using a targeted nuclease. This has been perhaps the most prolific area of 
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research particularly in the past 5 years since the discovery of the easily programmable 
CRISPR-Cas9 system (Dai et al., 2016). While there are still some limitations regarding 
where in the genome a nuclease can be targeted, the rapid proliferation of newly 
discovered and engineered nucleases with varying protospacer adjacent motif (PAM) 
sequences promises to render nearly the entire genome available for editing. The 
specificity of these nucleases has been demonstrated to be capable of allele-specific 
genome editing in disease loci (Smith et al., 2015), yet a remaining concern is the 
degree of off-target DNA cleavage, which could potentially lead to off-target integration 
and, more likely, off-target mutagenesis (Fu et al., 2013). This has led to the 
development of progressively more precise nuclease variants with minimal off-target 
effects (Kleinstiver et al., 2016) as well as a move towards transient expression of 
nuclease components in an attempt to minimize off-target DSBs (Yin et al., 2016).  
 Once the DSB is created, the transgene must be efficiently inserted into the 
genome. In dividing cells, homology directed repair (HDR) is capable of inserting a 
donor DNA template at the cut site, albeit at a relatively low frequency (Hirsch et al., 
2010). However, the efficiency of HDR drops to extremely low levels in non-dividing 
cells, such as neurons, necessitating a different insertion strategy. Several such 
strategies have been developed (Nami et al., 2018; Yamamoto et al., 2015), one of 
which is termed homology-independent targeted integration (HITI). HITI utilizes non-
homologous end joining machinery which is active in non-dividing cells and has been 
shown to be extremely efficient in vitro with close to 50% of cells containing the targeted 
gene modification (Suzuki et al., 2016). In vivo editing using HITI is significantly more 
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efficient than HDR and ongoing efforts in numerous labs are resulting in substantial 
incremental improvements.  
Stable transgene expression 
 As described in chapter I of this thesis as well as in the appendix, transgene 
silencing is a common occurrence even in in vitro models of chromosome silencing. 
XIST possesses the unique feature of laying down several redundant layers of 
heterochromatin marks. Thus, once the repressive chromatin structure is triggered by 
XIST, the RNA is no longer strictly required to maintain the silent chromosome state 
(Brown and Willard, 1994). However, expression of the XIST transgene will be 
absolutely required to initiate chromosome silencing in cells. Additionally, as described 
in chapter I, the silencing process can be significantly prolonged in differentiated cells, 
requiring XIST expression for at least several weeks in neural cells to lead to complete 
chromosome silencing. 
 Transgene silencing has also affected early gene therapy trials (Bestor, 2000), 
with one patient dying of his underlying disease likely due to the progressive silencing of 
the therapeutic gene (European Society of Gene Therapy (ESGT), 2006). Eukaryotic 
cells have evolved considerable defenses to prevent ectopic gene expression, 
particularly from viral sources, which makes their use a particular challenge. Several 
strategies can be employed to optimize transgene expression such as careful selection 
of ubiquitous or cell-specific promoters, inclusion of an efficient polyadenylation signal to 
the transgene of interest, as well as the inclusion of introns that can increase transgene 
expression (Powell et al., 2015). 
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Chromosome position effects also have a major impact on transgene silencing 
but are difficult to predict. Selection of purported “safe-harbor” locations for insertion of 
the transgene would be impractical for a chromosome therapy strategy due to the 
limited number of such sites which are not present on chr21 or other chromosomes 
compatible with trisomy. While certain strategies can be employed to maintain a 
euchromatic state at the site of insertion, such as utilizing a ubiquitous chromatin 
opening element (UCOE) (Kunkiel et al., 2017), ultimately selection of a target site may 
require empirical testing without the guarantee that a universally permissive site exists 
(Papapetrou and Schambach, 2016). The pervasive issue of transgene silencing is 
poorly understood and remains a technological hurdle for effective gene replacement 
therapies but can likely be overcome through a process of trial and error including 
testing in suitable human cell models. 
 The biological tools are largely in place to accurately insert a transgene into one 
copy of a trisomic chromosome in vivo, at least in theory. However, considerable 
incremental progress on multiple technical fronts is still required in order to increase the 
efficiency of each step described above, and to provide a meaningful chance at clinical 
improvement in trisomies.  
Conclusions 
 Thanks to recent advances in delivery systems, editing technologies, and 
improved safety profiles, the gene therapy revolution is finally making a significant 
impact on the lives of patients and families with rare monogenetic disorders. The rescue 
of natural trisomies by X;A translocations and the recent proof-of-concept that this 
strategy can be harnessed in the lab provide hope that XIST-mediated chromosome 
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therapy may one day offer a viable therapeutic approach to individuals and families with 
common trisomies like DS. Figure V-1 summarizes the biological considerations, some 
of which have been addressed in this thesis and previous work in the lab, as well as the 
technological barriers towards the development of chromosome therapy. Significant 
progress must still be made for this dream to become reality, and several important 
biological questions about potential efficacy remain unanswered. This new therapeutic 
strategy to trisomy also brings with it many important ethical considerations, including 
the need to safeguard the interests of vulnerable populations such as children with 
intellectual disabilities, and the need to consider the potential germline effects of 
targeted XIST insertion. Ultimately, we hope that the decades of research into the 
unique natural phenomenon of dosage compensation will finally be realized into 
promising strategies for improving the health and well-being of individuals with DS and 




Figure V-1: Summary of biological considerations and technical hurdles towards 
chromosome therapy 
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 All of the experiments and analysis described in this appendix were performed by 
me, with help from Meg Byron growing and processing organoids treated with 
antibiotics. The lentiviral plasmid was created by Melvys Valledor. Zdenka Matijašević 
performed experiments treating iPSCs with antibiotics that informed some of the studies 
described here.  
Introduction 
Transgene silencing is a broad problem affecting numerous biological systems 
and transgene vectors, and several pathways of silencing have been identified (Matzke 
et al., 2000). In general, transgenes are thought to be silenced by genome defense 
systems that have evolved over millions of years to prevent parasitic genomic elements, 
such as viruses, from invading and overtaking host machinery (Waterhouse et al., 
2001).  
In this thesis I have described the usage of an XIST transgene as a powerful 
experimental system with which to study DS pathogenesis. Additionally, I have outlined 
the potential therapeutic applications of this unique gene for treating trisomies. 
However, as alluded to in the introduction, in the course of this thesis research I and 
others in the lab have experienced significant XIST transgene silencing using our in 
vitro system. As described in chapter V, transgene silencing can have drastic 
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consequences when it involves a therapeutic gene replacement. While the stakes were 
not nearly so high in this case, transgene silencing poses a problem for effectively 
studying XIST-mediated silencing as an experimental tool and must be addressed 
before therapeutic approaches can be considered. 
Results 
XIST silencing in iPSCs 
 We first noticed a transgene silencing problem in iPSCs. While several early 
passages of the transgenic XIST-inducible cell lines (Jiang et al., 2013) showed stable 
expression of XIST in a very large fraction of iPSCs (Jun Jiang, personal 
communication), we noticed that over time, many cells lost the expression of the XIST 
transgene (Figure A-1A). The loss of XIST expression was patchy, in that some entire 
colonies would robustly express the transgene, while others had no XIST+ cells, and 
still others had a cluster of XIST+ cells clearly separated from cells with a silenced 
transgene. This suggested that the iPSCs were epigenetically silencing either the 
reverse tetracycline-controlled transactivator (rtTA) required for inducible XIST 
expression, or the tetracycline response element (TRE) upstream of the XIST 
transgene. Attempts to subclone the cells in order to obtain a stable line with a high 
fraction of XIST expressing cells were unsuccessful. Thus, many of the neural 
differentiation experiments conducted in this thesis used a heterogenous starting 
population of iPSCs with roughly 70-80% of cells expressing XIST at the onset of 
differentiation. 
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XIST silencing in aged organoids 
 In addition to a reduced starting population of XIST-expressing cells, I also ran 
into a much more drastic example of transgene silencing in long-term differentiation 
cultures. I found that in organoids grown for 90 days and treated with dox from the onset 
of differentiation, there was an extremely low fraction of XIST-expressing cells (Figure 
A-1B). We quickly made the realization that the “ubiquitous” promoter that was used to 
drive rtTA expression in our transgenic lines, EF-1a, has been reported to be 
completely silenced in human iPSC-derived neurons (Guillaume et al., 2006). This 
suggested to us that replacement of rtTA driven by another promoter could rescue the 
transgene silencing phenotype that we see in aged organoids. To test this hypothesis, I 
generated lentiviruses carrying rtTA driven by the ubiquitin C promoter and containing a 
fluorescent marker (Figure A-1C – pLV-rtTA). 7 days after transduction of day 83 
organoids that had been treated with dox since the onset of differentiation (d0 dox), we 
saw restricted patches of red fluorescent cells, indicating patchy transduction of the 
organoids (data not shown). After fixing, sectioning, and performing RNA FISH on these 
organoids, we saw areas with high numbers of XIST+ cells (Figure A-1B). Such a high 
degree of XIST expression was unprecedented in d90 organoids and was not seen in 
organoids without lentiviral transduction. This encouraged us to generate a stable cell 
line containing rtTA driven by CAG, a promoter that has been shown to resist silencing 
in human neurons (Muotri et al., 2005), inserted into one allele of the AAVS1 site using 
CRISPR/Cas9 technology (Figure A-1C – CAG-rtTA). This generated a cell line that 




Figure A-1: Rescuing transgene expression with reintroduction of rtTA 
 
A) Representative image of RNA FISH in iPSC colony with a patch of XIST expressing 
cells. B) RNA FISH for XIST in 90d organoids treated with dox from the onset of 
differentiation. Bottom panel demonstrates increase in XIST expression with pLV-rtTA 
transduction. C) Schematic of rtTA expression cassettes used in this study. Top two 
panels are cassettes inserted at AAVS1 locus on chr19. Bottom panel is randomly 
integrating lentiviral plasmid. Note the lack of dedicated promoter for NeoR in CAG-
rtTA. D) RNA FISH for XIST in organoids at days 14, 31, and 49 of differentiated treated 
with dox from day 0 and either treated with no antibiotic, puromycin, or G418. E) 
Representative phase contrast images of organoids at day 49. F) IF for SOX2 in d49 
organoids treated with puro or no antibiotics. Scale bars for (A, B, D, and F) are 100µm. 




Figure A-1: Rescuing transgene expression with reintroduction of rtTA 
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construct. I termed this cell line clone 5a (C5A), and it was used extensively in chapter II 
of this thesis. 
 Knowing that rtTA was the limiting factor in aged organoids that were treated with 
dox from the onset of differentiation, we reasoned that selecting for rtTA expression 
using the antibiotics present on the rtTA cassettes could increase XIST expression. To 
test this, we differentiated cerebral organoids, as described in chapter III, from the C5A 
line described above. Dox treatment was started at day 0, along with either no antibiotic 
selection, puromycin (puro), or G418. As shown in Figure A-1D, the level of XIST 
expression was similar at early stages of differentiation. At later stages, both the 
untreated and G418 treated samples lost significant XIST expression, while the puro 
treated organoids retained XIST expression in nearly all cells. However, the puro 
treated organoids were also significantly smaller at day 49 (Figure A-1E) when 
compared to untreated organoids and were composed almost entirely of SOX2+ neural 
progenitors (Figure A-1F), suggesting that puromycin is toxic to terminally differentiated 
neurons which silence the EF-1a promoter. These same effects of puro and G418 were 
confirmed in iPSCs, whereby puromycin selection leads to a pure population of XIST 
expressing cells, while G418 treatment has no effect. 
The different action of these two drugs may reflect differences in how the 
promoters are arranged in the two rtTA-expression cassettes (Figure A-1C). In the puro-
containing cassette, selection for puromycin resistance also selects for expression of 
rtTA likely due to the back-to-back arrangement of the promoters. In non-expressing 
cells, these promoters may be silenced by CpG methylation at that one locus. On the 
other hand, the CAG-rtTA cassette utilizes the endogenous AAVS1 site promoter to 
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drive neomycin resistance and the spatially separated CAG promoter to drive rtTA 
expression. In this case, selection with G418 does not concomitantly select for rtTA 
expression.  
Overall, these experiments suggest that in cells treated with dox from the onset 
of differentiation, silencing of the rtTA locus leads to loss of XIST expression with 
differentiation even in a cell line containing CAG-rtTA. A similar process occurs in 
iPSCs, where the rtTA locus is stochastically silenced in a population of cells leading 
them to lose the ability to initiate XIST expression. 
Attempting to initiate XIST expression in postmitotic neurons 
 As discussed in chapter II, in both in a pure monolayer culture of postmitotic 
neurons and in organoids where the NSCs and neurons can be spatially distinguished, 
addition of dox does not lead to the initiation of XIST expression in neurons. Based on 
the results from the previous section, we reasoned that the EF-1a promoter is likely 
silenced in these cells leading to a loss of rtTA expression, which may be responsible 
for the inability of these cells to initiate XIST expression. 
To test this hypothesis, I differentiated iPSCs into a pure population of neurons 
by adding the g-secretase inhibitor compound E (CE) at day 21 of differentiation, which 
causes synchronized neuronal differentiation with no remaining neural stem cells by day 
28 (Figure II-5A). On day 28, I added dox in order to initiate XIST expression and also 
transduced the cells with the previously described pLV-rtTA in order to exogenously 
express rtTA. Unlike neurons that had been treated with dox from the onset of 
differentiation (d0 dox), there were essentially no XIST+ cells in this condition (Figure A-
2A-B). This is despite the robust increase in rtTA expression levels in all conditions, as  
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Figure A-2: Introducing exogenous rtTA in postmitotic neurons to initiate XIST 
expression 
 
A) RNA FISH for XIST in d35 monolayer neurons treated with compound E on day 21 
for 7 days. pLV-rtTA was transduced in cells where indicated. Dox was added on the 
day indicated. B) Quantification of the fraction of XIST-expressing cells in each 
condition of (A). 123-305 cells were counted for each condition (median=176). C-D) 
qPCR for rtTA (C) and XIST (D) normalized to GAPDH for cells in each condition of (A). 
AU, arbitrary units. E) Schematic of hypothesized methylation status of rtTA and XIST 
loci in transgenic cells. EF-1a promoter is likely progressively silenced over time in 
neurons, but not completely at this stage. TRE upstream of XIST is suspected to be 
robustly silenced in dox naïve neurons. 
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measured by qPCR (Figure A-2C), which led to an expected increase in both the 
fraction of XIST+ cells (Figure A-2B) and XIST expression (Figure A-2D) in the d0 dox 
condition. 
Together, these results suggest that in d0 dox cells, rtTA is the limiting factor for 
XIST expression, while in dox-naïve neurons something other than rtTA is limiting. It is 
most likely that the TRE upstream of the XIST transgene is silenced by DNA 
methylation (Figure A-2E), as has been reported in the literature for tetracycline 
inducible systems (Gödecke et al., 2017). 
Discussion 
  The experiments described above outline my attempts to counteract the finding 
of a decreased proportion of XIST expression cells in long-term iPSC culture and in 
differentiated cells, especially neurons. There are several important lessons to be taken 
away from these findings that can be applied to any studies using the tetracycline 
inducible system as well as for general design of expression cassettes. 
Foremost, in this study the major cause of progressive loss of inducible 
transgene expression with differentiation was loss of rtTA expression. This happened 
both stochastically in iPSCs and due to silencing of a developmentally regulated 
promoter with differentiation. Transgene expression could be rescued with re-
introduction of rtTA. It seems that rtTA may protect the TRE from methylation, which is 
why this rescue was possible only in cells that had previously been exposed to dox and 
may mean that rescue is limited by the starting proportion of XIST expressing cells. In 
dox naïve cells, the TRE was not protected from methylation, likely leading to the 
inability for XIST to be initiated even with adequate rtTA expression. The fact that  
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NSCs, but not neurons, are capable of initiating XIST expression suggests that there 
could be developmentally regulated methylation of the TRE in the final transition from 
NSCs to neurons.  
Additionally, back-to-back transgene cassettes in this case led to joint expression 
profiles, which can be advantageous in that it allows for selection of continued 
transgene expression. It could also lead to silencing of a ubiquitous promoter when 
paired with a developmentally regulated promoter. The fact that C5A did not 
demonstrate an increase in XIST expressing cells could have several root causes. 
Perhaps most likely is that the spatial separation, and therefore uncoupled expression, 
of promoters driving antibiotic selection and rtTA expression means that selection for 
G418 only guarantees that the rtTA cassette is inserted in the AAVS1 locus, not that it is 
expressed. A low starting level of CAG driven rtTA expression would prevent robust 
expression of XIST in differentiated cells.  
 Because transgene expression is such a widespread phenomenon in biology, 
several common strategies for maintained expression have improved biological 
research. One recent paper examined a similar phenomenon to that described in this 
appendix, where tetracycline inducible expression was silenced with differentiation 
(Gödecke et al., 2017). In order to reverse the DNA methylation detected at the TRE 
locus, the researchers fused rtTA to the demethylase Ten-eleven translocation 
methylcytosine dioxygenase 1 (TET1). This led to demethylation of the TRE locus and 
allowed for transgene expression, albeit with relatively low efficiency. 
Excitingly, we have preliminary evidence that the rtTA-TET1 fusion may reverse 
transgene silencing in our system, allowing for the induction of XIST expression in 
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differentiated neurons. This prospect would allow the study of XIST-mediated silencing 
in a postmitotic cell type for the first time. From a disease modeling perspective, if 
neurons are capable of initiating silencing this would greatly increase the experimental 
utility of dosage compensation for studying DS neurobiology. The ability to transition a 
neuron from a trisomic to disomic state would provide a unique opportunity to the 
examine whether trisomic neurons have ongoing functional deficits that could be 
reversed with dosage compensation. This could also have exciting translational 
ramifications for the potential of XIST as a therapeutic strategy for DS. 
 Materials and Methods 
iPSC maintenance and differentiation 
iPSCs were grown and maintained as described in chapter II. Organoids were 
generated using the Paşca (2015) protocol with the modifications described in chapter 
III. Monolayer neurons were generated with the protocol described in chapter II and 
were treated with 200µM CE at day 21 for 7 days. Dox was used at a concentration of 
500ng/ml. Puromycin was used at a concentration of 3µg/ml. G418 was used at a 
concentration of 40µg/ml. 
Generation of iPSC line with CAG-driven rtTA 
First, transgenic iPSC clones (Jiang et al., 2013) were screened for heterozygous 
insertion of EF-1a-driven rtTA using genomic PCR. These clones were then transfected 
with a CAG-driven rtTA plasmid with AAVS1 homology arms (CAG-rtTA) which was a 
gift from Paul Gadue (Addgene plasmid #60431) and a sgRNA/Cas9 plasmid directed at 
AAVS1 which was a gift from Masato Kanemaki (Addgene plasmid #72833) using 
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PBAE nanoparticles (Eltoukhy et al., 2012; Zugates et al., 2007) at a 30:1 dilution. After 
3 hours, media was changed to E8 with 10µM of the ROCK inhibitor Y-27632. A total of 
5µg DNA were transfected. After 48 hours, selection with 40µg/ml G418 was started 
and continued for 2 weeks. Insertion of the transgene was confirmed with genomic 
PCR. 
Lentiviral production and transduction 
 293FT cells (ThermoFisher) were used to generate lentiviral particles. 293FT 
cells were passaged 1:2 into a T75 flask the day before transfection. On the day of 
transfection, 9µg of transfer plasmid, 3µg of envelope plasmid, and 5.5µg of packaging 
plasmid were transfected using Lipofectamine 2000 (ThermoFisher) per the 
manufacturer’s instructions into one T75 flask containing 293FT cells at ~80% 
confluence. The pLV-rtTA plasmid is also known as pSLIK3 and was created by Melvys 
Valledor (Valledor et al., 2018). The envelope (PMD2.G, addgene plasmid #12259) and 
packaging (PsPax2, addgene plasmid #12260) plasmids were a gift from Didier Trono. 
The day after transfection, the media was changed to either neuron media (for 
monolayer culture, as described in chapter II) or organoid media. Two days after 
transfection, the conditioned media was filtered through a 0.45µm low binding filter 
(ThermoFisher) and added directly to the neurons (d28 of differentiation) or organoids 
(d83 of differentiation). The next day, the media was replaced with fresh unconditioned 
media. About 3 days after transduction and dox treatment, cells began to fluoresce in 
the red channel with close to 100% efficiency in monolayer neurons and at a much 
lower efficiency with patchy distribution in organoids. 
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Cell fixation, immunofluorescence, and RNA FISH 
 These steps were performed as described in chapter II for both iPSCs, 
monolayer neurons, and organoids. The Stellaris XIST probe was used for RNA FISH.  
RNA extraction, reverse transcription, and qPCR 
 These steps were performed as described in chapter III. 50-100ng of RNA was 
reverse transcribed and cDNA was used at a 1:10 dilution for qPCR. The primers used 
for qPCR are listed in Table A.1. GAPDH was used for normalization and quantification 
was performed using the DDCt method (Livak and Schmittgen, 2001) with normalization 
performed separately for each clone. 
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Table A-1: qPCR primers used in appendix 
Gene Primer Sequence 
rtTA F 5’-AAA-TCA-GCT-CGC-GTT-CCT-GT-3’ 
R 5’-TGT-TCC-AAT-ACG-CAG-CC-3’ 
XIST F 5’-GCA-GGT-CCA-AGA-AAT-TTG-AAC-AC-3’ 
R 5’-AGA-GTG-CCA-GGC-ATG-TTG-ATC-3’ 
GAPDH F 5’-TGC-ACC-ACC-AAC-TGC-TTA-GC-3’ 
R 5’-GGC-ATG-GAC-TGT-GGT-CAT-GAG-3’ 
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